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Beyond summary statistics: extracting etiological insights from genome-wide association cohorts
Jie Yuan
Over the past 20 years, Genome-Wide Association Studies (GWAS) have identified
thousands of variants in the genome linked to genetic diseases. However, these associations often
reveal little about underlying genetic etiology, which for many phenotypes is thought to be highly
heterogeneous. This work investigates statistical methods to move beyond conventional GWAS
methods to both improve estimation of associations and to extract additional etiological insights
from known associations, with a focus on schizophrenia. This thesis addresses the above aim
through three primary topics: First, we describe DNA.Land, a web platform to crowdsource the
collection of genomic data with user consent and active participation, thereby rapidly increasing
sample sizes and power required for GWAS. Second, we describe methods to characterize the
latent genomic contributors to heterogeneity in GWAS phenotypes. We develop a Z-score test to
detect heterogeneity using correlations between variants among affected individuals, and we
develop a contrastive tensor decomposition to explicitly characterize subtype-specific SNP effects
independently of confounding heterogeneity such as ancestry. Using these methods we provide
evidence of significant heterogeneity in GWAS cohorts for schizophrenia. Lastly, a major avenue
of investigation beyond GWAS is identifying the genes through which associated SNPs
mechanistically affect the presentation of phenotypes. We develop a method to improve
estimation of expression quantitative trait loci by joint inference over gene expression reference
data and GWAS data, incorporating insights from the liability threshold model. These methods
will advance ongoing efforts to explain the complex etiology of genetic diseases as well as
improve the accuracy of disease prediction models based on these insights.
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Chapter 1: Introduction and Background
Nearly two decades since the preliminary sequencing of the human genome [1, 2], genomic
data is now an ubiquitous component of epidemiology and medicine [3]. The development of
Next Generation Sequencing technologies enabled faster and cheaper generation of genotype data,
with cost reductions outpacing Moore’s law since 2008 [4, 5]. This has allowed research consortia
to recruit large cohorts for genomic studies, such as the UK Biobank with nearly 500k partic-
ipants and the Precision Medicine Initiative which aims to recruit 1 million participants [6, 7].
Direct-To-Consumer genotyping companies have achieved even greater success in recruitment,
with 23andMe claiming more than 12 million customers and Ancestry.com more than 15 million
[8, 9].
Throughout these advancements, the Genome-Wide Association Study (GWAS) has been a
fixture of statistical assessments of genomic disease risks. Between 2005 and 2018, nearly 3,700
GWAS have been conducted on 3,500 unique traits, discovering tens of thousands of genomic
variants associated with a trait [10]. GWAS have also produced actionable insights into disease
etiology by tagging genes with known disease-relevant mutations and drug interaction sites in traits
such as type 2 diabetes, lipid levels and Crohn’s disease [11, 12]. Despite these achievements, the
GWAS framework also carries many drawbacks [12]. The summary statistics reported by GWAS
tend to explain only a small fraction of the total variance of most complex traits, and as reported
signals are merely associations, they give little insight into whether relevant variants are causal,
or what their roles are in the broader etiology of diseases. Further exacerbating these issues,
the high polygenicity observed in most complex traits often result in weak associations dispersed
throughout most of the genome, possibly due to highly inter-connected gene regulatory networks
[13].
Despite these drawbacks, few alternative models have been proposed to supplant GWAS, due
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to the aforementioned polygenicity resulting in very weak and widespread signals. While deep
learning has made significant inroads into the discovery of interaction sites with gene regulatory
elements [14, 15], preliminary work applying neural networks to predict disease status from geno-
type data found that the predictive accuracy of these networks did not significantly outperform the
additive linear estimates currently derived from GWAS [16]. These findings suggest the drawbacks
of GWAS may not be primarily attributable to the limitations of the linear models currently in use.
In this thesis, I explore methods to extract additional insights from case/control GWAS data be-
yond conventionally reported summary statistics, with a focus on schizophrenia GWAS. First, large
sample sizes are required to detect the small and widely dispersed associations typical of GWAS
but can be difficult to obtain by traditional recruitment and sequencing of human participants. In
Chapter 2, I present DNA.Land, a web framework for the rapid collection of genotype and phe-
notype data from customers of direct-to-consumer genotyping companies. This section describes
measures taken to ensure privacy and consent of users and encourage continued participation in the
website, the resources required, as well as lessons learned from operation of the website, during
which we collected over 50k genomes within two years of operation.
Next, I describe efforts to both detect and characterize heterogeneity in genotype data at-
tributable to sub-types with distinct genomic risk factors. In some diseases comprising observ-
able differences between sub-types, such as type-I and type-II bipolar disorder, sub-type specific
variant associations may be identified, further clarifying the etiology of the disease as a whole
[17]. Schizophrenia is widely understood to be heterogeneous with unique subtype-specific ge-
nomic contributors [18], and these subtypes are suspected to have unique genetic correlations with
other traits such as educational attainment [19]. However, to date there are few methods which are
well-powered to investigate heterogeneity in single case/control traits in an unsupervised genome-
wide approach and are capable of disentangling heterogeneity attributable to disease etiology from
background stratification such as ancestry. In Chapter 3, I describe CLiP, a method which trades
discriminativeness for increased power. Rather than decompose sub-type specific SNP associa-
tions, CLiP relies on expected correlation patterns between variants in non-heterogeneous cohorts
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to detect heterogeneity present in cases and not controls. In Chapter 4, I describe a mixture model
method to explicitly characterize subtype-specific variant effects. This method relies on a con-
trastive spectral decomposition [20], which identifies mixtures in cases while ignoring those also
present in controls. Using these methods, we detect significant heterogeneity in schizophrenia
cohorts and identify potential subtypes with unique variant associations.
Lastly, in recent years Transcriptome-Wide Association Studies (TWAS) have emerged as a
popular tool to enhance the explanatory power of GWAS by incorporating gene expression data.
TWAS are conducted in a two-stage process in which variant-gene effects are estimated from typi-
cally small reference panels, and these are then used to impute gene expression for gene-trait asso-
ciation tests in large GWAS cohorts. In Chapter 5, I describe EMBER, a method which improves
estimation of variant-gene effects over regression in a reference panel by performing inference
over both the reference panel and a separate GWAS cohort simultaneously. We demonstrate that
EMBER improves estimation accuracy over linear regression as measured by concordance with
results from replication data.
The remaining sections of this introduction give a brief overview of GWAS and TWAS.
1.1 Genome-Wide Association
Genome-Wide Association Studies (GWAS) concern the identification of particular loci in the
genome that are predictive of a phenotype, often case/control status with respect to a disease. This
analysis is performed typically over Single Nucleotide Polymorphisms (SNPs) which are known to
vary widely between individuals. A discovered SNP-trait association may be the result of several
mechanisms: the SNP may be located within a gene coding for a protein that ultimately has some
causal effect on the disease; the SNP may be located in a promoter or enhancer region, and SNP
variability influences expression of a gene; or the SNP may only be in close proximity to a gene,
and a particular effect allele co-occurs with a particular gene variant. The latter results from a
phenomenon called Linkage Disequilibrium (LD), in which SNPs or genes in close proximity
tend to be correlated, due to the block-wise nature in which chromosomes are recombined during
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meiosis.
1.1.1 Linear regression and covariates
GWAS conventionally employ linear regression models to discover additive effects among a set
of SNP predictors. Assume a quantitative trait such as height or BMI is measured and standardized
as . ∼ # (0, 1), and a set of " SNPs is collected for # individuals and stored in the # ×" matrix
- ∈ {0, 1, 2}. The objective is to find the effect sizes V maximizing the prediction of the trait in
the equation . = -V. The SNPs whose effect sizes V are sufficiently large to pass a significance
threshold are reported in summary statistics. It is also important to remove the effect of covariates
in the GWAS study, such as age, sex, and ancestry which may result in spurious associations with
the sample data. This is achieved in linear regression by adding these labels as additional predictors
in the linear model. Ancestry is incorporated by performing a principal component analysis on the
genotyped data [21]: the degree to which each individual’s genotype vector aligns along a number
of top eigenvectors, typically 10 to 20, are also added as covariates. In practice, GWAS typically
regresses a single SNP along with the full set of covariates, and reports the p-values of association
in a Manhattan plot. Modern GWAS methods often apply assumptions from multi-SNP linear
mixed models to re-estimate effect sizes accounting for LD between SNPs, such as LDpred [22],
or to estimate the additive variance explained by all genome-wide SNPs, such as GCTA or BOLT-
REML [23, 24].
1.1.2 Polygenic Risk Scores and heritability
The set of learned effect sizes V can serve as a linear prediction model for disease risk. If a vec-
tor of the same SNPs is constructed for a new set of individuals -′, then -′V will be a continuous
score called a Polygenic Risk Score (PRS) quantifying risk of disease for that set of individuals.
For clinical applications, these scores are often binned into ranges of increasing risk with the high-
est scoring bins warranting some further investigation [25]. Oftentimes the predictability, or the
fraction of trait variance explained of these models, is low. The heritability, or total fraction of
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variance explained by all genomic variants, can be estimated from twin studies, and in a meta-
analysis of nearly 18,000 traits was found to be on average 49% [26]. But the variances explained
of summary statistics obtained from GWAS are frequently much lower, in the neighborhood of 1
to 5%, in what has been called the “missing heritability” problem [27]. Over time, consensus has
arisen that this is due to the high polygenicity of most traits: thousands of SNPs each contribute
additively a very small effect to determination of a trait, and the vast majority of these effects re-
main undetected due to the underpowered status of most modern GWAS studies. For this reason
PRS explain only a very small percentage of variance and may not be very predictive on an indi-
vidual basis. The very low signal to noise ratio of almost all GWAS applications is also a principal
challenge in detecting heterogeneity in GWAS.
1.1.3 Case/Control GWAS and the Liability Threshold Model
Most disease traits are not reported as quantitative variables, but as cases or controls. For this
reason logistic regression is used instead: rather than the trait value, the log function of the odds of
acquiring the trait for a given individual is the prediction variable. This permits the interpretation
of the effect sizes as the log odds ratio of acquiring the disease given one risk allele for the given
SNP is added, and these odds ratios are typically reported in summary statistics.
However, the logistic regression model does not explicitly define the variance explained by the
model, and this must be estimated using pseudo-A2 methods. For ease of simulation and interpre-
tation, another popular model in use is the liability threshold model [28]. This model assumes an
underlying standard normal variable quantifies subjects’ disease status, and one is assigned to be
a case if one passes some fixed threshold ) in the distribution of this variable, as shown in Figure
1.1. The threshold location is determined by the prevalence of the disease in the population. The
PRS -V contributes to the hidden variable, but only by a small percentage ℎ2
V
, and the remaining
variance explained is modeled as normally distributed noise with variance 1 − ℎ2
V
. As the noise
variance is unaccounted for by the model, an individual’s probability of being classified as a case
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is determined by the individual’s PRS, specifically, the probability that the unobserved total score
passes the threshold, as determined by the normal CDF function Φ:







Figure 1.1: Liability Threshold Model
1.1.4 Transcriptome-Wide Association
Transcriptome-Wide Association Studies (TWAS) leverages gene expression data to derive fur-
ther insights into causal relationships between genomic variants and phenotypes [29, 30, 31, 32].
While gene expression data can be measured through methods quantifying the amount of tran-
scribed RNA through methods such as RNAseq, a persistent challenge is the increased cost of
acquiring gene expression data in comparison to genomic sequence data. Therefore gene expres-
sion data sets tend to be far smaller, often numbering in the hundreds of samples. To discover
gene-trait associations, rather than regressing on the transcriptome directly, TWAS instead learns
models to predict expression levels based on genomic variants located in cis with the locus of the
gene. This first step is performed over small cohorts of individuals who have available both ge-
nomic and transcriptomic data to learn a set of effects V predicting the transcript. Then for much
larger cohorts of individuals with only genomic data - , expression levels are inferred using the
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linear model, calculated with -V. The inferred expression variables are then regressed against
phenotype data H of the larger cohorts. The regression effects U of these inferred transcripts can be




As TWAS is in essence a two-stage regression, it can also be conducted when only summary
statistics and LD information is available by representing imputed gene-trait effects as linear func-
tions of known SNP-trait associations scaled by matrices of SNP-gene and SNP-SNP covariances.
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Chapter 2: A digital biobank framework for the era of abundancy of genetic
information
This work is published in Nature Genetics and was coauthored with Assaf Gordon (co-first
author), Daniel Speyer, Richard Aufrichtig, Dina Zielinski, Joseph Pickrell, and Yaniv Erlich.
doi: https://doi.org/10.1038/s41588-017-0021-8
2.1 Abstract
Precision medicine necessitates large scale collections of genomes and phenomes. Despite de-
creases in the costs of genomic technologies, creating genome/phenome collections at scale is still
a daunting task that usually requires consortium-scale resources. Here, we describe DNA.Land,
a digital biobank to collect genomes and phenomes with a fraction of the resources of traditional
studies at the same scale. Our approach relies on crowd-sourcing data from a growing number of
individuals that have access to their own genomic datasets through consumer genomic companies.
To recruit participants, we developed a series of automatic return-of-results features in DNA.Land
that increase users’ engagement while complying with human subject research protection. So far,
DNA.Land has collected over 50,000 genomes in 20 months of operation, orders of magnitude
higher than previous digital attempts by academic groups. We report lessons learned in running
a digital biobank, our technical framework, and our approach regarding ethical, legal, and social
implications.
2.2 Introduction
Elucidating the genetic basis of complex traits requires substantial quantities of genomic data
[33]. In the last twenty years, the field has seen an exponential decline in the cost of genomic
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technologies. As of today, a genotyping array costs on the order of tens of dollars and whole
genome sequencing costs about one thousand dollars. However, collecting genetic and phenotype
data at scale is a time and resource consuming task that poses massive logistical and operational
challenges. On top of the costs of genotyping, researchers need to advertise the study, recruit
participants, obtain consent, provide DNA collection kits, track and store samples, extract DNA,
and prepare the DNA library before data is available in a digital format. Phenotyping requires
further resources even if it is done using online questionnaires. These operations are labor intensive
and translate to massive costs. For example, the NIH’s Precision Medicine Initiative (“All of Us”)
has recently allocated $50 million for recruitment centers (“HPO”) and biobank operations that
collectively proposed to recruit and handle bio-specimens and basic phenotypic information from a
total of 500,000 participants. These costs translate to about $100 per participant before genotyping
and the inclusion of more advanced data collection methods such as wearable devices (Table A.1).
In Europe, the UK Biobank reported that it needed “careful configuration” of its operational chain
to support the recruitment of one hundred participants per day in each of its centers [34, 35].
We sought to develop a cost-effective alternative for collecting genome and phenome data at
scale. The past five years have witnessed the advent of large-scale direct-to-consumer (DTC)
genetic services for genealogy and personal curiosity, with companies such as 23andMe, Ances-
tryDNA, FamilyTreeDNA, and MyHeritage [36]. These services provide a dense genotyping array
with approximately half a million SNPs for about $69 to $99 per participant. As of today, more
than eight million individuals have been tested with these services and over ten thousand new
DTC kits are purchased daily. None of these companies currently share individual level data with
researchers and to the best of our knowledge only 23andMe and MyHeritage collect phenotype
information on disease traits. These policies restrict the ability to migrate data to academic studies
by collaborating with these companies. However, all of these services hold the view that the raw
genetic information belongs to the tested individual and allow downloading the genomic data in
a tabulated textual format. The ability to download the raw genotypes provides an opportunity to
reach out to individuals to crowd source the raw genetic data and repurpose the data for academic
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studies, circumventing the cumbersome sample processing procedures of traditional studies.
Previous efforts to crowd source DTC genomic data using an online platform have shown mixed
results. For example, OpenSNP.org offers a not-for-profit service and provides a basic mechanism
for users to upload their DTC genomic data and publicly share their data, but do not offer features
such as privacy controls or a IRB-protections to participate in research [37]. While serving as an
important open resource for the community, OpenSNP’s approach has yet to become a viable alter-
native to traditional genomic data collection. Analysis of uploading dates shows that the website
attracts only 1 to 2 participants per day. After five years of operation, this website has reached
only five thousand participants. Another website for crowdsourcing DTC genomic data is Ged-
Match.com, which is operated by a small for-profit company. This website offers a wide repertoire
of genetic-genealogy tools that extend the features offered by DTC companies. By serving the
genetic genealogy community, GedMatch has reached critical mass and grown a large commu-
nity of hundreds of thousands of individuals in approximately five years of operation. However,
the website does not focus on basic research: it neither consents users nor collects phenotypic
information, and provides minimal privacy settings, reducing its attractiveness for human genetic
research by academic groups. Nonetheless, its success highlights the possibility of reaching a large
scale collection of DTC data by developing a 3rd party service offering added value in the form of
genetic-genealogy analysis for participants.
Building upon these observations, we developed DNA.Land, a website to crowd source ge-
nomic and phenotypic information for human genetics research. DNA.Land has two overall goals:
(a) to demonstrate the potential for genotype and phenotype collection by crowdsourcing data from
users of direct-to-consumer companies, and (b) to promote the idea of patient-led genetic research,
with controls left to the participants such as a choice of the degree of sharing of phenotype data,
and avenues for providing feedback to researchers. In 20 months of operation, DNA.Land has
collected over 50,000 genomic datasets from DTC participants and growing daily. Importantly,
this effort was accomplished by a small team in an academic environment. In this manuscript, we
describe the operating guidelines, ELSI approach, and technical details of our website, while high-
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lighting key points and lessons learned to operate a digital biobank. We hope this information can
be useful for other academic efforts seeking alternatives to traditional approaches of constructing
genetic databases, for start-ups that operate in the growing DTC domain, and for bioinformaticians
interested in learning more about the architecture of scalable pipelines for the analysis of genetic
data.
2.3 Design principles and user experience
The design and operation of DNA.Land have emphasized two principles: reciprocation and
autonomy, which were highlighted by previous studies as a viable route for large scale engagement
in genomics [38, 39, 40]. Participants who volunteer their genomic data contribute an essential
resource for advancing research. We hypothesized that providing services in return would help
maintain user interest and interaction with our study and encourage participation from new users.
For every piece of information requested of the user, we aim to reciprocate by displaying online
reports detailing interesting information about his or her genome. In addition, we provide a “Learn
More” link that explains the value of the information for science and for the user. To respect
the autonomy of individuals, we give our users the ability to choose the extent of involvement
in the website in terms of data contribution and information sharing. Lastly, security is a major
concern of the website, and we discuss measures taken to safeguard uploaded genetic data and user
information in the Supplementary Material (Chapter A).
New users start their interaction with DNA.Land with account creation and a consent form.
Previous studies have shown that users rarely read the terms of service of websites [41], but despite
that IRBs insist on overly long consent forms [42, 43]. To address this challenge, our consent
philosophy uses a ‘just-in-time’ presentation of information. Rather than enumerating all possible
scenarios as in a traditional consent form for broad research [44, 45], our consent sets only the
framework for the relationships between the user and the study and describes the risks and benefits
for sharing genetic data in plain language. While exploring the website, users may decide to
increase their involvement by answering questionnaires about health traits or contributing their
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genealogy data. In these cases, we present additional consent forms that are geared towards the
specific feature before allowing the user to contribute more data. The ‘just-in-time’ approach
allows the general consent form to be only 1500 words long, or a five-minute read in a normal
pace, increasing the chance that users will read it. We share the consent language under CC-BY-
2.0 to facilitate adoption by the community (see Supplementary Material in Chapter A).
We found that the amount of time users spent on the consent documents corresponds to their
length. For example, the users spent approximately 17sec (sd=22sec) on the ‘just-in-time’ consent
page displayed for a breast cancer survey that has approximately 250 words. For the trait consent
with twice as many words, the users spent 34sec (sd=22sec) on average. These reading rates
correspond to 15 words/sec. The increased dwell time on longer consent pieces suggest that most
users do not just “click through” the page. However, the fast reading time indicates that the users
mostly skim through the language, presumably to detect major issues, and argues against lengthy
consent forms.
After the consent, participants upload their genetic data and can optionally provide minimal
information about themselves. We currently accept data files from all major DTC companies:
23andMe, AncestryDNA, FamilyTreeDNA, and MyHeritage.
Once the user has logged in, the main profile page presents three primary types of reports to
users: ancestry composition, relative matching, and trait prediction (Figure 2.1). On average, the
ancestry reports are available after 7.1 hours (median: 4.6 hours) and the relative matching and the
trait predictions are processed by batch every 12 hours, so typically users will wait a maximum of
24 hours for results.
Currently, our trait prediction reports describe only physical and wellness features such as
height and neuroticism and do not include any disease-related traits to avoid regulatory complex-
ities. However, we do collect questionnaires about disease traits, such as family history of breast
cancer. The relative finder and trait prediction reports are opt-in and implement a ‘just-in-time’
consent for participation. About 90% of the users opted-in for the relative matching report that
includes making their username and email address publicly visible for other genetically-related
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Figure 2.1: The DNA.Land reports (A) Ancestry Report based on a STRUCTURE-like algorithm
and a specialized reference of world-wide populations (B) Trait Prediction Report. Predictions
are calculated from published GWAS summary statistics and users’ imputed genomes. The report
also displays the distribution of DNA.Land predicted scores and the effect sizes and locations of
relevant SNPs (C) Relative matching is based on finding shared IBD segments and calculating
the most likely genealogical relationship. Each row of the report indicates a matching user and
statistics relevant to the match such as degree of relatedness, total length of matching segments,
the likelihood distribution on the degree of relatedness, and a display of the location of matching
segments on the chromosomes.
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DNA.Land users. The trait prediction report, having launched a year after the main site, currently
has a 34% opt-in rate, likely since early users have not visited the website to activate this feature.
Interestingly, the popularity of the reports did not match our initial expectations. We initially
believed that the ancestry report would generate only secondary interest among users as similar
reports are returned by DTC services. However, the ancestry report has proven to be one of the most
popular features and generates nearly equal traffic to the relative matching report (Figure A.1A).
The launch of a more visually appealing ancestry report in April 2016 generated a massive spike
in traffic, and we have since observed many participants publicly sharing their ancestry results in
Facebook pages dedicated to genetic genealogy. On the other hand, we believed that users would
highly value the option to download their fully imputed genome with 39 million variants compared
to their half a million array. We instead found that most users do not have the computational
resources to analyze their genome and this feature proved to be infrequently used [46].
Finally, we provide tech support and engagement for our users through a dedicated member of
our team. The need for this task became apparent when we were flooded with hundreds of emails
after the launch, which strained our ability to respond and diverted significant amounts of time from
the development team. In addition, our DNA.Land Facebook page has become a place for users to
report bugs and pose questions about the website, whereas our initial expectation was that it would
only serve for promotional purposes with minor importance. Our tech support answers emails,
responds to user comments on our Facebook page, and writes blog posts promoting DNA.Land on
social media, keeping users appraised of our development efforts.
2.4 Data Acquisition during the project
DNA.Land collects several forms of data from users: genome-wide genotyping data, basic
demographic information about the participant and their immediate family, and questionnaires
about traits. With exception of the genomic information, all other types of data are optional for
participation in DNA.Land.
We launched DNA.Land on Oct. 2015. As of July 2017, the project has collected 50,000
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Figure 2.2: The growth of DNA.Land (A) The number of new users participating in DNA.Land
during the first 16 months of operation. Pink indicates the number of new user registrations. Green
indicates the net number of user genomes uploaded, with users who subsequently deleted their
accounts subtracted. Dark Blue indicates the number of users completing at least one of the trait
prediction questionnaires. Large spikes in new user uploads occurred during launch and after the
release of an updated ancestry report in April 2016 (B) Cumulative new users per week since
launch. (C) The bar graph corresponds to the net genomes uploaded and indicates the proportion
of total genomes arriving from each currently-accepted direct-to-consumer genotyping company.
genomic datasets from participants (Figure 2.2A-B; Figure A.1B-C). In general, we can divide
the participation rates into three phases. The launch phase in the first month saw a rapid rate of
growth of nearly 8,000 genomes. Then, after the initial excitement, the rate declined to an average
of 900 genomes per month. Finally, after launching the improved ancestry report in April 2016,
we have seen a steady growth of nearly 2,000 new genomic datasets per month. About 45% of
the users submit files from AncestryDNA, 40% from 23andMe, and 15% from FamilyTreeDNA
(Figure 2.2C).
We also allow users to delete their account at any time. Since the launch of the website,
the deletion rate has remained at an average fraction of 4.9% of new user uploads. The reasons
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for deletions are mostly technical and reflect users that encountered technical problems such as
uploading a truncated genome file. In addition, about 6.3% of all submitted the genomes are
essentially identical. These cases mostly reflect users that were tested with more than one company
and created a separate profile for each one of their genome datasets.
We gather phenotypes by providing users with various questionnaires about physical and health
traits (Figure A.2A-B). Each questionnaire pertains to a single trait, and users may choose which
questionnaires to complete. To facilitate participation, we limited the number of questions in each
questionnaire to a maximum of 15, and most users spend less than 2 minutes completing each ques-
tionnaire (Figure A.2C). We launched the questionnaires in October 2016, a year after DNA.Land
launched, and since then about 12,000 of our users have completed at least one questionnaire.
Users have since answered over 275,000 questions in total, or about 3,100 questions per day since
the feature’s launch. We did not discover any significant differences between participation rate in
the questionnaires although they sampled very different traits.
We also give users the opportunity to provide detailed information about relatives, with an
emphasis on identifying nuclear families. We have integrated into DNA.Land’s relative finder an
option for users of Geni.com, a website for building family trees, to link their Geni accounts with
those of their matching relatives on DNA.Land. Family trees built by Geni.com users have been
shown to facilitate large-scale analyses of populations, such as historical migration patterns [47].
We also provide survey questions for users to directly identify their mother and father. Lastly, an
analysis of the results of the relative matching algorithm across all DNA.Land users shows that
7,100 profiles have at least one immediate family member. Additional information about relative
matching statistics of DNA.Land users are presented in Figure A.3.
Analysis of the demographic data provided by users shows that the average participant is of
North European ancestry in her late 40s (interquartile region: 36-63 years old) (Figure A.4A). We
see a slight over-presentation of self-reported females (53%) versus male (47%). To understand the
ethnic composition of our study, we analyzed the genetic ancestry of individuals and identified the
leading ancestry component of each individual. While this measure may not directly correspond to
16
how users self-identify their ancestry [48], it provides a proxy for the demography of in our data.
The genetic analysis shows that the primary ancestry of 53.9% of our users is Northern European,
with the next most common groups from other parts of Europe (Table A.2; Figure A.4B-C).
2.5 Data acquisition costs
DNA.Land employs a hybrid cloud design to reach a cost-effective, scalable operation (Fig-
ure 2.3A). The Supplementary Note (Chapter A) extensively documents the architecture of the
project, and we outline here only general details important to the operation costs. Briefly, the
front-end of the website operates on an Amazon Web Services (AWS) EC2 reserved instance. It
provides the web interface for managing users, collecting genomic and phenotypic data, compiling
surveys, and reporting relative matching and trait prediction results. The pipeline for processing
of genomic data (e.g. imputation and ancestry analysis) is executed on AWS spot instances, which
process each genome in parallel and allow us to scale out quickly in periods of high demand. The
imputation and ancestry results are stored on AWS S3 storage. A physical in-house server then
runs relative matching and trait prediction processes, which are CPU, RAM, and disk intensive.
These processed results, including lists of inferred relatives, are transferred to the database on the
front-end server.
The data acquisition costs of our digital approach are low and translate to a few dollars per
genome. The costs of running our hybrid cloud operation is on the order of $5000 per month
(Figure 2.3B), which includes compute engines, storage, and transfer costs, in addition to irregular
costs for development and purchase of our in-house server. To keep the costs low, we have devel-
oped an automated bidding system that will bid for spot instances for up to $0.60 per hour, but we
can manually decide to bid higher prices in situations of acute need, such as the days following
a feature launch during which we experience an influx of new users. As of December 2016, the
cumulative cost has been approximately $73.4k, or about $2 per genome-wide genotyping array, a
phenome that consist of tens of data points, and genealogy information. In addition, the DNA.Land
team has consisted of approximately two full time academic programmers who are mainly required
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Figure 2.3: DNA.Land operation and expenses (A) Overview of DNA.Land architecture. EC2
spot instances process uploaded genome files and perform imputation and ancestry inference. The
physical server performs computation involved in relative matching and trait prediction, and per-
forms backups of genotype data. Genotype files and output files of the impute pipeline are stored
in an S3 repository, and selected results are stored in a database on the frontend server. SQS is
used to manage assignment of new users to spot instances or processing by the physical server
(B) Monthly expenses for all AWS services. EC2 services (Blue) are used to process new users
in the pipeline. S3 (Yellow) is used to store uploaded genotype files and any output files from the
imputation pipeline. Transfer costs (Green) pertain to user downloads of their imputed genome
files. Irregular costs (Pink) indicate purchases of EC2 reserved instances, as well as purchase of
our current physical server, in February 2016.
for the development of new features to collect new types of information, and a part-time position
for technical support.
2.6 Discussion
We have described a scalable, software-based method to gather direct-to-consumer genotype
data at low cost and low personnel requirements relative to traditional bio-banking methods. In the
span of 20 months, we have managed to obtain over 50,000 genomes, many of which are paired
with additional phenotypic, demographic, and family data.
We credit the success of DNA.Land to several factors. First, we achieved great momentum
immediately after the launch of the project, and within the first month of operation we had collected
over 8,000 genomes. We attribute the successful launch to working closely with leaders in the
genetic genealogy community, who promoted the resource to their social media followers and
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were paramount to communicating to us the needs of the community. Indeed, only less than half of
our traffic comes from Google searches and a substantial portion of the users comes from Facebook
pages mentioning DNA.Land, genetic genealogy community websites, and blog posts (Table A.3).
In addition, the initial website already included several interesting features not presented in existing
DTC reports, such as a visualization of shared IBD segments between matching relatives, which is
not shown by some DTC companies. Second, we invested considerable efforts into addressing user
concerns on a variety of issues including the quality of our results, privacy and consent policies, and
even suggestions for improving our user-interface, such as making our visualizations color-blind
friendly. We posit that this process, while resource-intensive, has signaled to the community that
we are serious partners that can be trusted with their information. Third, we placed an emphasis
on scalable software. After the initial growing pains of stabilizing the website, the day-to-day
operation of DNA.Land has required only minimal efforts to maintain. This has allowed our small
team to mainly focus on development of new features and reports, which further drive participation.
This stands in contrast to traditional bio-banking techniques that requires scaling personnel to
increase their sample collection efforts.
We also faced a few challenges in running DNA.Land. First, in academia, the availability of
scientific software is usually welcomed regardless of its quality. This is not the case when providing
a public website for a non-academic population. Most of our users showed little patience for
technical issues in our website, and we found very quickly that we needed to operate on the highest
standards of software development and quality assurance, such as support for various browsers as
well as mobile and laptop devices. Initially, this led to high stress levels when launching new
features and longer development cycles than anticipated. We addressed this issue in part by having
a development environment that enables prototyping and testing of code before the launch. In
addition, we found that soft launching (launching without substantial promotion) to be a more
reliable path. This technique has allowed us to test the feature with a smaller set of users and detect
technical issues before the feature is discussed and promoted widely on the Facebook groups of
our participants. In the future, we hope also to be able to launch a feature only to a small subset of
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users, but currently our framework does not support this option.
Second, our experience highlights the necessity of a ‘customer support’ function. We were
initially overwhelmed by the amount of communication from participants, mainly on our Facebook
page which we had established to release messages to the community. We did not anticipate the
necessity of a support function before the launch and found ourselves answering thousands of
emails and Facebook posts in the first week of operation while managing development issues that
occurred during the launch. We encourage others that undertake such a similar endeavor to dedicate
a member of the team to answering those emails. In addition, we greatly benefited from an internal
system developed by the team that allows tracking the status of each sample in the computational
pipeline. This has allowed us to serve participants with accurate information and manage technical
issues.
Third, unlike traditional bio-banking, DNA.Land can only recruit people that were already
tested with one of the DTC companies. Not every person can participate in our biobank. Thus,
our marketing needs to focus on this much smaller group compared to the general population.
We partly overcame this problem by introducing the website to leaders in the genetic genealogy
community, but even this community only encompasses a fraction of the overall people that were
tested with DTC companies. In addition to create a marketing challenge, this restriction means
that the ethnic composition of our users reflects the DTC customer base and consists mostly of
Northern European ancestry. We hope that as the price of genotyping DTC services continues to
decrease, our website will see an increased representation of minority groups.
Finally, we learned to pay closer attention to the “actionability” of the data from the user
perspective. The research community usually encourage sharing of various types of raw data, but
we found some challenges to that philosophy among our participants. For example, we thought
that the imputation feature would be of high demand, as we generate for participants the status
of 39 million variants from an array which may have only 700,000 SNPs. However, this feature
met negative feedback from many users who found that it was not clear what to do with the file
and noted that the file is impossible to open with standard applications such as Excel or Notepad.
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We have addressed this by development of more tools, such as DNA.Land Compass [46], which
provides a GUI-based website to browse the data and learn about each SNP.
The future for DNA.Land involves more granular consent and expansion of the ways we col-
lect phenotypic information. We are developing a method for participants to share their data with
other organizations using an organization-specific consent. In a first attempt, we recently partnered
with the National Breast Cancer Coalition (NBCC), a patient advocacy group, to collect genotype
and phenotype information for breast cancer research. We re-consent users who participant in our
survey and allow them to opt-in for sharing their genome with the NBCC under a specific code of
conduct provided by the NBCC. Six month after launching the feature, more than 10,000 partici-
pants have completed the survey. We aim to create more opportunities that will empower partici-
pants to decide for themselves about sharing their data. In addition, we plan to reduce the burden
on our participants when collecting phenotypic information. The current procedure of answering
questionnaires is cumbersome and does not scale well, as it requires participants to repeatedly visit
the website. The last few years have highlighted the rise of digital phenotypes, which refers to
quantifying phenotypes from human interactions with digital technology [49]. Recent studies have
shown that a range of traits can be measured with data collected on web activity. These include
measuring five factor personality traits from Facebook likes [50], highly accurate quantification of
heart rate from videos [51], and finding early signals of pancreatic cancer from Internet searches
[52]. Unlike traditional questionnaires, digital phenotypes require less labor from the participant
as they leverage existing data using APIs of social media sites such as Facebook and allow mea-
surement of longitudinal changes. We hope to focus on collecting such phenotypes after proper
consent from our participants.
As an ultimate goal, we hope to create a digital biobank that integrates streams of data from
genetic, genealogical, and social media resources. This approach will establish a complementary
effort to existing large-scale traditional studies. Our data-intensive society offers growing numbers
of opportunities to harness existing resources, and we envision that the value and scope of such
integrative approaches will continue to rise.
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Chapter 3: Leveraging correlations between variants in polygenic risk
scores to detect heterogeneity in GWAS cohorts
This work is published in PLOS Genetics and was coauthored with Hengrui Xing, Alexandre
Louis Lamy, The Schizophrenia Working Group of the Psychiatric Genomics Consortium, Todd
Lencz, and Itsik Pe’er
doi: https://doi.org/10.1371/journal.pgen.1009015
3.1 Abstract
Evidence from both GWAS and clinical observation has suggested that certain psychiatric,
metabolic, and autoimmune diseases are heterogeneous, comprising multiple subtypes with dis-
tinct genomic etiologies and Polygenic Risk Scores (PRS). However, the presence of subtypes
within many phenotypes is frequently unknown. We present CLiP (Correlated Liability Predic-
tors), a method to detect heterogeneity in single GWAS cohorts. CLiP calculates a weighted sum
of correlations between SNPs contributing to a PRS on the case/control liability scale. We demon-
strate mathematically and through simulation that among i.i.d. homogeneous cases generated by a
liability threshold model, significant anti-correlations are expected between otherwise independent
predictors due to ascertainment on the hidden liability score. In the presence of heterogeneity from
distinct etiologies, confounding by covariates, or mislabeling, these correlation patterns are altered
predictably. We further extend our method to two additional association study designs: CLiP-X
for quantitative predictors in applications such as transcriptome-wide association, and CLiP-Y for
quantitative phenotypes, where there is no clear distinction between cases and controls. Through
simulations, we demonstrate that CLiP and its extensions reliably distinguish between homoge-
neous and heterogeneous cohorts when the PRS explains as low as 3% of variance on the liability
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scale and cohorts comprise 50, 000 − 100, 000 samples, an increasingly practical size for modern
GWAS. We apply CLiP to heterogeneity detection in schizophrenia cohorts totaling > 50, 000
cases and controls collected by the Psychiatric Genomics Consortium. We observe significant het-
erogeneity in mega-analysis of the combined PGC data (p-value 8.54×10−4), as well as in individ-
ual cohorts meta-analyzed using Fisher’s method (p-value 0.03), based on significantly associated
variants. We also apply CLiP-Y to detect heterogeneity in neuroticism in over 10, 000 individu-
als from the UK Biobank and detect heterogeneity with a p-value of 1.68 × 10−9. Scores were
not significantly reduced when partitioning by known subclusters (“Depression” and “Worry”),
suggesting that these factors are not the primary source of observed heterogeneity.
3.2 Author Summary
Several traits, such as bipolar disease, are known to be heterogeneous and comprise distinct
subtypes with unique genomic associations. For other traits such as schizophrenia, heterogeneity
may be suspected, but specific subtypes are less well characterized. Furthermore, conventional
mixture model-based methods to detect subtypes in genome-wide association data struggle with the
high polygenicity of complex traits. We propose CLiP (Correlated Liability Predictors), a method
that does not identify subtype-specific effects, but is very well-powered to detect heterogeneity
of any kind within the very weak signals of GWAS. CLiP serves as a method to flag particular
phenotypes for potential further study into the genomic factors driving heterogeneity, as well as
a means to evaluate the transferability of polygenic risk scores. We also develop extensions of
CLiP applicable to scoring heterogeneity in quantitative phenotypes and quantitative predictors
such as gene expression. We apply CLiP to scoring heterogeneity in schizophrenia cohorts from
the Psychiatric Genomics Consortium and neuroticism in individuals in the UK Biobank and find
significant heterogeneity in both phenotypes, warranting further study.
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3.3 Introduction
In recent years Genome-Wide Association Studies (GWAS) have identified thousands of ge-
nomic risk factors and generated insights into disease etiologies and potential treatments [53, 54,
55]. Many GWAS apply logistic regression to case/control data to report SNPs with odds ratios
of significant magnitude. An alternate formulation is the liability threshold model, which assumes
case/control labels are sampled by thresholding a hidden quantitative polygenic risk score (PRS)
with linear effects over SNPs [56]. This view of GWAS underlies a large body of work in pre-
dicting risks of disease using PRSs [55, 57] as well as quantifying the variance explained of the
PRS [23, 58]. The logistic and liability models have been reported to be largely interchangeable by
transforming log odds ratios to effects on the liability scale [59] and produce similar estimates of
disease risk [28, 60]. Increasingly, there has been interest in advancing beyond these associations
towards obtaining a deeper understanding the mechanisms by which genomic factors influence
disease [53, 61]. These require models beyond simply combining linear effects of variants, as they
often modulate phenotypes indirectly, through the expression of other genes [13, 62].
One such avenue has concerned the apparent heterogeneity of diseases which has not been
sufficiently recognized by GWAS: while individuals in cohorts for these studies are frequently
classified simply as cases or controls, clinical evidence for several GWAS traits have suggested
that there are multiple different subtypes consisting of distinct sets of symptoms and association
with distinct rare risk alleles [63, 64]. For example, polygenic risk scores for major depressive
disorder explain more of the phenotypic variance when cases are partitioned into two known sub-
types (typical and atypical), and the two subtypes exhibit polygenicity with distinct traits [65].
Similarly, by separating bipolar disorder into its two known subtypes corresponding to manic and
hypomanic episodes, distinct polygenic risk scores comprising different associated SNPs are dis-
covered, with genetic correlation being significantly lower than when individuals are partitioned
otherwise, e.g. by batch. Additionally, only the manic subtype shares a high degree of pleiotropy
with schizophrenia [17]. Aside from psychiatric traits, heterogeneity of genomic associations be-
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tween known subtypes has been observed in diseases such as lupus [66], multiple sclerosis [67],
epilepsy [68], encephalopathy [69], and juvenile idiopathic arthritis [70]. Elucidating the nature of
heterogeneity in these traits may also play a role in addressing the missing heritability problem in
GWAS, as hidden heterogeneity reduces power to detect SNP associations [56].
Heterogeneity in disease etiology has also become a concern for clinical applications, as the
predictive accuracy of polygenic risk scores is known to vary across different demographics of
patients. As most genomic studies to date have been conducted on primarily Northern European
populations, accuracy of the discovered predictors, measured as R-squared, is lower in other pop-
ulations, raising the possibility of inequities in care by the direct application of these PRSs [71].
Even if these concerns are mitigated by future large studies conducted in under-served populations,
recent work has shown that PRS accuracy further varies across other covariates such as age and sex
[72]. Therefore, methods to develop population-differentiated PRSs and detect deficiencies in ex-
isting PRSs are urgently needed before predictive genomics can be widely integrated into precision
medicine.
To date there have been few strategies to identify subtypes in GWAS cohorts, largely due to
two challenges: the very small signals typically found in polygenic traits, and the presence of con-
founding sources of heterogeneity such as batch effects. One method [73] purports to discover
strong evidence of subtyping in schizophrenia by non-negative matrix factorization of the cohort
genotype data, interpreting the hidden factors as different subtypes. However, this work failed to
take into account alternative sources of heterogeneity, such as population stratification and linkage
disequilibrium, that might produce spurious results [74, 75]. Another method, reverse GWAS [76],
applies a Bayesian latent factor model to partition SNP effect sizes and individual membership into
a set of latent subtypes so that the likelihood of phenotype predictions within each subtype is max-
imized. The method is reported to detect subtypes that may be suggestive of clinical implications,
such as a possible differential effect of statins on blood glucose levels. However, this approach is
under-powered to detect heterogeneity in single phenotypes, and thus is intended for simultaneous
predictions across multiple observed phenotypes. Additionally, many of the reported phenotypes
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are quantitative, which allows for more accurate estimation of effect sizes, and thus more accurate
subtyping, than in case/control phenotypes. Therefore methods of this flavor may struggle to detect
subtypes among single case/control phenotypes, in which the quantitative liability score is hidden.
Within-phenotype heterogeneity has also surfaced as a possible confounding factor in the dis-
covery of pleiotropic associations between phenotypes [77]. Assuming a GWAS model of disease
risk, ideal pleiotropy would involve a single variant significantly associated with two observed
phenotypes, producing a genomic correlation between those phenotypes. However, the presence
of distinct subtypes in one or both phenotypes may alter the conclusions derived from pleiotropic
analysis. For example, two additional subtypes of depression have been characterized by either
episodic or persistent experiences of low mood. Of the two, the persistent subtype is more closely
associated with childhood maltreatment, and only in persistent cases is an association found be-
tween childhood maltreatment and a particular variant of the serotonin transporter gene [78, 79].
Misclassification is another possible source of heterogeneity leading to spurious pleiotropic rela-
tionships between phenotypes. For example, a significant percentage of patients diagnosed with
either bipolar disorder or schizophrenia have their diagnoses later corrected to reflect the other
disease [80]. As bipolar disease and schizophrenia are understood to be highly pleiotropic [57, 81,
82], these misclassifications have the potential to skew analyses of genetic correlation between the
two phenotypes.
Recent work by Han et al. [83] has sought to address the detection of heterogeneity specifically
in the context of pleiotropic phenotypes. The proposed method, BUHMBOX, operates on a matrix
comprising cases for one disease genotyped over the associated SNPs for a second disease. When
only a subset of cases are also cases for a second disease, individuals within that subset will exhibit
a slightly higher ascertainment for the risk alleles included in the matrix. In a non-heterogeneous
pleiotropic scenario, these risk alleles would instead be randomly distributed among all included
individuals rather than co-occurring in a subset. When multiple risk alleles are overrepresented
in a subset, they are positively correlated across all individuals in the matrix, and these positive
correlations serve as evidence of heterogeneity.
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We propose a generalized method called CLiP (Correlation of Liability Predictors) that lever-
ages these correlations more broadly to detect heterogeneity in single-trait GWAS, rather than
strictly in two labeled pleiotropic traits. In comparison to BUHMBOX, CLiP improves overall
power to detect heterogeneity while remaining robust to false positive confounding factors such
as ancestry. CLiP also detects heterogeneity arising from multiple subtypes with highly dissimi-
lar PRSs, which produce specific correlation patterns that attenuate positive heterogeneity signals.
These benefits, however, are contingent on the assumption that case/control GWAS behaves ac-
cording to a liability threshold model rather than a logistic model. Although these models are
commonly interpreted to be interchangeable [28], they produce differing SNP-SNP correlations
among cases, resulting in different heterogeneity scores.
The goals of this work are fourfold: First, we demonstrate that in a homogeneous (null) set of
cases in a case/control cohort, predictors with effect sizes of the same sign are not uncorrelated
as stated by Han et al. [83] but negatively correlated, and are expected to produce negative het-
erogeneity scores. However, the magnitude of the negative bias differs significantly depending on
whether the logistic or liability threshold model is assumed for polygenic traits. Second, we eval-
uate the power of CLiP across realistic GWAS scenarios, and demonstrate its utility by identifying
heterogeneity in schizophrenia. Third, we develop an extension of CLiP to accommodate param-
eters that are not binomial genotypes, but rather continuous predictors such as expression data,
which we term CLiP-X. Finally, we further extend CLiP to identify heterogeneous subgroups in
quantitative phenotypes, where no clear delineation between cases and controls exists, by weight-
ing correlations according to polygenic risk scores, which we term CLiP-Y.
3.4 Methods
In a case-control GWAS, a heterogeneous cohort of cases can be interpreted as comprising a
mixture of hidden case subtypes, each exhibiting an elevated risks of disease according to a unique
polygenic risk score. These subtype-specific PRSs are unobserved and may confound discovery
of case-control associations. We define two models for generating genotype matrices of heteroge-
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neous cohorts: First, misclassification, where ideally a subset of individuals are not really cases,
but have been rather labeled as such despite being controls. This may occur due to erroneous phe-
notyping, but it may also suggest distinct disease etiologies, some of which are not ascertained for
the PRS of interest. Second, a mixture of multiple unobserved sub-phenotypes which are all cap-
tured to some degree by the PRS of interest. An idealized example would involve SNPs of a PRS
divided between sub-types such that each SNP was truly associated with only one subtype, and no
SNP shared associations with multiple subtypes. A case is observed if the individual passes the
liability threshold of at least one of these sub-phenotype PRSs. Figure 3.1 displays idealized geno-
type matrices and correlation matrices for each of these models along with the homogeneous null
scenario, in which all cases are selected according to the same PRS. The column set ( comprises
associated SNPs reported in GWAS summary statistics, with the counted allele selected so that the
corresponding effect size is positive. As described in Results, associated SNPs participating in the
same PRS are negatively correlated over a set of cases selected according to that PRS (panel B).
When the cohort comprises both cases and misclassified controls, the pattern of ascertainment of
risk-alleles is consistent for particular individuals across all SNPs, resulting in positive correlations
between SNPs (panel D). Panel E depicts a mixture scenario with two hidden disjoint PRSs. In-
dividuals labeled as cases of the observed phenotype may be in reality a case for sub-phenotype 1
only (blue), sub-phenotype 2 only (orange), or both, whereas controls are observed as such (grey).
The presence of cases for multiple hidden sub-phenotypes produces a mixture of positively and
negatively correlated SNPs depending on the membership of the compared SNPs (panel G).
The goal of CLiP is to distinguish a heterogeneous cohort from one that comprises only ho-
mogeneous cases and controls for a single PRS. In the following sections, we first describe a
correction (CLiP) to current applications of heterogeneity scores [83], where we account for neg-
ative correlations expected of case/control data sampled from a liability threshold model. Next we
present adaptations of this general method to studies with quantitative predictors such as expres-
sion measurements rather than SNPs (CLiP-X), and also with quantitative phenotypes for which
there is no strict definition of a “case” (CLiP-Y). Additionally, we describe the generative process
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for simulations of homogeneous and heterogeneous PRS data used to test the performance of these
methods.
3.4.1 Regression models for case-control data
Here we describe three models characterizing risks of disease based on odds ratios or effects of
SNPs. We will demonstrate in the Results section that only in the Risch method is independence
of PRS SNPs preserved among cases, whereas both the logistic and liability threshold models
introduce correlations between these SNPs after ascertaining for disease status.
Multiplicative (Risch) model
The Risch model describes disease risk as a prior disease prevalence multiplied by a product
of relative risks corresponding to each risk factor. For " SNPs in a PRS with relative risks ''<
and constant , an individual with genotypes G has the following disease risk:




For our simulations with prevalence + = 0.01, we substitute odds ratios for relative risks.






] so that cases are sampled at the correct preva-
lence. If we assume all " SNPs have a constant odds ratio $' and allele frequency ?, then
 = +exp(−("?)2+(("?(1−?))2 (log$')+"?)2) . This generates the correct prevalence among randomly
sampled controls, whereas simply mean-centering the genotypes or estimating the denominator as
$'
∑
E[G<] may produce inflated prevalences depending on model parameters. Additional informa-
tion regarding estimation of  and appropriateness of substituting odds ratios for relative risks is
shown in the Supplementary Text.
Logistic regression
The logistic regression model describes the log odds of disease risk as a linear function over
" SNPs. Rearranging this function, the disease risk can be expressed as a sigmoid function over
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the log odds. The effects V< are interpreted as log$'< where $'< is the odds ratio of SNP <
with respect to disease H. To ensure the fraction of cases in a random sample equals the desired
prevalence + , the intercept term V0 is set to − log( 1+ − 1), and genotypes in - are mean-centered
to 0. For a particular individual G,
%(H = 1|G) = 1
1 + exp[−(V0 +
∑"
<=1 V< (G< − E[-<])
)] (3.2)
Liability threshold model
The liability threshold model assumes that case/control labels are assigned according to a hid-
den continuous liability score. Here V< no longer corresponds to an odds ratio, but rather an effect
size on the standard normal liability scale. The fraction of variance explained by the PRS -) V is
subtracted from the total variance 1. Individuals are assigned to cases if their liability scores pass
a threshold ) on the standard normal distribution. If Φ denotes the standard normal cumulative
distribution function, then ) is placed such that 1 − Φ()) equals the prevalence of the disease.
Likewise, for any individual G, the disease risk is denoted by the probability of surpassing ) given
that only the value of the PRS G) V is known.
%(H = 1|G) = Φ
(
(G − E[-])) V − )√
1 − Var(G) V)
)
(3.3)
We evaluated the existing BUHMBOX method in homogeneous and heterogeneous cohorts sim-
ulated from each of these GWAS models, with heterogeneous cases comprising a mixture of true
cases and controls.
3.4.2 CLiP: Correcting for negative correlation bias
A central assumption of the hypothesis test in Han et al. [83] is that SNPs conferring risk for
a disease are uncorrelated among cases for the disease as well as controls. However, the authors
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prove this for only a multiplicative binary model, in which an individual’s risk is the product of
odds ratios of probability of disease for associated SNPs. GWAS are commonly interpreted as
either a logistic or liability threshold model, both of which are generalized linear models with
similar S-shaped inverse link functions over a sum of SNP effects. Particularly in the liability
threshold model, the additive contribution of SNP effects to a thresholded score suggests that
among individuals ascertained on that thresholded score, there may be correlatedness between
those additive effects.
CLiP calculates the same heterogeneity score as previous work [83], but adjusts the null dis-
tribution to account for expected correlations between SNPs when the cohort is homogeneous and
generated from a liability threshold model. The test is performed over a genotype matrix - com-
prising # cases and " SNPs counting the number of risk-alleles, as well as a matrix of controls
-0 with #0 individuals. The SNPs included in - are typically those reported in summary statistics
at unique loci, and should be selected so that there is little LD between them and their correlation
among controls is near 0. Pairwise SNP correlations are calculated over cases and controls sepa-
rately and stored in ' and '0 respectively. These correlations are then compared against their null
expected values. If we interpret controls as population controls in that they are sampled from the
full liability distribution, then the expected correlation among controls E['0
9 :
] is always 0 as SNPs
are sampled independently. This modified heterogeneity score is computed as follows:



















where if ? 9 and W 9 are the allele frequency and odds ratio, respectively, for SNP 9 ,
F 9 =
√
? 9 (1 − ? 9 ) (W 9 − 1)
(W 9 − 1)? 9 + 1
(3.5)
The score (!8% is a weighted sum of differences in correlation between cases and controls,
to account for prior sources of SNP-SNP correlation such as ancestry. A high score resulting
31
from a bias towards positive correlations would suggest the presence of subtypes with differing
ascertainment for the included risk-alleles, and thus heterogeneity. The weights are intended to
adjust the score’s sensitivity to certain SNPs based on their allele frequency ? and odds ratio W,
with larger odds ratios and frequencies close to 0.5 producing greater weights. The BUHMBOX
score is shown by Han et al. [83] to be asymptotically standard normally distributed under the
null as sample sizes increase. CLiP modifies the score by shifting the expected null score from
0 to a negative value expected of homogeneous cases under the liability threshold model. This
amounts to subtracting a constant from the score, which does not change the variance, ensuring
(!8% remains a valid Z-score test.
The expected value of the correlation E[' 9 : ] between two SNPs - 9 and -: in homogeneous
cases can be calculated from the individual expectations comprising the correlation. We assume
the expected value among controls, E['0
9 :
], is zero, provided that the SNPs comprising the PRS
are not in LD.
' 9 : =
E[- 9-: ] − E[- 9 ]E[-: ]√
E[-2
9




] − E[-: ]2
(3.6)
We use Bayes theorem to calculate each of these expectations given the individuals are cases
(. = 1). This can be done efficiently over SNPs, which take on discrete values.
E[- 9 |Y=1] =
∑
9∈{0,1,2}
- 9 ?(- 9 |Y=1) =
∑
9∈{0,1,2} - 9%(Y=1|- 9 )%(- 9 )∑









%(Y=1|- 9 )%(- 9 )∑
9∈{0,1,2} %(Y=1|- 9 )%(- 9 )










:∈{0,1,2} - 9-:%(Y=1|- 9 , -: )%(- 9 , -: )∑
9∈{0,1,2}
∑
:∈{0,1,2} %(Y=1|- 9 , -: )%(- 9 , -: )
(3.7)
The case probabilities conditioned on SNP values %(Y=1|- 9 ) are calculated from the liability
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threshold model in equation 3.3. As SNP associations are typically reported as odds ratios cor-
responding to a logistic regression model, we convert these to effects on the liability scale using
equation 3.28 in the Methods section, based on Gillett et al. [59].
3.4.3 CLiP-X: Heterogeneity Detection with quantitative predictors
While heterogeneous subtypes may occur in transcriptome-wide association studies, the hetero-
geneity score cannot be computed directly over continuously distributed gene expression variables
rather than discrete SNPs. In CLiP, the weights F are important for scaling the contributions of
individual SNPs to the final heterogeneity Z-score, and they are dependent on risk-allele frequen-
cies and odds ratios, quantities not strictly defined for continuous variables. In the case of binary
variables, higher weights are assigned to SNPs with more extreme risk-allele frequencies as well
as effect sizes, as these variables are more likely to generate highly positive correlations in the
presence of heterogeneity. Here we generalize this weighting scheme to accommodate arbitrarily
distributed continuous input variables, which may be applied in particular to expression analyses.
3.4.4 CLiP-X Simulation Procedure
To fully simulate expression variables as modeled in transcriptome-wide association, expres-
sion predictors are generated from a linear model of randomly sampled genotypes, rather than
directly sampling expression. Although the input into CLiP-X includes only the expression vari-
ables, explicitly modeling the genotype layer allows for inclusion of prior correlations resulting
from SNPs associated with multiple transcripts, rather than from ascertainment by the liability
threshold model.
For a single case/control phenotype, transcript effect sizes U are fixed to a single value so
that the variance explained of all modeled transcripts is a desired value. Likewise, genotype-
transcript effect sizes V are also fixed so that variance explained of each transcript by genomic
variants is a second specified value. Although fixing effect sizes at the genotype-transcript layer
is admittedly unrealistic, the results are only simplified when these interactions are removed, with
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no interactions reducing to expression sampled from the standard normal distribution. Cases are
determined according to the liability threshold model. For individuals in transcript matrix / , a
hidden quantitative liability score . ∗ is calculated, with the variance of error n set so that . ∗ has
a total variance of 1. The observed case/control label . is set according to whether . ∗ passes the
liability scale threshold ) , which is placed on the standard normal distribution so that affected
individuals constitute a prevalence of 0.01.
. ∗ = /)U + n
. =

1 if . ∗ ≥ )
0 if . ∗ < )
(3.8)
To generate cases and controls, we iteratively generate batches of transcripts by random sam-
pling, and compile those that pass or fail the threshold cutoff into case and control cohorts. We
generate heterogeneous cohorts by concatenating simulated cases and controls, with the fraction
of cases set to 0.5 for simplicity. A full description of the simulation procedure is provided in the
Supplementary Material in section B.1 and illustrated in Figure B.15. Note that the variance of
the random noise n in equation 3.8 is determined by the desired total variance explained by the









Characterizing correlations between continuous variables
Given # × ! matrices of quantitative expression measurements / among cases and /0 among
controls, we would like to determine whether / comprises a homogeneous or heterogeneous set
of cases as generated in Algorithm B.1. When / is heterogeneous, we assume the individuals
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in / can be assigned to one of two subtypes: one sampled according to the liability threshold
model for the simulated phenotype, and one sampled randomly as controls. For a given predictor
indexed by 9 ∈ [1, . . . , !], assume /8 9 is sampled according to a mean and variance specific to the
subtype of individual 8, denoted by /+
8· for the case subtype and /
−
8· for the control subtype. The
distribution of the variables need not be discrete or even normally distributed, as the heterogeneity
score is computed from correlations, which in turn rely only on the mean and variance of the input
variables. Therefore the score can be calculated assuming any probability distribution provided
that the mean and standard deviation are obtainable. For an arbitrary probability distribution D
parameterized by its mean and standard deviation, we have:
-+· 9 ∼ D(`+9 , f+9 )
-−· 9 ∼ D(`−9 , f−9 )
(3.10)
Assume that the proportion of individuals belonging to the group − is c. For a homogeneous
group of cases, c = 0, and our simulations assume c = 0.5 for heterogeneous cases, but in practice
this proportion is unknown. Incorporating this proportion allows the redefinition of expectations
over the entire cohort as weighted sums of the expectations over the subgroups. The expected
correlation evaluated over the entire group can then be calculated according to within-group ex-
pectations:
A 9 : =
E[/ 9/: ] − E[/ 9 ]E[/: ]√















































































where Ac (G, H) = cG + (1 − c)H.
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Definition of weights for continuous variables
We would like to make use of these expectations over correlations by incorporating them as
weights in the heterogeneity score. As predictors with high mean differences between subgroups
and high effects are expected to contribute more signal to the score, weighting them higher than
other predictors will increase power to detect heterogeneity. Therefore, we would like to define a
set of weights F 9 : for each expected A 9 : .
We derive the weights for continuous variables in an analogous manner to Han et al. [83], by
taking the derivative of the expected sample correlation with respect to c at the null value, c = 0.















] in equation 3.11, we assume as in [83] that
within a subgroup of cases or controls, the correlation between any two predictors, even those
associated with the phenotype, is approximately zero. This allows us to express expectations of
products as products of expectations. Note that this does not mean that correlations over the entire
cohort E[/ 9/: ] are zero: these correlations are calculated inclusive of all subgroups, and their
nonzero correlations are what determines the heterogeneity score. While we demonstrate in the
Results that theoretically and by simulation this assumption is violated in logistic and liability
threshold models, we found it to be nevertheless a convenient method to estimate the weights F 9 : .
Given the assumption of no correlation within subgroups, the correlation between two variables
/· 9 and /·: can be expressed as the following. For further details on the derivation, please see the
Supplementary Material.






































The same weights defined in Han et al. [83] for Bernoulli variables is a special case of this
general formulation. These weights can now be substituted into the heterogeneity score.
Additionally, in practice we do not know the value of `+
9
because the membership of individuals
in each of the subsets is unknown. However, we do know the mean values of the heterogeneous
case group as a whole which we denote as ` 9 . We can use this value as an approximation for `+9 ,
and calculate an approximate weight:
F̂ 9 : =






We can also quantify the errors we are making by this approximation. We have the following
relationship for any distribution of the genotype random variables:







The approximation in Eq. 3.15 will attenuate the magnitude of `+
9
with respect to the true value



































As each weight is scaled by a constant factor, their relative magnitudes are unchanged. Conse-
quently, the heterogeneity score for continuous input variables does not change after this approxi-
mation. Thus we can still achieve optimal estimates of heterogeneity despite lacking access to the
true mean for the underlying case subgroup.
3.4.5 CLiP-Y: Heterogeneity Detection in Quantitative Phenotypes
The basic CLiP test for heterogeneity relies on differential enrichment of SNP effect sizes
or odds ratios across subtypes, and thus requires ascertainment for cases. But one can presume
that heterogeneity exists in quantitative phenotypes as well; e.g., are there distinct genetic mecha-
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nisms predisposing individuals to being tall? But extending this method to quantitative phenotypes
presents a challenge as there is no dichotomous delineation between cases and controls. A naive
solution may be to pick an arbitrary z-score as a threshold and denote samples who score higher as
“cases” and those lower as “controls.” This introduces a trade-off between sample size and signal
specificity, as lowering this threshold provides more samples for the correlation analysis but also
introduces more control-like samples which will attenuate SNP associations, and the correlations
themselves. A more principled method would allow for the inclusion of all continuous samples,
but give higher weight to those with large polygenic SNP scores. Thus we propose to score het-
erogeneity by a weighted correlation with phenotypes serving as a measure of the importance of a
sample in the case set. These weights determine the degree to which individuals count as a “case”,
and therefore their contribution to the total heterogeneity score of the genotype matrix. Artificially
creating the two groups by applying a hard threshold over the quantitative phenotype values is a
special case of this method with a step function as the weighting scheme, equally weighting all
individuals above the threshold “step.”
3.4.6 CLiP-Y Simulation Procedure
Here SNPs as input predictors are sampled directly from binomial distributions with fixed
minor allele frequency of 0.5. The quantitative phenotype . is calculated from the PRS score
with normally distributed noise added according to the desired PRS variance explained. As in
the CLiP-X simulation procedure, we generate heterogeneous cohorts by concatenating a subset
of cases and controls together into a single putative set of cases. For quantitative phenotypes,
the “control” subset is generated so that the quantitative phenotype value is simply sampled from
the normal distribution with zero PRS variance explained. A more detailed description of the
simulation procedure is provided in Algorithm B.2.
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Definition of individual weights by phenotype values
We define a weight over individuals based on phenotype such that those with higher weight
contribute more to the heterogeneity score. For a cohort of # individuals let -8 9 ∈ {0, 1, 2} be
the number of risk alleles of SNP 9 in individual 8, and let . = (H1, . . . , H# ) be values of the
quantitative trait. We introduce a normalized weight vector across the # individuals defined as
5 ∈ R# such that ∀8, q8 ≥ 0 and
∑#
8 q8 = 1. For an arbitrary function F , we define 5 ≡ 5(F ),
where the weight values would reflect normalized scaling of the trait q8 =
F (H8)∑
9 F (H 9 ) . Dichotomous,





Uniform weighting is obtained by F 1(H8) ≡ 1. To obtain the optimal weight function which most
clearly contrasts the scores of heterogeneous and homogeneous cohorts, we tested several possible
functions and also performed a local search over polynomials of degree 2, 4, and 6 by iteratively
updating and testing the performance of individual polynomial coefficients. This local search is
described in detail in Algorithm B.3. First, a small number of homogeneous and heterogeneous
cohorts are generated as described before. These serve as the training data by which the weight
function is optimized. All weight functions are applied over the raw phenotype values directly, or
their conversion to percentiles in the sample distribution, in the range [0,1]. After initially random-
izing a set of coefficients, at each iteration, a coefficient is randomly selected and incremented by
a random quantity sampled from a normal distribution. The resulting polynomial is tested against
the training data, and the change to the coefficient is kept if the difference in score between het-
erogeneous and homogeneous cohorts increases. After a set of high-performing weight functions
are selected, they are each evaluated against a larger sample of validation data comprising homo-
geneous and heterogeneous cohorts as before. Of these candidates, the polynomial that performs
best on the validation data is selected.
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Definition of weighted correlations
To compute correlations we define, for each SNP 9 , a random variable D5
9
with values in
{0, 1, 2} by sampling from the genotypes of the sample cohort -· 9 with probability equal to the
weight q8 assigned to each individual 8. Rather than calculate the correlations directly over SNPs
in - , we now calculate correlations over these random variables. We omit the superscript 5 in Dq
when it is clear from context. For a single SNP 9 , we define the weighted mean value across #
individuals as:




Between two SNPs 9 and : , we define the weighted covariance as:




q8 (G8 9 − E[D 9 ]) (G8: − E[D: ])
(3.19)





























The heterogeneity score tallies the entries of the upper-triangular correlation matrix for the
phenotype-weighted individuals '5(F ) . As we now lack a held-out set of controls to cancel the
contribution of correlations unrelated to the phenotype, we instead calculate a conventional corre-
lation uniformly weighted across all individuals '0 ≡ '5(F
1) . Additionally, we introduce a scaling
factor of
√
(∑#8=1 q28 ) − 1# to correct for the change in variance resulting from re-weighting the
correlation according to individual weights q8. These changes produce the following preliminary
40










(∑#8=1 q28 ) − 1# (3.21)
Lastly, we incorporate into the test statistic & a weighting scheme over SNPs as described in
Han et al. [83]. This second set of weights w ∈ R" is introduced to correct for larger contributions
to the score by SNPs with large effect sizes or risk allele frequencies close to 0.5. These weights







2 , the sample allele frequency weighted by the individual phenotype, as opposed





. The contribution of SNP 9 to the heterogeneity




































is a weighted generalization of an odds ratio. These weights are analogous to those found in Han et
al. [83], where given case allele frequency ?+
9
, control allele frequency ?0
9


















) (W 9 − 1)
((W 9 − 1)?09 + 1)
(3.24)
.
Combining these intermediate calculations, the heterogeneity test statistic for continuous phe-
notypes is:






























For high # , this test statistic approaches the standard normal distribution, and can be evaluated
as a z-score hypothesis test.
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Note that even when applying a dichotomous weighting scheme, dividing the cohort with quan-
titative phenotypes into artificial cases and controls, CLiP-Y still differs slightly from a direct ap-
plication of the case/control score. If a dichotomous weight function produces #q artificial cases,









#−# q instead of the slightly smaller
√
# q#
#+# q in the





these differently-weighted correlations are taken over a single cohort of individuals rather than
disjoint sets of cases and controls. In practice, we find this correction factor performs very well in
scaling the test statistic variance to 1.
3.4.7 Evaluating heterogeneity in SCZ
We applied CLiP to test for heterogeneity in case/control data for schizophrenia collected by
the Psychiatric Genomics Consortium (PGC). The data comprise in total roughly 23,000 cases
and 28,000 controls and was the subject of a 2014 meta-analysis reporting 108 schizophrenia-
associated loci [84]. These cohorts were collected largely from European populations in the United
Kingdom, Sweden, Finland, United States, Australia, and others, along with populations in Por-
tugal, Bulgaria, and Israel. Most cohorts were diagnosed with schizophrenia clinically according
to standards in DSM-IV. The average sex distribution of all cohorts is 60.4% male, with a min-
imum of 39.4% (dubl) and maximum of 91.8% (lacw). Sex information for the cohort s234 is
missing. Further information for each cohort can be found in Ripke et al. [84]. We would like to
test whether heterogeneity suggested from clinical observation is also detectable at the level of the
PRS comprising these loci. The PGC data is an aggregate of cohorts collected from many studies
conducted in different populations. Therefore a test for heterogeneity over the all cohorts is likely
to be confounded by ancestry stratification or batch effects between cohorts. We attempt to cir-
cumvent these confounding variables by applying GWAS meta-analysis methods to CLiP scores
evaluated over individual cohorts, as well as evaluating the p-value of the sum of all CLiP scores.
As the CLiP score of each cohort has a variance of 1 under the null, the distribution of their sum
has a standard deviation of
√
# if # is the number of cohorts in the sum. The expectation of the
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sum is the sum of the calculated expected values of each cohort. To evaluate the significance of





where  is the total number of cohorts and ?8 is the p-value of the CLiP heterogeneity score for
cohort 8. The p-value of this test statistic is evaluated on a chi-square distribution with 2 degrees
of freedom. Additionally, we calculated the meta-analysis Z-score of the CLiP score in a manner
analogous to the conventional GWAS approach, but with a 1-tail test for highly positive scores
only. The meta-analysis Z score is calculated according to








where /!8% is the CLiP Z-score evaluated against the expected score with a standard deviation
of 1, and =8 is the sample size of cohort 8.
While hidden batch effects may still be present in single cohorts, these effects are not expected
to bias heterogeneity scores to the same extent as scoring cases and controls combined across
all cohorts. By calculating the difference in summed correlations between cases and controls of
a single cohort, CLiP cancels the effect of confounding heterogeneity present in both cases and
controls provided that this heterogeneity is near-equally represented in both sets. Combining all
cohorts from different populations introduces more confounding heterogeneity into the analysis by
virtue of the increased diversity of the combined populations. Additionally, the differing sizes of
the cohorts ensures that the representation of populations differs between the cases and controls.
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3.4.8 Application to Genomic Data Sets
We applied CLiP to GWAS data from the PGC, phased and imputed using SHAPEIT [86] and
IMPUTE2 [87], a pipeline with similar or better accuracy compared to other tools according to a
recent evaluation [88]. Imputation was performed using the 1000Genomes Phase 3 reference panel.
Roughly half of the PGC cohorts were mapped with assembly NCBI36, and the SNP coordinates
of these data sets were converted to GRCh37 using the LiftOver tool in the UCSC genome browser
database [89]. Individuals were excluded from further analysis if their percentage of missing data
was greater than 0.1 in the 1 Mb region flanking each SNP. Additionally, of the 108 associated
SNPs and indels reported in Ripke et al. [84], three SNPs located on the X chromosome were
excluded, three were excluded because they are not listed in the 1000Genomes Phase 3 reference
panel, one was excluded due to low variance in many individual study cohorts, and one was ex-
cluded due to mismatching alleles between reported summary statistics and the reference panel,
for a total of 100 variants included in the heterogeneity analysis.
To accurately estimate expected heterogeneity scores, the odds ratios reported in Ripke et al.
[84] must be converted to effect sizes on the liability scale. We apply an approximate method
reported by Gillett et al. [59] to convert for variant 9 an odds ratio $' 9 to the liability effect V 9 :
V 9 ' Φ−1(!>68BC82 (log
+
1 −+ + log$' 9 )) −Φ
−1(+) (3.28)
where V is the disease prevalence (0.01 for schizophrenia), and !>68BC82 (G) = 11+exp(−G) .
We likewise ran SHAPEIT and IMPUTE2 with the 1000Genomes Phase 3 reference panel to
perform imputation of UK Biobank data. We obtained summary statistics for 119 associated SNPs
for the neuroticism sum-score from Nagel et al. [90], using a p-value cutoff of 1 × 10−8. Of these,
we were able to match 108 SNPs to the 1000 Genomes Phase 3 reference panel. We estimated the
variance explained of these SNPs with the sum-score to be 0.1 as reported in Supplementary Figure
19 in Nagel et al. [90]. Lastly, to speed up computation time, we estimated the expected CLiP-Y
score for homogeneous cohorts by simulating 400 cohorts of equivalent size to the neuroticism
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cohort in lieu of calculating the expected correlation for all pairs of SNPs, which requires numeric
integration. In Figure B.10A and Figure B.11A, mean scores obtained by sampling fit closely the
calculated expected scores across all weight functions over only 20 simulated trials for each set of
parameters.
3.5 Results
While the Introduction described previous methods to partition heterogeneous SNP effects or
cohorts into distinct clusters, the highly polygenic nature of most phenotypes renders these meth-
ods largely under-powered for single trait GWAS even when data sizes are large. CLiP serves as a
compromise on this task by providing a well-powered method to detect potentially disease-relevant
heterogeneity, without further decomposing detected signals into clusters. In this regard CLiP can
serve as an initial test to flag heterogeneous data sets for further study. CLiP increases power by ag-
gregating pairwise correlations between disease-associated SNPs from summary statistics. Figure
3.1 depicts genotype and SNP correlation matrices for cases in homogeneous and heterogeneous
scenarios. These scenarios are described further in the Methods section.
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Figure 3.1: Depictions of genotype matrices (A,C,F) and SNP correlation matrices (B,D,G)
expected of homogeneous and heterogeneous case cohorts. For homogeneous cases (A,B),
SNPs are uniformly ascertained, but negative correlations exist between any pair of associated
SNPs. For heterogeneous cases comprising a mixture of true cases and misclassified controls
(C,D), SNPs are ascertained in a subset of individuals, creating positive correlations between SNPs.
For heterogeneous cases comprising disjoint sub-phenotypes (E,F,G), associated SNP subsets (1
and (2 pertain to two independent PRSs, and passing the threshold of at least one of these PRSs is
sufficient to select a case (E). Genotypes sampled from this model produce a mixture of positive
and negative correlations.
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3.5.1 SNP-SNP correlations differ in logistic and liability threshold models
Both the logistic and liability threshold models are generalized linear models that transform a
linear predictor (the log-odds or the liability score) into a probability of assigning a binary label.
The models share highly similar inverse link functions (a sigmoid versus a normal CDF function),
and they are understood to produce regression coefficients that can be directly transformed from
one model to another by an invertible function (see Methods). However, we found in practice
that case/control genotype data simulated from a logistic model and its conversion into a liability
threshold model do not produce identical correlation patterns. To demonstrate this, we simulated
10 associated SNPs with allele frequency fixed to 0.5 and a disease prevalence of 0.01. The re-
sults of these tests are shown in Figure 3.2 as a function of increasing odds ratio. At low odds
ratios expected of GWAS, genotypes generated from a logistic model produce a largely equivalent
ascertainment for risk alleles as its converted liability threshold model, as measured by the mean
difference in effect allele count between cases and controls (Figure 3.2A). Likewise, sample preva-
lences of randomly sampled population controls from both methods are largely equivalent at low
odds ratios (Supplementary Text and Figure B.2). But over the same simulations the heterogene-
ity scores, produced by summing pairwise correlations between associated SNPs (see Methods),
become significantly more negative when simulating from a liability threshold model than from a
logistic model. The expected heterogeneity scores of homogeneous sets of cases generated from
logistic and liability threshold models are shown in Figure 3.2B. Expected scores in the logistic
model begin to deviate significantly from zero at an odds ratio of 1.3, larger than SNP effects
typically seen in polygenic traits. The sensitivity and specificity of heterogeneity detection by
correlations is therefore dependent on the selection of regression model. To further understand
the difference between these two models, we compared the standard normal liability distribution
against its equivalent in the logistic model, the derivative of the sigmoid function. These distri-
butions are shown in Figure 3.2C, in which we observe that the sigmoid derivative has a larger
variance than the standard normal distribution.
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Figure 3.2: Diverging correlation behavior of homogeneous cases generated from logistic and
liability threshold models. In all panels, performance of cases generated from a logistic model are
shown in cyan, whereas cases generated from a liability threshold model with equivalent properties
and converted effect sizes is shown in blue. (A) The mean difference in allele count between
homogeneous cases and controls in simulated cohorts from logistic models and their conversions
to liability threshold models. For each odds ratio, the equivalent per-SNP variance explained on the
liability scale is shown in parentheses. Homogeneous cases were generated with a prior prevalence
of 0.01 and 10 SNPs with allele frequency 0.5 and odds ratio specified on the x-axis. The mean
and standard deviation of 10 trials is plotted for each parameter set. For most of the range of
odds ratios expected in GWAS, these models behave identically. (B) Heterogeneity scores of the
same simulated cohorts in Panel A, with blue denoting the liability threshold model and cyan the
logistic model. For each model, a black dotted line denotes the expected value of the score based
on effect sizes and allele frequencies. While both models produce negative scores due to negative
correlations between SNPs in cases, the bias is notably less negative in the logistic model, and
within the range of values typical of complex traits, can be assumed to be close to 0. (C) The
liability (normal) distribution (blue) and the derivative of the sigmoid function (cyan).
To contrast the performance of the logistic model with the Risch model, in which SNPs are un-
correlated (see Methods), we simulated case/control cohorts from both models using the same odds
ratios, cohort sizes, and prevalence of 0.01. Heterogeneity scores from these simulated cohorts are
shown in Figure B.3 under large odds ratios of 1.2 (panel A) and smaller odds ratios of 1.06 (panel
B). Although both models are multiplicative over odds ratios, the resulting SNP-SNP correlations
among their respective cases differs. The Risch model guarantees independence between SNPs in
cases due to disease risk being a simple product of odds ratios, so homogeneous cases generated
from this model produce heterogeneity scores of 0 regardless of odds ratio magnitude, and het-
erogeneous cases produce highly positive scores. When generated by a logistic model, however,
homogeneous cases become significantly negative due to SNP-SNP anti-correlations, and positive
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scores of heterogeneous cases are similarly attenuated. But this behavior only occurs when odds
ratios are large, and for the majority of highly polygenic traits, the behavior of heterogeneity scores
does not differ appreciably from the Risch model, as shown in Figure B.3B.
3.5.2 CLiP: correction for negative correlation bias in the liability threshold model
To demonstrate the effects of correlated predictors on heterogeneity detection in the liability
threshold model, we evaluated CLiP and BUHMBOX scores on simulated homogeneous and het-
erogeneous cohorts. Simulation parameters were set to approximate those reported for schizophre-
nia in Ripke et al. [84]: genotypes over 100 associated SNPs were sampled according to a fixed
risk-allele frequency of ? = 0.2. Effect sizes were set to a fixed value to produce a desired vari-
ance explained of 0.034 in a standard normal PRS distribution. SNPs of control cohorts were
sampled independently according to population allele frequencies. Homogeneous case sets were
generated by repeatedly sampling controls and selecting individuals whose PRSs pass a thresh-
old corresponding to a prevalence of 0.01. Heterogeneous cohorts were created by combining an
equal number of homogeneous cases and controls. The scores of these cohorts were evaluated over
a range of sample sizes keeping variance explained constant at 0.034 (Figure 3.3A), and a range
of total variance explained values keeping the sample size constant at 30,000 cases and 30,000
controls (Figure 3.3B). Regardless of both parameters, heterogeneity scores of control populations
with independently sampled SNPs (black) follow a standard normal distribution centered at 0. Het-
erogeneous cohorts (green) exhibit ascertainment of PRS SNPs in one subset of individuals and
not the other, resulting in positive correlations between those SNPs taken over all individuals. The
weighted sum of these correlations then produces positive heterogeneity scores, which increase
when signals increase either by increasing the sample cohort size or the SNP variance explained.
Lastly, as these cohorts are simulated from a liability threshold model, homogeneous cases (red)
produce negative scores due to competing ascertainment between SNPs as described in the Sup-
plementary Material, and this negative bias likewise increases with increasing signal. Given only
knowledge of the SNP effect sizes, effect allele frequencies, and number of cases and controls, we
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can accurately predict the expected score of homogeneous cohorts (blue) at any cohort size and
variance explained.
Figure 3.3: CLiP performance on simulated control, homogeneous, and heterogeneous co-
horts generated with a liability threshold model. (A) Heterogeneity scores (y-axis) on simulated
case/control cohorts as a function of sample size (x-axis). Simulations are run with a PRS of 100
SNPs with total variance explained of 0.034. Heterogeneous cohorts (Green) are equal-proportion
mixtures of controls (Black) and homogeneous cases (Red). The expected homogeneous score
(Blue) is calculated from effect sizes and allele frequencies of PRS SNPs only, and should be used
as the true null score in CLiP. (B) Heterogeneity scores (y-axis) as a function of variance explained
(x-axis) with a fixed sample size of 30,000 cases and 30,000 controls. For each panel, the mean
and standard deviation of 20 trials is plotted.
Power calculations for these results are shown in B.1 Table. In Figure 3.3, we define a positive
result to be a true heterogeneous cohort passing a one-sided standard normal confidence interval
threshold of 95% given the null CLiP score of a liability threshold homogeneous case set. We
compare p-values assuming the liability threshold null given by CLiP and assuming a null value of
zero in conventional BUHMBOX. It is clear that correcting for the liability threshold null improves
power: for a fixed variance explained of 0.034, CLiP achieves a 99% sensitivity among 20 trials
with only 10,000 cases, whereas BUHMBOX requires 30,000 cases to achieve a 100% sensitivity.
Additionally, we tested the performance of CLiP with respect to the fraction of individuals in
the case mixture that are true cases, shown in Figure B.4 and Table B.2. Predictably, we found that
maximum power to detect heterogeneity was achieved with an even split between true and misclas-
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sified cases, maximizing the entropy. A high percentage representation of true cases decreases the
score to negative values, converging to that of homogeneous case sets, whereas a high percentage
representation of controls decreases the score to 0.
Lastly, CLiP is robust to confounding factors generating heterogeneity, provided that these
factors exhibit the same patterns in both cases and controls. In particular, ancestry is a source
of heterogeneity which must be accounted for in all cohorts. To demonstrate that CLiP is ro-
bust to background heterogeneity, we simulated case/control cohorts assuming that the population
comprises two ancestry subgroups. The set of simulated SNPs is subdivided so that within each
ancestry subgroup alternating halves of the SNPs are assigned effect allele frequencies of 0.5 + ?′
and 0.5 − ?′, with the value of ?′ set so that the BC among controls is a specified value. Controls
are sampled equally from the two subgroups, but cases are selected by thresholding sampled sets
of these controls and so are not guaranteed to contain equal subgroup representation. Performance
of CLiP in these simulations is shown in Figure B.5. We find that increasing the value of BC at-
tenuates the magnitudes of both homogeneous and heterogeneous case scores toward zero. While
power is largely unaffected, the greater concern is specificity, as the presence of these two sub-
groups creates an alternate heterogeneity signal from disease-related subtyping. In Figure B.5B,
we find that specificity over 20 trials remains at 0.8 for an BC of 0.05, with the performance of
trials with smaller BC values not differing appreciably from the expected homogeneous score. An
BC of 0.05 is double that observed between Finnish and Southern Italian populations, the largest
value among pair-wise comparisons of European populations [91]. We conclude that CLiP is ro-
bust for cohorts sampled within single well-defined populations, for which BC is expected to be far
smaller.
3.5.3 Heterogeneity by distinct subtypes
In contrast to heterogeneity created by subsets of misclassified cases, we also consider hetero-
geneity arising from multiple potentially independent sub-phenotypes, each with a distinct PRS,
such that an individual is considered to be a case when it is a case for one or more of these sub-
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phenotypes. Discovering heterogeneity in these cohorts is more challenging because correlations
between SNPs involved in different sub-phenotype PRSs may be negative as depicted in Figure
3.1G, reducing the heterogeneity score when summed. Additionally, while we depict misclassifi-
cation and subtyping as two distinct sources of heterogeneity, most phenotypes and case/control
cohorts will fall between these two extremes as PRSs exhibit different variances explained with
respect to different subtypes. We can interpret misclassification as a particular form of subtyping
in which one subgroup exhibits a very small variance explained with respect to known SNP asso-
ciations, as can occur when transferring PRSs between different populations or age or sex cohorts
[72]. We have modeled the spectrum between misclassification and subtyping in Figure 3.4A. As-
suming there exist two subtypes within a case set with associated SNP (1 and (2 and effect sizes V1
and V2 fixed across all SNPs, we keep V1 fixed to a positive value while varying the magnitude of
V2. When V2 is 0, the risk alleles of set (2 are not ascertained for any subgroup of cases, resulting
in small weight factors F and a negligible contribution to the CLiP score. The remaining SNPs
(1 then reduce to the misclassification scenario. As the magnitude of V2 increases, the subtyping
pattern approaches that depicted in Figure 3.1F.
We find in Figure 3.4B that both subtyping and misclassification produce score significantly
larger than that expected of a homogeneous case set in a liability threshold model, but also that
the raw score prior to correcting by the null expectation differs between the misclassification and
subtyping scenarios. Misclassification (V2 → 0) tends to produce highly positive scores, as all
ascertained SNPs are ascertained among one subgroup, and not ascertained in the other, producing
identical correlation patterns between all SNP pairs. In the subtyping scenario (V2 → V1), SNP
pairs within either (1 or (2 are positively correlated, but SNP pairs with one (1 SNP and one (2
SNP are negatively correlated, significantly attenuating the score. This pattern is also observed
in the logistic model in Figure 3.4C, but simulations approaching the subtyping extreme have
heterogeneity scores which converge to the null score near zero, indicating that under a logistic
model, subtyping is not detected as heterogeneity. The subtyping scores, however, do not converge
to zero in the liability threshold model but to a negative value. As SNPs in both (1 and (2 are
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slightly ascertained over the entire case set, a negative correlation bias in the liability model is still
observed in these SNPs, decreasing the score from zero.
Lastly, we tested the performance of CLiP in the subtyping scenario when associated SNPs are
subdivided amongst an increasing number of hidden subtypes. We tested the performance of CLiP
by fixing the number of cases and controls at 50,000 each, the total number of SNPs at 100, and the
total variance explained at 0.05, while varying the number of sub-phenotypes and the fraction of
SNPs that are shared across all sub-phenotypes. When this fraction is zero, the sub-phenotypes are
completely independent, and the SNPs are divided into mutually exclusive subsets associated with
each sub-phenotype. When the fraction is non-zero, that fraction of SNPs has the same effect size
across all sub-phenotypes. Results of these simulations are shown in Figure B.6 as well as Table
B.3. Note that by dividing associated SNPs into associations with particular sub-phenotypes, the
total variance explained for each sub-phenotype is reduced, and the observed variance explained
of the entire heterogeneous cohort will be lower in a simple linear regression.
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Figure 3.4: Performance of heterogeneous scores on case sets heterogeneous by misclassifi-
cation and by subtype. While misclassification and subtyping represent two alternate etiologies
for observed heterogeneity, most real case sets likely fall between these two extremes. (A) Given
two subtypes (1 and (2 with fixed subtype-specific SNP effect sizes V1 and V2, as well as cases
belonging to each, a spectrum can be drawn over increasing variance explained of one of the sub-
types. When V2 is zero, the SNPs in (2 do not contribute to the PRS of any subset of cases and
so the heterogeneity score is driven by the set (1, mimicking the misclassification scenario. As
V2 increases in magnitude, two distinct subtypes are formed. (B) Heterogeneity scores (green) of
cohorts simulated from a liability threshold model according to the subtype pattern depicted in A,
with equal proportion of cases generated from each subtype. The x-axis represents the liability
variance explained by SNPs in (2 as a fraction of the variance explained by SNPs in (1.
The blue line depicts the expected score of homogeneous cases under the liability threshold model,
absent distinct subtypes. All scores of the simulated heterogeneous cohorts are significantly larger
than the null value, indicating heterogeneity is detectable at both extremes, but the raw value of the
score in cases is highly positive under the misclassification scenario and slightly negative under
subtyping. (C) The same experiment in B but generated from a logistic model with (1 odds ratio
set to 1.06, and (2 odds ratio set to a fraction of that value denoted on the x-axis. Without the high
negative correlation bias present in the liability threshold model, the subtyping scenario under the
logistic model produces heterogeneity scores near 0 and so cannot be detected.
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3.5.4 CLiP-Y: Quantitative Phenotypes
To demonstrate heterogeneity detection in quantitative phenotypes, we simulated homogeneous
cohorts by sampling phenotypes from the true PRS-dependent distribution . ∼ # (-V, 1 − ℎ2
(#%
),
and we simulated heterogeneous cohorts by combining equal-sized samples from the true dis-
tribution and from a PRS-independent standard normal distribution. In lieu of scoring the differ-
ence between case and control correlations, CLiP-Y scores a weighted correlation with phenotype-
dependent function q(. ) against a conventional unweighted correlation over the same individuals.
In practice, we found evaluating a given choice of q over phenotypes converted to percentiles
improved performance for all learned weight functions, possibly because percentiles limit the do-
main of the phenotype over which the weight function must be positive, reducing the contribution
to the score calculation by extreme PRS values. In addition to testing pre-selected functions for
q, we performed a local search over polynomials of increasing degree (see Methods), finding the
optimal polynomial functions shown in Figure 3.5A. All polynomial functions converged to highly
similar concave functions. This is due to the balancing effect of the normalization factor on the
sum of correlations: while correlations of PRSs at the high end of the distribution are more ex-
treme because these individuals more closely resemble “cases,” a high weight value at the higher
end of the PRS spectrum means that the normalization factor also shrinks the magnitude of the
score. To demonstrate that optimal weight functions are concave functions over the range of PRS
percentiles, we tested weight functions that sum up two indicator functions scanning across the
range of percentiles in [0, 1], one increasing, for an interval ending at 1, and another decreasing,
for an interval ending at 0, and evaluated heterogeneity detection performance as shown in Figure
B.7. The best performing functions are those where the increasing function threshold is near but
not at 0, and the decreasing function threshold is near but not at 1, producing a function similar to
the concave polynomials found in Figure 3.5A.
In the absence of a method for scoring continuous phenotypes, a naive approach using con-
ventional case/control heterogeneity scoring would involve setting an arbitrary threshold in the
distribution of phenotypes by which to partition the cohort from a continuous phenotype into cases
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and controls. This is equivalent to applying a step weight function over the phenotypes. We com-
pare our continuous heterogeneity test to thresholds at various phenotype percentiles. CLiP-Y
scores using a step weight function are calculated on simulated data over varying sample sizes and
values of variance explained, shown in Figure B.8 and Figure B.9. Both the continuous hetero-
geneity test and the arbitrary threshold tests are standard normally distributed in the null scenario,
when no heterogeneity is present.
We evaluated the performance of our polynomial weight functions against the step function and
other weight functions by the difference between the CLiP-Y score of simulated heterogeneous co-
horts and the calculated expected homogeneous score. A derivation for the expected score is shown
in the Supplementary Text, and comparisons with randomly sampled cohorts are shown in Figure
B.10A and Figure B.11A. The mean scores over 20 trials conducted in 100,000 cases and 100,000
controls are shown in Figure 3.5B, as a function of variance of the quantitative trait explained by
SNPs. We observe that the sigmoid function, a smoothed step function, slightly outperforms the
step function, whereas a linear function and − log(1 − G), intended to assign large weights to the
positive extreme of the phenotype distribution, both underperform. The three learned polynomial
functions perform similarly and significantly outperform all manually selected functions.
The same relative performance of the weight functions is observed when tested against an
increasing cohort size with a fixed variance explained of 0.1, shown in the left plot of Figure
3.5C. For comparison, the right plot shows CLiP-Y scores on the same scale for step functions
with thresholds set at different percentiles of the phenotype distribution and simulated in cohorts
of 100,000 cases and 100,000 controls. Note that as expected, the best performing percentile
threshold is some intermediate rather than extreme value.
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Figure 3.5: CLiP-Y performance on simulated cohorts with a quantitative phenotype. (A)
Learned weight functions q(G) for scoring heterogeneity in quantitative phenotypes. A local
search over polynomial coefficients is performed such that the resulting function maximizes the
difference between the CLiP-Y scores of simulated samples of homogeneous and heterogeneous
cohorts. These functions are fixed for all subsequent tests. (B) Tests for heterogeneity in quantita-
tive phenotypes using multiple weighting functions over individuals, including those in panel A, as
a function of variance explained by the PRS. Plotted are mean scores of simulated heterogeneous
cohorts over 20 trials minus the expected score of a homogeneous cohort. One Hundred SNPs are
simulated with cohorts of 100,000 cases and 100,000 controls. (C) The left panel depicts the same
simulations in B, but over varying sample size with a fixed variance explained of 0.1. For compar-
ison these scores are plotted on the same Y-axis as scores generated from step function weights at
various thresholds on the percentile scale of a standard normal quantitative phenotype distribution.
For each of these step function scores, the expected homogeneous score is estimated by the mean
of 20 sampled homogeneous cohorts, to limit computation time.
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3.5.5 CLiP-X: Quantitative Predictors
CLiP-X performs heterogeneity detection in case/control liability threshold models with quan-
titative predictors. While the identity of these predictors may be arbitrary, we consider in particular
the application of CLiP-X to Transcriptome-Wide Association Studies (TWAS), in which imputed
gene expression variables are tested for association with disease status [30, 31]. In a cohort with
observed genotypes  and gene expression / , TWAS performs association tests to estimate SNP-
gene effect sizes V. In a larger genotype cohort ′, gene expression is then imputed by /′ = ′V
and used to estimate gene-trait effect sizes U. The effect sizes U are interpreted as the fraction of
SNP variance mediated by the involved genes. CLiP-X tests for heterogeneity among these quan-
titative gene-trait associations. In our simulations, we allow for correlations between genes due to
shared SNP effects. To model this, we generate gene expression variables as linear functions over
a common set of SNPs along with normally distributed error, with a specified SNP-gene variance
explained.
To demonstrate the performance of CLiP-X in case/control cohorts with continuous predictors
instead of binomial SNPs, we simulated quantitative expression data by first sampling 100 SNPs,
and then sampling 10 normally-distributed expression variables as linear functions of these SNPs
with variance explained +2

set to 0.1 for each gene (see Methods). These 10 genes determine
simulated individuals’ case/control disease status according to a liability threshold model with
variance explained +2

. This simulation scenario mimics a transcriptome-wide association study,
but we additionally allow for the inclusion of a high frequency of trans-effects by generating all
simulated genes from the same 100 SNPs, and correct for the resulting confounding correlations
between genes. We ran 20 trials across a range of sample sizes and total trait variance explained by
expression +2

, to evaluate the performance of the continuous variable test statistic in true hetero-
geneous cases, homogeneous cases, and independently sampled controls. The results are presented
in Figure 3.6 and Figure B.12.
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Figure 3.6: CLiP-X performance on simulated control, homogeneous, and heterogeneous co-
horts with quantitative predictors. Controls (black) have no criteria for selection placed on their
generated quantitative predictors; homogeneous cases (red) are selected according to a liability
threshold over predictors; and heterogeneous cases (green) are an even combination of controls
and homogeneous cases. The blue line indicates expected mean scores of homogeneous cohorts
calculated from summary statistics of the quantitative predictors. As with discrete SNPs, quantita-
tive predictors are negatively correlated among homogeneous cases.
We observe that for all sample sizes, the heterogeneity score is approximately distributed with
mean 0 and standard deviation 1 in control cohorts. As predicted, the homogeneous case group
exhibits highly negative correlations between associated SNPs, and the resulting CLiP-X score can
be accurately estimated from expected correlations (blue) using knowledge of summary statistics
only. Additionally, because the input predictors of CLiP-X are normally distributed, we can con-
firm by Fisher’s transformation that sample correlations between predictors exhibit the expected
variance around the calculated null score, indicating the null score accurately estimates the true
expected correlation (Figure B.13). This estimate should serve as the null when evaluating GWAS
cohorts in practice, when a truly homogeneous cohort is not available. By comparison to this true
null, many more heterogeneous cohorts are detectable which would not have passed a significance
threshold with the null centered at 0, especially those with sample sizes of less than 10,000 cases.
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3.5.6 Application to Schizophrenia and Neuroticism
To evaluate the performance of CLiP on real genomic data sets, we tested for the presence of
heterogeneity in case/control cohorts collected by the Psychiatric Genomics Consortium (PGC) for
schizophrenia, from which 108 associated loci were discovered by GWAS [84]. After transform-
ing these known effect sizes to the liability scale and excluding 8 SNPs from further study (see
Methods), the total variance explained by the remaining 100 genome-wide significant SNPs was
approximately 0.027, suitably close to the 0.034 SNP variance explained reported in Ripke et al.
[84] when accounting for removed SNPs. We calculated heterogeneity scores for cases and con-
trols over individual cohorts, shown in Figure 3.7, as well as meta-analysis scores over all cohorts
as described in the Methods, shown in Table 3.1. Generally, we observe more positive heterogene-
ity scores for larger cohorts, though few pass a significance p-value threshold of 0.05. The scores in
Table 3.1 are organized by ascending p-value, and a Benjamini-Hochberg procedure is conducted
with a false-discovery rate of 13 . Cohorts with p-values lower than the critical values determined by
this FDR are separated by a dashed line. On an individual basis the vast majority of these cohorts
are too small to be conclusively tested for heterogeneity, as the sample variances of correlations
between SNPs is high. By performing a single test over all cases and controls combined, we ob-
tain a significant p-value of 8.54 × 10−4, though some heterogeneity may be contributed by batch
effects. By summing scores across cohorts, we obtain a larger but still significant p-value of 0.011,
suggesting that while batch effects contribute to detected heterogeneity, they do not completely
account for all heterogeneity observed in the data. Lastly, by applying meta-analysis methods over
individual cohort scores, we obtain a Fisher’s j2 p-value of 0.030, and a Z-score of 2.03, also
supporting the presence of a significant heterogeneity signal.
To investigate the potential contribution of demographics to observed heterogeneity, we in-
ferred ancestry subgroups of the largest four case/control cohorts in the PGC data set (clm2, clo3,
s234, and boco) and scored cases and controls belonging to each subgroup individually. Ancestry
inference was performed using fastStructure [92] with the total number of subgroups set to 2, 3,
and 4. Generally, we found that the heterogeneity scores of these subgroups were not consistently
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smaller than the score of the entire cohorts, suggesting that the source of observed heterogeneity
in these cohorts is not attributable to ancestry. The results of these tests plotted against the size
of the subgroups and whole cohorts are shown in Figure B.14. Unfortunately, the same analysis
could not be performed for sex as among the four largest cohorts, sex information was unavailable
for the cohort s234 and significantly imbalanced toward males in clm2.
Figure 3.7: CLiP heterogeneity scores evaluated over single cohorts in the PGC schizophrenia
data set, plotted by the number of genotyped cases. The black line denotes the expected score
given summary statistics reported for schizophrenia and sample sizes specific to each cohort, and
colored lines denote z-score thresholds corresponding to particular p-values of significance.
We also applied CLiP-Y to test for heterogeneity in neuroticism in a sample of 10719 individ-
uals from the UK Biobank [6, 34]. Participants are predominantly of Northern European ancestry
residing in the United Kingdom. Neuroticism was scored by the UK Biobank according to the
revised short form of the Eysenck personality questionnaire [93]. The quantitative phenotype to
be evaluated for heterogeneity is the number of yes responses in the 12 questions of the form.
Heterogeneity was evaluated in CLiP-Y using all learned polynomial weight functions over the
neuroticism score distribution, along with the 0.5 percentile step function representing a balanced
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Cohort Num Cases/Conts CLiP Score Expected Score p-value FDR critical val
clm2 3466/4297 1.42 -0.77 0.014 (0.078) 0.010
gras 1077/1226 1.55 -0.42 0.025 (0.061) 0.020
zhh1* 191/190 1.79 -0.17 0.025 (0.036) 0.029
s234 2076/2341 1.23 -0.57 0.036 (0.110) 0.039
pews 150/236 1.45 -0.16 0.054 (0.074) 0.049
boco 1847/2169 1.05 -0.55 0.056 (0.148) 0.059
cou3 539/692 1.14 -0.31 0.073 (0.127) 0.069
pewb 640/1892 0.60 -0.38 0.163 (0.273) 0.078
clo3 2150/2083 0.16 -0.57 0.233 (0.438) 0.088
lie2 137/268 0.56 -0.17 0.234 (0.287) 0.098
msaf 327/139 0.53 -0.17 0.241 (0.297) 0.108
umeb 375/584 0.30 -0.26 0.286 (0.382) 0.118
munc 437/351 0.30 -0.24 0.294 (0.383) 0.127
caws* 424/305 0.27 -0.23 0.307 (0.392) 0.137
buls 195/608 0.22 -0.21 0.332 (0.412) 0.147
swe6 1093/1217 -0.04 -0.42 0.352 (0.515) 0.157
irwt 1307/1022 -0.04 -0.41 0.357 (0.518) 0.167
top8 377/403 -0.02 -0.24 0.414 (0.508) 0.176
asrb 509/310 -0.05 -0.24 0.426 (0.522) 0.186
ersw 322/332 -0.04 -0.23 0.428 (0.517) 0.196
lacw 157/466 -0.05 -0.19 0.445 (0.521) 0.206
cims 71/69 -0.01 -0.10 0.463 (0.504) 0.216
aber 720/699 -0.32 -0.33 0.497 (0.626) 0.225
lie5 506/387 -0.28 -0.25 0.510 (0.609) 0.235
umes 197/713 -0.31 -0.21 0.539 (0.622) 0.245
uclo* 521/494 -0.37 -0.27 0.540 (0.646) 0.255
dubl 272/860 -0.41 -0.25 0.562 (0.659) 0.265
swe1 221/214 -0.35 -0.18 0.567 (0.638) 0.274
ajsz 895/1593 -0.59 -0.41 0.572 (0.722) 0.284
denm 492/458 -0.83 -0.27 0.713 (0.796) 0.294
port* 346/216 -0.97 -0.20 0.781 (0.834) 0.304
cati 407/391 -1.32 -0.24 0.860 (0.907) 0.314
edin 368/284 -1.60 -0.22 0.916 (0.946) 0.323
ucla 705/637 -1.75 -0.32 0.925 (0.960) 0.333
All 23517/28146 1.20 -1.93 8.54e-4 (0.114)
Table 3.1: CLiP heterogeneity scores for PGC schizophrenia cohorts and their combination.
Cohorts with an asterisk have had a SNP excluded which has zero variance within either the case
or control cohort, which would result in an undefined correlation. P-values of scores using the
liability threshold null (CLiP) are shown along with p-values using a null of zero (BUHMBOX) in
parentheses. An FDR of 13 was used for Benjamini-Hochberg analysis.
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pseudo-case/control split. We also tested subsets of the cohort by sex and by known neuroticism
subcluster to investigate whether these partitions were responsible for any observed heterogeneity
signal. The known subclusters of neuroticism are each obtained by scoring a subset of 4 out of 12
questions on the Esenck short form. These are reported in [90] along with their relevant survey
questions to be “Depression” (“lonely”, “miserable”, “mood up/down”, and “fed-up”) and “Worry”
(“worrier”, “nerves”, “nervous person”, “tense/high-strung”). Individuals were included in these
subclusters if they answered “yes” for at least 3 out of 4 questions, and their full 12-question sum-
scores were evaluated as before. Results from these tests are shown in Table 3.2. As described
in the Methods, to save on computation time the expected scores for each test were calculated by
averaging the CLiP-Y scores of 400 simulated cohorts with independently sampled SNPs given
the input summary statistics. We found that CLiP-Y scores for the entire cohort indicated signif-
icant heterogeneity across all tested weight functions, with p-values ranging from 1.68 × 10−9 to
8.45 × 10−11. As expected, all polynomial functions performed similarly, so only the degree-6
polynomial was applied to further analyses. After partitioning by sex and neuroticism subcluster,
we obtained scores which no longer passed a p-value threshold of 0.01 for heterogeneity: a value
of .0165 in males, and .0249 in the “Worry” subcluster. However, from simulation results in Figure
3.5C, we also know that the magnitude of heterogeneity scores is sensitive to cohort sample size
and decreases for small sizes. To account for this scenario, for each sex or subcluster partition we
calculated the average heterogeneity score of an equivalently-sized random sample of the entire
cohort. The difference between the CLiP-Y scores of the partitions and these random samples is
not statistically significant, indicating that the lower scores are indeed due to smaller sample size.
Therefore the observed heterogeneity in neuroticism is not primarily driven by these variables, and
further investigation is needed to identify these sources of heterogeneity.
3.6 Discussion
We present a general framework for identifying hidden heterogeneity among cases given only
genotype and phenotype data for a single disease, while being robust to confounding heterogeneity
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Cohort Num Indivs Weight Fcn CLiP-Y Score Expected Score p-value subsample mean(std)
all 10719 poly deg-6 -1.967 -7.880 1.68E-09
10719 poly deg-4 -2.138 -8.474 1.17E-10
10719 poly deg-2 -2.155 -8.542 8.45E-11
10719 step 0.827 -5.368 2.92E-10
Males only 4949 poly deg-6 -3.401 -5.534 1.65E-02 -2.189 (0.955)
Females only 5770 poly deg-6 -0.702 -5.974 6.75E-08 -2.008 (0.961)
Depressed subcluster 3037 poly deg-6 -1.440 -4.884 2.86E-04 -2.552 (1.107)
Worry subcluster 1815 poly deg-6 -2.621 -4.583 2.49E-02 -2.887 (1.242)
Table 3.2: CLiP-Y heterogeneity scores for neuroticism and sub-clusters in the UK Biobank.
Significant heterogeneity was detected in the cohort across all weight functions. When scoring
partitions of the data by sex and by known neuroticism subtype, lower scores are observed, but
these scores are not significantly distinct from random samples of the cohort of equivalent size
(“subsample mean(std)”), indicating that the observed heterogeneity cannot be primarily attributed
to these variables.
from sources such as ancestry. We derive modified test statistics to account for non-genotype input
variables such as expression data, which may be continuous and exhibit confounding correlations
in controls due to shared eQTLs. Additionally, we allow for heterogeneity to be scored in quanti-
tative phenotypes that lack a clear distinction between cases and controls which would facilitate a
simple dichotomous contrast of correlation patterns.
In addition to detecting heterogeneity, we describe an informal method to discern between
heterogeneity arising from misclassification, in which a significant subset of cases do not exhibit
elevated risk with respect to the PRS, and subtyping, in which the PRS comprises hidden sub-
PRSs with distinct effect sizes and ascertained individuals. Prior to correction by the control score,
misclassification produces highly positive scores, whereas subtyping produces negative scores in
the liability threshold model and scores near zero in the logistic model (and are thus undetectable).
However, the magnitude of the heterogeneity score itself is highly dependent on many variables
including sample size, number of SNPs in the PRS, and the magnitude and distribution of effect
sizes, and this precludes us from devising a more formal test for one or the other heterogeneity
scenario.
Our analysis of SNP correlations among cases also reveals a distinction between the logistic
and liability threshold models which until now has been unreported. Wray and Goddard [28] report
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that when considering both the estimation of individual risk and the magnitude of effect sizes, the
logistic and liability models are interchangeable for practical use despite small discrepancies such
as the significance of disease prevalence. But as we show in Figure 3.2, for the same set of simula-
tions, the effect sizes themselves may be highly similar while correlations between SNPs in cases
sampled from each of these models differ widely. The magnitude and sign of these correlations
depend on the magnitudes and signs of the effect sizes of the SNP pair (see Supplementary Text),
which may impede their discovery: due to high polygenicity, individual correlations are small, and
if effect sizes are a mixture of positive and negative values with mean 0, then the mean correlation
over all pairs of SNPs will likewise be 0. But when all SNP effects are set to be positive, the sum
of all pair-wise correlations among homogeneous cases does differ significantly from the stan-
dard normal distribution centered at 0. When scoring heterogeneity, do we then adopt the liability
threshold model to explain case/control GWAS (CLiP), or do we adopt the logistic regression
model (BUHMBOX)? There are reasons to assume that the liability threshold model is a better
reflection of the underlying etiology. First, the logistic model is itself a threshold model in the
space of log odds ratios, with the overall PRS distribution defined by the derivative of the sigmoid
function. However, given the central limit theorem, we would expect the PRS distribution to tend
toward normality rather than this derivative (see Supplementary Text for discussion on the nor-
mality of PRSs). Additionally, while correlations between SNP pairs are likely too small to detect
with confidence, there has been evidence to suggest that entire PRSs are negatively correlated with
rare variants. Bergen et al. [94] report that among cases for schizophrenia, individuals possessing
rare copy number variants of large effect tend to have lower PRSs over common alleles, a negative
correlation. The authors propose that increased risk from rare CNVs decreases the required risk
load of the PRS, and that this implies both CNVs and common alleles participate in a single addi-
tive liability threshold model. Martin et al. [95] report the same relationship between rare CNVs
and PRSs in Attention-Deficit/Hyperactivity Disorder. As the variance explained of rare variants
and entire PRSs is larger, we would expect negative correlations to be easier to detect at current
sample sizes. In practice however, no cohort can be expected to be truly homogeneous: sam-
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pling differences between cases and controls may produce unequal representation of demographic
variables or a difference in residual LD after filtering for uncorrelated loci, resulting in slight het-
erogeneous signals. For these reasons we recommend interpreting the respective null scores of
CLiP and BUHMBOX as lower and upper bounds on the score expected of a homogeneous cohort
with the given PRS parameters.
We caution against attributing detected heterogeneity directly to the underlying disease eti-
ology. The source of heterogeneity may instead be due to issues such as batch effects arising
from data collection or stratification of the PRS across demographic features such as age or sex.
Depending on the degree to which these features are known, they can be ruled out as primary con-
tributors to detected heterogeneity by separately scoring subsets of the data partitioned on these
features, though this requires data sets large enough post-partition. Detecting heterogeneity due to
demographic variables may be of interest itself in certain applications, such as evaluating the per-
formance of PRSs for scoring disease risk when applied across diverse populations. While CLiP
does not positively determine the source of heterogeneity within a data set, it serves as a lightweight
method to screen for the presence of heterogeneity and a starting point for further investigation.
Lastly, the real data results presented in this manuscript only consider PRS based on SNPs
whose association signals are genome-wide significant. This removes concerns of false positive
associations within the PRS. PRS constructions that do include lower-significance SNPs explain
more heritability, and are an attractive next challenge for finding heterogeneity signals. Aside for
the statistical challenge, this future work would require handling much larger sets of SNPs, and
therefore larger matrices of correlations.
We envision CLiP as a method to quickly screen many polygenic risk scores for heterogene-
ity and flag particular traits for further investigation, either as a way to further elucidate poten-
tial subtype-specific etiologies, or to detect unwanted transferability issues across different demo-
graphic groups. At the grander scheme of human genetics, generalized testing for heterogeneity
paves the way for recovering additional layers of the network of effects that explain traits by inter-
acting genetic and other factors. Going beyond the first-order, linear approximation of these effects
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holds the promise of better explaining mechanisms beyond identification of their contributing input
factors.
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Chapter 4: Identifying Polygenic Risk Score subtypes by contrastive tensor
decomposition of Bayesian mixture models
This work was co-authored with Itsik Pe’er and has not yet been published.
4.1 Abstract
Many phenotypes studied in GWAS are suspected to comprise subtypes with distinct genomic
risk factors. However, unsupervised methods to detect these subtypes must avoid detecting sig-
nificant stratification from non-phenotypic sources such as ancestry. We propose a contrastive
binomial mixture model to identify clusters in single-trait genotype cohorts which are present
in cases but not controls. We demonstrate in simulations that this method successfully separates
disease-relevant subtypes from background heterogeneity at variances explained typical of GWAS.
We present preliminary results on schizophrenia cohorts from the Psychiatric Genomics Consor-
tium and discover subtypes in cases with variance components orthogonal to principal components
of controls. Discovered subtypes are significantly and positively correlated across independently-
analyzed cohorts (p-value = 3.75 × 10−5), suggesting the possible recovery of common disease-
relevant signals.
4.2 Introduction
In the previous chapter, we described existing methods to characterize distinct sub-types within
PRSs and their challenges in detecting signals due to high polygenicity. While CLiP represents
a trade-off to boost signals by only detecting heterogeneity instead of decomposing the specific
clusters comprising that heterogeneity, we also developed a method to partition SNP effects and
individuals into defined subtypes. Like in CLiP, we consider genotypes of only a selection of SNPs
68
reported in summary statistics to be significantly associated with disease status.
First, we reinterpret the regression problem as a binomial mixture model: every subtype has its
own set of independent binomial parameters, namely, a risk allele frequency for each SNP. As a
nonzero effect size arises from a difference in ascertainment of this risk allele between cases and
controls, a difference in allele frequency between hidden subtypes can also be interpreted as an
effect size between those subtypes. While a binomial mixture model has been proposed before to
identify heterogeneity in GWAS [96] [97], previous methods test for heterogeneity in only single
SNPs during the discovery phase of GWAS, a process subject to a high number of false positive
results. In contrast, we identify multi-SNP clusters spanning the set of previously identified SNP
associations, a strategy more likely to identify etiologically relevant subtypes.
A mixture model alone is not sufficient to discover heterogeneity attributable to disease eti-
ology, as much larger signals are present in all human cohorts due to ancestry stratification, the
likely source of unexpectedly high variance explained decompositions found in Arnedo et al. [73].
Therefore, our objective is to infer clusters in case cohorts for a disease which are distinct from
clusters found in controls, given the admittedly imperfect assumption that population structure in
both cases and controls is largely identical. Our approach relies on work in contrastive spectral
methods by Zou et al. (2013) [20]. The authors describe a reinterpretation of the inference pro-
cesses of many Bayesian mixture models as method of moments-like decompositions of second
and third order tensor moments of the data, with examples provided of latent Dirichlet allocation
and hidden Markov models. While this approach has been underutilized in genomics applications,
an extension of this method to contrastive PCA [98] demonstrates the utility of this method for
identifying meaningful principal components representing features in foreground images and not
background images, as well as ancestry clusters unique to particular genomic cohorts. We adapt the
contrastive decomposition to identify subtypes in genomic data by recasting the regression prob-
lem as a binomial mixture model over independent SNPs known to be associated from summary
statistics. We then identify mixtures unique to cases and not controls.
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4.3 Methods
Figure 4.1: Binomial mixture model with allele frequencies c and subtype mixture probabilities [.
The input into our method is the same as in CLiP: case/control genotype matrices with columns
representing a selection of SNPs known to be associated with disease status from summary statis-
tics of previous GWAS. The binomial mixture model is visualized in the plate diagram in Figure
4.1. A subtype probability [ over  subtypes is used to sample a subtype label ℎ for a particular
individual. The set of risk allele frequencies c specific to that subtype are then sampled for that
individual. The likelihood of this model is then the product of binomial probabilities for producing
















To account for confounding heterogeneity, we apply a contrastive eigendecomposition to cancel
out confounding clusters learned from control data. This method constructs second and third-order
tensors representing the moments of the genotype matrix, and the inference task is to learn a set
of eigenvectors of this tensor which correspond to subtype-specific parameters. The contrastive
component is incorporated by submitting a difference tensor between a case and control genotype
matrix: the eigenvectors learned will correspond to the difference of cases from controls, and be
orthogonal to the eigenvectors of controls only [20]. If we assume for a particular cohort the same
ancestry structure exists in cases and controls, this method should cancel out these axes of variation
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reasonably well.
A simplified version of the contrastive eigendecomposition for the binomial mixture model is
shown in Algorithm 4.1. For full details of the tensor power method calculation, see Zou et al. [20].
The tensor power method receives second and third order moment tensors and identifies a set of  
clusters, here a vector of independent binomial distributions, whose outer product sum weighted by
cluster weights F produces the input tensors. For many mixture models, the resulting eigenvectors
correspond to mixture parameters. As we are modeling binomial SNPs, we add scaling factors
of 12 and
1
4 to the second and third order moments, respectively, to obtain correct expected value
estimates. To identify contrastive clusters, the tensor power method is fed a scaled difference in
the moments of the case and control matrices, with the constant W controlling the contribution of
the controls.
Algorithm 4.1: Contrastive binomial mixture model
function TensorPower("2, "3,  )
// calculate eigendecomposition

















Input: genotypes 20B4, 2>=C , constant W, num clusters  
// calculate moments























3 ,  );
4.4 Results
4.4.1 Simulated Data
We simulated GWAS data to test the performance of both the basic binomial mixture model on
unstratified genotypes and of the contrastive binomial mixture model on case/control data with ad-
ditional population stratification. To demonstrate that a binomial mixture model can successfully
separate heterogeneous cohorts with independent SNPs, we simulated heterogeneous cohorts com-
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prising subtypes of varying cohort sizes using parameters inspired by Ripke et al. [84]: 100 SNPs
with a total variance explained of 0.034 and total case/control cohort sizes of 30,000. To simulate
unique subtypes within cases, we split the SNPs into equal-sized halves in which effect sizes are
set to zero for one subtype and sampled from a normal distribution for the other subtype. Figure
4.2A shows the results of one such simulation, in which the nonzero SNP effects are correctly
grouped into their appropriate inferred subtypes. For the same simulation, panel B shows inferred
cluster assignment probabilities for individuals, with their true simulated membership arranged on
the x-axis. Here we successfully partition cluster membership despite differently sized clusters,
which may cause issues for other methods such as PCA. Figure 4.2C shows the same data parti-
tioned unsuccessfully by PCA, as the means of the two true clusters are not significantly separated
along principal component 1 on the x-axis. When clusters are different sizes, PCA will identify
components describing within-cluster variance of the larger cluster rather than strictly identifying
and partitioning unique clusters.
We next tested the performance of the contrastive binomial mixture model on data with back-
ground heterogeneity. We simulated ancestry stratification by sampling from 10 simulated popu-
lations. Population-specific allele frequencies were generated from a beta distribution with mean
0.5 and variance set by a fixation index of 0.1. This results in allele frequency differences between
populations at least an order of magnitude larger than those expected between case subtypes. We
then generate cases as before by repeatedly sampling sets of stratified controls and aggregating
those whose sampled liability passes a threshold.
We found in practice that introducing subtype-specific risks and additional stratification into
both cases and controls alters the total SNP variance explained of the case set as a whole. We
instead sampled many cohorts and calculated their average SNP variance explained using a variant
of Haseman-Elston regression for liability threshold models (see next chapter for further details).
Given the aforementioned simulation procedure, we found that generating samples using a per-SNP
variance explained of 0.01 in each subtype under no stratification resulted in an average per-SNP




Figure 4.2: Results of inferring risk allele frequencies to partition two simulated subtypes. Sim-
ulation parameters are meant to mimic those of Ripke et al. [84]: 100 SNPs with total variance
explained of 3.4%, with a cohort size of 30,000 cases and controls each. To simulate heterogene-
ity, we split the cases into two subtypes with mutually exclusive SNP effects and 15,000 sub-type
cases each. (A) Simulated SNPs associated with each subtype are arranged together on the x-axis.
These associations are correctly recovered: allele frequency differences from controls for within-
group SNPs are significantly nonzero, while out-group frequency differences are close to zero. (B)
Inferred cluster membership probabilities with true cluster membership on the x-axis. Across both
clusters, we achieve an accuracy of 59.8%. (C) PCA performed on cases fails to identify subtypes.
Plotted are cases and first two principal components over all cases, with red and blue being the true
subtype membership. The dotted lines are means of each subtype in PC 1.
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Figure 4.3: Contrastive binomial mixture model successfully recovers clusters corresponding to
case subtypes and not ancestry stratification. This simulation uses parameters expected of running
single cohorts from the PGC, with 3,000 controls and cases (divided into two subtypes of size
1,500). Ten SNPs associated with each subtype are sampled, with average variance explained of
2.96 × 10−3 in 50 simulated trials (s.e. 2.80 × 10−4), a per-SNP variance explained close to 0.034
in 108 SNPs in the PGC. (A) With  = 2, the inferred cluster eigenvectors plotted against the
true simulated allele frequency difference between the two latent case subtypes. (B) The same
cluster eigenvectors plotted against the first principal component of a PCA conducted on simulated
controls. The recovered clusters align more closely with the contrast between case subtypes than
with background stratification.
over 50 trials), slightly lower than the per-SNP variance explained of 3.4× 10−4 reported by Ripke
et al. [84]. We used these parameters to generate all performance results on simulations.
Figure 4.3 depicts the accuracy of inferred subtypes in one simulation. The learned subtype
components align more closely with the true differences in subtype allele frequencies in panel A
than with the largest principal component of the controls in panel B. We tested the performance
of this model as a function of sample size and value of W, the constant setting the magnitude of
the cancellation factor for the controls in the tensor moments, by evaluating the difference in A2
of the inferred subtype features with the true differences between subtypes and with a PCA of the
controls, representing the background stratification. These results are shown in Figure 4.4, where
we observe that for even small sample sizes of only a few thousands cases, a value of W = 0.9
allows the contrastive model to achieve a max A2 of 0.71, accurately recovering the simulated
disease-relevant subtypes despite significant heterogeneity contributed by ancestry stratification.
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Figure 4.4: Performance of contrastive binomial mixture model as a function of sample size and
values for constant W. (A) Performance is measured as the difference in A2 of inferred subtype
features with those of the true generating subtypes and with the first principal component of the
control set. Colors indicate values of W. For optimal values of W, we see a slight improvement in
performance with larger samples. (B) Performance as a function of W with sample sizes fixed to
4000. Correlation of inferred subtype features with those of true subtypes is shown in green, and
correlation with PCA of controls is shown in red. Twenty trials were conducted for all parameter
sets.
4.4.2 Validation in schizophrenia cohorts
We evaluated the same case/control data for schizophrenia used in testing of CLiP, provided
by the Psychiatric Genomics Consortium (PGC) [99]. (See Chapter 3 for further information on
preprocessing.) We ran the contrastive binomial mixture model on cases and controls from single
cohorts in the PGC data independently, to ensure that foreground and background stratification
patterns due to ancestry are consistent and free of cross-cohort batch effects. As the sizes of these
cohorts ranges from several hundred to roughly 3500 samples, we selected an inferred cluster
number of  = 3 to ensure we can recover clusters of reasonable size. We selected W = 0.1 for
all cohorts as this value produces clusters of balanced size in terms of sample membership and
whose eigenvectors closely align with the true allele frequencies of the modeled SNPs in controls.
Results from the contrastive method are shown in Figure 4.5 for the two largest cohorts, clm2 and
s234. In each, we find that we recover clusters with distinct allele frequencies and with significant
representation in sample membership (Figure 4.5A, 4.5D). As expected, the clusters tend to differ
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in SNPs with overall allele frequencies near 0.5 because these SNPs exhibit the largest variances
across the cohort. We also observe that the eigendecomposition discovered by the contrastive
method does not correlate strongly with the largest principal component of controls, as would
be expected if the decomposition recapitulated ancestry stratification present in both cases and
controls (Figure 4.5B, 4.5E). Instead, we observe that SNPs with a large absolute value weight in
the first principal component tend to have a small magnitude in learned subtypes, and vice versa,
indicating that the model is successfully canceling large axes of variation in the controls. Finally,
to confirm that the contrastive method successfully ignores background stratification, we perform
a two-component PCA on the controls, as well as assign each control sample to a subtype with
highest likelihood. If the contrastive method fails to ignore ancestry stratification, we should see
separation in the subtype-assigned control clusters along the plotted principal components, but
we instead see that these clusters largely overlap across cohorts (Figure 4.5C, 4.5F), indicating a
successful application of the contrastive method.
Although there is no known ground truth for subtype-specific SNP associations in schizophre-
nia, we sought to evaluate the potential etiological significance of the discovered subtypes by
observing their consistency across cohorts. To facilitate comparisons of clusters discovered in dif-
ferent cohorts, we reported the average A2 across 3 pairs of clusters using the pairwise permutation.
We subtract the mean allele frequency of controls from cluster-specific allele frequencies prior to
calculations of A2, otherwise differences in allele frequency across all samples would inflate cor-
relations between pairs of SNPs. As this is likely to inflate scores slightly, as a null distribution
we simulated the same process with 3 sets of subtype weights sampled from a standard normal
distribution for two hypothetical cohorts. We performed the same permutation process identify-
ing the best-matching clusters in 1000 trials, obtaining a mean A2 of 0.010 ± 0.0088. Calculated
correlations between inferred subtypes is shown in Figure 4.6. To improve consistency of inferred
clusters, we included only clusters with a combined case and control sample size greater than 2000
samples. Between all pairs of cohorts, we observe positive correlations with a minimum value of
0.045. Given the above null distribution obtained by sampling random vectors, this produces a
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least significant p-value of 3.75× 10−5. We therefore observe a statistically significant consistency
in the subtypes discovered independently in these cohorts.
4.5 Discussion
In this preliminary work we demonstrate that fully decomposing subtypes with unique genomic
associations is possible in single-phenotype GWAS cohorts. We show in simulated data that a
binomial mixture model is well-powered to detect subtypes when the total variance explained
across all subtypes is very low as expected in most GWAS traits. Further, we show that using a
contrastive mixture model, we can disentangle observed subtypes with unique phenotype-relevant
risks from background heterogeneity arising from ancestry stratification, provided that cases and
controls are sampled from the same population. Although this requirement precludes us from
combining data from multiple cohorts as is typical of GWAS meta-analysis, we nevertheless show
that subtypes can be recovered in cohorts of only several thousand individuals.
We also successfully detect unique subtypes within individual case sets for schizophrenia.
While further investigation must be conducted to confirm that the inferred clusters correspond
to true genomic subtypes, analyses conducted so far indicate that we do recover clusters unique to
cases. First, in the largest cohorts we observe that the clusters tend to split the data such that each
includes a non-trivial sample of the cases, rather than membership of most samples falling into a
single cluster. Second, the clusters tend to differ in SNPs with effect allele frequencies in the range
of 0.3 to 0.7, which we may expect as these SNPs contribute the largest variance to the sample.
However, this point may complicate the discovery of subtypes which partition along rare alleles
with large effect. Third, we observe that inferred clusters tend to differ along SNP components
which are largely orthogonal to the first principal component of controls, and that assigning sub-
type labels to controls does not separate them into unique clusters in principal components space
space. Lastly, we observe modest but statistically significant positive correlations in the features
of subtypes inferred independently from different cohorts. We compare subtype features after sub-
tracting the mean allele frequencies of control sets, such that the population level allele frequency
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differences are not contributing to these positive correlations. Future work will evaluate whether
this contrastive mixture model can recover known subtypes in phenotypes such as bipolar disorder.
A B C
D E F
Figure 4.5: Contrastive binomial mixture models for two of the largest PGC cohorts evaluated
independently: clm2 (A,B,C) and s234 (D,E,F) with W = 0.1 and  = 3. (A, D) Effect allele
frequencies of inferred subtypes against allele frequencies of the controls. The legend displays
the size of each subtype in parentheses if each subject in the case set is assigned to the highest
probability subtype. (B, E) Effect allele frequencies of inferred subtypes against SNP weights in
the largest principal component of controls, representing ancestry stratification. Alleles with large
magnitudes in the principal component tend to have smaller magnitudes in the inferred subtypes
and vice versa. (C,F) Control samples plotted according to their loadings on the first two principal
components describing variance in controls only. Each sample is colored according to the highest
probability inferred subtype. That the subtype assignments largely overlap is a sign that the in-
ferred subtypes represent a unique decomposition independent of ancestry stratification. Plots for
additional cohorts are shown in Figure C.1.
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Figure 4.6: Correlation of learned subtypes between cohorts. Included are cohorts in the PGC
with more than 2000 samples (cases + controls), sorted from largest (clm2) to smallest (gras). To
remove inflation in correlations from overall differences in SNP allele frequencies, subtype fea-
tures are compared by the difference in their risk allele frequencies from the corresponding mean
frequencies in the control set. To compare clusters, we selected the pair-wise cluster permutation
which produces the maximum A2. As a fair null distribution, we simulated the same permutation
process with randomized vectors. Of the plotted correlations, the least significant p-value using
this null is 3.75 × 10−5.
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Chapter 5: Reversing Transcriptome-Wide Association Studies to improve
expression Quantitative Trait Loci associations
This work is posted on bioRxiv and was coauthored with Boqiao Lai and Itsik Pe’er
doi: https://doi.org/10.1101/2020.12.27.424460
5.1 Abstract
Transcriptome-Wide Association Studies discover SNP effects mediated by gene expression
through a two-stage process: a typically small reference panel is used to infer SNP-expression
effects, and then these are applied to discover associations between imputed expression and phe-
notypes. We investigate whether the accuracy of SNP-expression and expression-phenotype as-
sociations can be increased by performing inference on both the reference panel and independent
GWAS cohorts simultaneously. We develop EMBER (Estimation of Mediated Binary Effects in
Regression) to re-estimate these effects using a liability threshold model with an adjustment to
variance components accounting for imputed expression from GWAS data. In simulated data with
only gene-mediated effects, EMBER more than doubles the performance of SNP-expression linear
regression, increasing mean A2 from 0.3 to 0.65 with a gene-mediated variance explained of 0.01.
EMBER also improves estimation accuracy when the fraction of cis-SNP variance mediated by
genes is as low as 30%. We apply EMBER to genotype and gene expression data in schizophre-
nia by combining 512 samples from the CommonMind Consortium and 56,081 samples from the
Psychiatric Genomic Consortium. We evaluate performance of EMBER in 36 genes suggested by
TWAS by concordance of inferred effects with effects reported independently for frontal cortex
expression. Applying the EMBER framework to a baseline linear regression model increases per-




Genome-wide association methods have to date discovered thousands of associations with dis-
ease risks and other phenotypes [10]. However, functional studies to determine the causal genes or
mechanisms behind these associations have yet to be fully explored [100]. One such strategy is to
identify expression Quantitative Trait Loci (eQTLs), variants in the genome which are implicated
in mRNA expression. eQTLs have been shown to be enriched in GWAS-significant SNPs and fur-
ther enrichment is found over fine-mapped cis-eQTLs both across all tissues and for specific pairs
of tissues and phenotypes [101, 102]. Large consortia such as GTEx [103, 104] have discovered
numerous eQTLs by repeating single-variant regressions over cis-SNPs [105, 106], though chal-
lenges remain such as low power and winner’s curse stemming from small sample sizes of current
RNA-seq experiments [107].
Transcriptome-Wide Association Studies (TWAS) have played a promising role in discover-
ing eQTL associations with disease risk [29, 30]. The method uses reference panels of known
SNP-gene effect sizes obtained from smaller gene expression experiments to predict associations
between expression and disease phenotypes. SNP-gene effects are trained using multi-SNP re-
gression methods: Gusev et al. [30] use primarily the best linear unbiased predictor (BLUP)
whereas the PrediXcan model by Gamazon et al. [29] uses elastic net. Associations between
imputed gene expression and disease phenotypes are then assessed either by imputing expression
for each individual in large GWAS cohorts or computed directly from summary statistic informa-
tion. While TWAS performs only a Z-score to test imputed gene-trait association, other iterations
of this framework include MR-Egger, a method for estimating of the imputed gene effect size
through Mendelian randomization, which accounts for direct SNP-trait effects not mediated by
genes, and further refinements of these methods to factor out correlations between SNPs due to
linkage disequilibrium [108]. To date, TWAS has discovered a large number of imputed gene-
phenotype associations in a wide variety of phenotypes including schizophrenia [31]. However,
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challenges to interpretation remain, as TWAS associations are not necessarily causal, and genes
may be mistakenly tagged due to pleiotropy at the SNP level. Additional noise is provided by
small sample sizes in SNP-expression reference panels [32].
We developed EMBER (Estimation of Mediated Binary Effects in Regression) to investigate
whether SNP-gene and gene-trait effect sizes in TWAS can be improved by performing inference
on both a reference panel and GWAS data simultaneously, rather than a two-step process in which
eQTLs are first inferred, then assumed to be fixed and true. As this model must account for both
observed gene expression from the reference panel and imputed gene expression from an estimate
of eQTLs, EMBER applies the liability threshold model and its treatment of variance explained to
represent differing levels of confidence in gene expression estimates [28]. The liability threshold
model assumes an observed binary trait, such as disease status, is sampled by thresholding a latent
normally distributed liability function. The variance explained by a set of predictors, such as SNPs
or imputed gene expression, is then a fraction of the variance of the standard normal liability
distribution.
We find in simulations that EMBER significantly improves estimation of SNP-expression ef-
fects when SNP effects are mediated by gene expression. Even when non-mediated effects are
present, EMBER can still improve SNP-expression estimation when the variance explained of
mediated effects is at least 30%. In practice, we obtained the largest boost in SNP-expression esti-
mation performance from a variable reduction preprocessing step, far outperforming the BLUP and
elastic net on schizoprenia cohorts from the CommonMind Consortium [109] and the Schizophre-
nia Working Group of the Psychiatric Genomics Consortium [84]. After the variable reduction
step, we evaluate EMBER in 36 genes with significant TWAS effects as reported by Gusev et al.
[30]. While most of these genes mediate far less than 30% of the variance explained of their cis-
SNPs, we nevertheless find that for a subset of these genes, EMBER results in slight improvements
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Figure 5.1: For a small reference panel cohort of size # , we observe SNPs - , transcripts / , and
binary trait . . Assume we have a large GWAS cohort of size #′ with only -′ and . ′ observed.
EMBER attempts to improve inference of V1 (the SNP-gene effects) given V2 (the TWAS gene-trait
effect).
We assume we have access to reference panel data comprising # individuals with genotype ma-
trix - , gene expression matrix / , and case/control phenotype vector . . The conventional method
for calculating eQTLs involves a linear model over the observed - and / . We also assume that
we have a large GWAS data set comprising #′ >> # individuals with genotype matrix -′ and
case/control labels for the same phenotype /′. All SNPs and transcripts are normalized to mean 0
and standard deviation 1. We denote the set of SNP-gene linear effects V1 and the gene-trait linear
effects V2. For our simulations, we oversimplify the genotypes to be sampled independently with
an effect allele frequency set to 0.5 across all genes. We assume true gene expression quantities are
distributed / = -V1 + n with n ∼ # (0, 1−f2-), where f2- is the fraction of variance in / explained
by all predictors in - . The mediated SNP-trait effect is then their product V1V2, given all SNPs are
sampled independently. For now, we assume there are no direct SNP-trait effects not mediated by
gene expression. As . is a binary variable, we opt to use a liability threshold model over the total
SNP and gene effects - V̂1 V̂2, described in the next section.
The TWAS approach assumes first that an estimate V̂1 is calculated from the reference panel
only, and then V2 is obtained by regressing . against - V̂1. Therefore the accuracy of V̂1 is one
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limitation of TWAS, as current sample sizes for gene expression data tend to be much smaller
than for genotype data. Our goal is to perform the analysis in reverse: given the same data and
an estimate of the TWAS effect size V̂2, we would like to improve estimates of V̂1. This relies
on an assumption that V̂2, likely estimated initially from the same data, is robust to errors in V̂1
to a degree that allows its use to improve re-estimation of V1, provided that the gene in question
mediates a significant fraction of the observed SNP-trait effects. Improving the accuracy of SNP-
gene effects has the potential to improve TWAS estimates further through more accurate gene
imputation. Additionally, re-estimating significance of eQTLs may provide more insights into
regulation of gene expression by SNPs.
5.3.2 Liability Threshold Model
The liability threshold model is an alternative to logistic regression for identifying predictors
(SNPs or genes) that are highly associated with disease status. This model assumes that the vari-
ance of all modeled predictors is a fraction of a normally distributed underlying quantitative liabil-
ity, which is thresholded to generate case/control status. This model provides an advantage over
the more conventional logistic model by explicitly modeling the variance explained, rather than
estimating it by pseudo-A2 methods. It also provides a more natural interpretation of the Polygenic
Risk Score (PRS).
Assume we are regressing measured or imputed quantitative gene expression values / against
case/control status . . The liability threshold model assumes an underlying standard normal distri-
bution representing the hidden liability. The PRS vector /) V explains a fraction of the variance of
this liability, represented by f2
/
. We describe in Section 5.3.3 a method to estimate f2
/
indepen-
dently of the inference process for effect sizes in V. The liability is dichotomized into a sampled
phenotype by labeling the sampled individual a case if the total liability score passes a threshold
) , set such that 1−Φ()) is equal to the population prevalence if Φ(·) is the standard normal CDF.
If an individual has polygenic risk score /)
8
V, then the conditional mean of the liability is shifted
by that value, and the variance of the liability is reduced by the variance of the PRS. Therefore, the
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probability of disease .8 for an individual with predictors /8 is given by Wray et al. [28]









Our objective is to infer values of the coefficients V such that the probability of observed disease
statuses across all individuals is maximized given their PRS. We assume the prior for all V to be
a normal distribution with standard deviation 1. Therefore, the joint log likelihood of the liability
threshold model is


























However, inference with respect to V is difficult because of the dependence of f2
/
in the de-
nominator on values of V.
5.3.3 Correction for effect size inflation
To resolve the dependence of f2
/
on V during inference, we instead independently estimate
f2
/
using the sample data prior to inference of V itself. A separate step to estimate total variance
explained of predictors serves two roles: first, it decouples the PRS variance explained from the
predictors themselves, facilitating inference, and second, it allows for correction of inflated effect
size magnitudes inherent to both liability threshold model and logistic regression. Even when
the relative magnitudes of effect sizes are accurately estimated, the overall scale of the effects is
poorly controlled in both liability threshold and logistic models (see Results for simulations in
which inflated effects produce larger likelihoods). By estimating the true total variance explained
f2
/
, we can correct for this inflation by re-scaling all effect sizes by a constant factor such that the
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theoretical total variance explained as a function of V equals the observed f2
/
.
When regressing predictors against a quantitative label, the total fraction of variance explained
by the predictors can be obtained using Haseman-Elston regression [110, 111]. Golan et al.
[112] demonstrate that a similar proportionality between labels and predictors applies to binary
case/control labels in a liability threshold model. Assume the disease has a population prevalence
 , study prevalence %, and liability threshold ) = 1−Φ( ) corresponding to the population preva-
lence. We can define a correlation between samples in . by taking the outer product of all pairs
(8, 9) of standardized labels: a Bernoulli label .8 is standardized as .8−%√
%(1−%)
. As in quantitative
traits, this label correlation can be regressed against the correlation between pairs of samples in / .
Specifically, Golan et al. [112] show that correlations between labels and between predictors are
related by the following linear function
2>AA (.8, . 9 ) :=
(.8 − %) (. 9 − %)
%(1 − %)
≈ %(1 − %)
 2(1 −  )2




is the variance explained by / . Therefore, we can regress the two sets of correlations
over pairs of samples to obtain a slope, and then solve for f2
/
given observed population parameters
of %,  , and ) .
5.3.4 Expectation Maximization of the liability threshold model
By estimating a fixed value for f2
/
, we have decoupled it from inference on V, resolving the
aforementioned intractability. Therefore, we can perform inference by the conventional probit
expectation maximization. First, we introduce a hidden variable ; denoting the unobserved quan-
titative liability which determines case/control status . = %(; > )). This results in the following





?(., ;, V |/)
@(;)
)
+  ! (@(;) | |?(; |., /, V)) (5.4)
We assume ; follows a standard normal distribution, with a fraction of variance explained
by SNP effects: therefore ; ∼ # (/V, 1 − f2
/
). Furthermore, the distribution of ;8 is dependent on
disease label.8, as ; must fall on the correct side of the threshold) to impart the correct case/control
status. Therefore, we have the following for the distribution @(;)
@(;) = ?(; |., /, V) =
#∏
8=1




)#.8 ,) (/8V, 1 − f2/ )
(5.5)
where )#. (·) is the truncated normal distribution over values greater than or less than ) de-
pending on whether .8 indicates a case or control, respectively. We can then plug this distribution
into the EM equation with joint log likelihood !!. By setting @(;) = ?(; |., /, V), the KL diver-
gence term cancels, allowing us to maximize V with respect to the expected log likelihood over
@(;). This term can be expanded as follows
#∑
8=1













V) V +  (5.6)
where  denotes terms which are constant with respect to V. Therefore, we have the following
EM procedure, where in the E-step we update expected values of the hidden liability, and in the






































At each step the joint log likelihood is evaluated for convergence, after which the inferred V is
returned.
Constrained EM incorporating ℎ2 correction
The method to estimate f2
/
independently of V inference described by Golan et al. [112]
allows us to correct for the aforementioned inflation inferred effect size magnitudes. As effect
sizes tend to be scaled by an arbitrary constant factor, we can simply re-scale all effects such that
their theoretical variance explained (V) V if predictors in / are standardized) equals f2
/
obtained
by the method of Golan et al.
However, we also investigated whether the re-scaling procedure can instead be incorporated
directly into the EM algorithm as a constraint. Having obtained an estimate of f2
/
from the sample
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V) V + _
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(V) V − f2/ ) (5.10)
We notice that this modification conveniently adds only a constant term to the coefficient of






















Note that the addition of lambda effectively re-scales the variance of the prior distribution of V,
which has until now been assumed to be 1. At every iteration, we would like to solve for lambda







is satisfied. However, this operation does not appear to have
an analytical solution, and we would like to limit the number of matrix inverse calculations required









−1. We also substitute _′ = _ + 1. Therefore, the matrix inverse
in equation 5.11 can be avoided by retaining the decomposition and only updating the diagonal
matrix Λ, which requires only a vector division.
(&Λ&−1 + _)−1 = &(Λ + _)−1&−1 (5.12)
We can then express the predictors V in equation 5.11 in terms of their eigendecomposition,











V) V = ) (Λ + _)−2 ≤ f2/ (5.14)
To our knowledge there is still no analytical solution for _ such that V) V is close to f2
/
. We instead
take the numeric inverse to obtain 5 −1(f2
/
) = _. We perform this using the Python package
pynverse, which performs a search over scalar values for _. The operation in equation 5.13, though
performed repeatedly, is relatively efficient as it can be performed as a dot product over 1-D vectors.
In the Supplementary Text, we have additionally derived an extension of the Lagrangian
method for correlated predictors, in which case the variance of their weighted sum is dependent on
the covariance between predictors.
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5.3.5 Improving V1 estimation
Here we describe the main contribution of EMBER: a method to improve SNP-gene associa-
tions (V1) given an existing estimate of TWAS gene-trait effects (V2). Instead of a linear regression
over the reference panel only, we combine this stage with a liability threshold regression passing
estimates of V1 to scoring -′V1V2 against case/control status in a much larger GWAS cohort. We
model one gene at a time, so V2 is a scalar value. First, we describe an adjust to the liability
threshold model which accounts for increased error in imputed gene samples.
Accounting for imputed gene expression in the liability model
To combine both observed expression / and imputed expression /′ = -′V1 into a single model,
we introduce a hidden variable l ∼ # (-′V1V2, 1 − f2- V22) representing the distribution of the
imputed gene effect on disease liability, where f2
-
is the total fraction of variance in / explained
by predictors in - . We can now redefine disease risk with respect to -′ and V1 by marginalizing
over the distribution of l.












(-′8 V1)V2, 1 − f2- V22
)
3l (5.15)
We can simplify this expression by applying the following lemma described by Own [113]
∫ ∞
−∞































































Therefore the only change from the liability model with observed / instead of imputed -′V1
is the non-explained liability variance is multiplied by a factor of 2. This distinction in variance
explained allows us to perform regression on both observed gene expression in the reference panel
and imputed gene expression from GWAS simultaneously.
Inference incorporating both observed and imputed gene expression
Our goal is to infer SNP-gene effects given access to both observed genotype and gene expres-
sion data from a small reference panel as well as genotype and trait data only from a large GWAS
cohort. Therefore, the log joint likelihood now comprises a sum between the normal prior on V,
a linear regression over observed gene expression in the reference panel, and liability threshold
regression over imputed gene expression in a GWAS cohort. We first estimate f2
-
, the variance
explained of SNPs on gene expression, using either H-E regression on the reference panel or the
liability method by Golan et al. [112], making sure to divide by V22 to remove the contribution of
91
the gene-trait effect. The joint log likelihood can then be expressed as
! = − 1
2








































The inclusion of linear regression terms can be accommodated easily in the EM algorithm. The
new updates are































































The inferred V can be corrected for effect size inflation by either re-scaling according to f2
-
after EM inference, or since the form of the EM algorithm is largely unchanged, the Lagrangian
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can be incorporated as described in section 5.3.4.
5.4 Results
5.4.1 Robustness of TWAS estimates (V2) to sample size
Broadly, we are interested in whether simultaneous inference of SNP-gene (V1) and gene-trait
(V2) effect sizes can improve accuracy over two-stage regression, given access to both a reference
panel and an independent GWAS cohort. As GWAS cohorts are often orders of magnitude larger,
hidden gene expression quantities must be inferred for a large majority of the data. The accuracy
of these hidden values, which rely on estimates of V1, may in turn improve estimation of V2. But
to improve V1 estimation over an initial result from the observed reference panel data, we must
incorporate the GWAS cohort and our best estimate of V2. As the potential benefit of EMBER
derives from providing additional samples with only partially observed data, we first investigate
the robustness of TWAS associations to sample size. While Gusev et al. [30] report that increasing
the size of reference panels past several hundred samples does not improve eQTL estimation,
Wainberg et al. [32] nevertheless claim more recently that dependence on small eQTL reference
panels is a potential limitation for TWAS.
We found in simulations that TWAS-imputed gene-trait effects are very robust to small sam-
ple size in the reference panel, corroborating Gusev et al. [30], and therefore we do not expect
significant improvement in V2 estimation from combining reference and GWAS data sets. We ran
simulations comparing A2 of inferred results from a probit regression to the true generating effects.
These results are shown in Figure D.1 as a function of sample size and varying expression-trait
variance explained. We find across all conditions that the performance of TWAS plateaus at an
A2 of 0.8, and this value is reached at a reference panel size of roughly 500, similar to that of the
CommonMind Consortium (CMC) data, for all values of gene-mediated variance explained except
for the smallest of 0.01. These results indicate that TWAS is quite robust to sampling error due
to small reference panel sizes, and there is little room for improvement on this front. This also
suggests that an estimate of V2 from data is sufficient to improve estimation of eQTLs (V1) in one
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step, rather than requiring repeated updates of one set of effects given newer estimates of the other.
5.4.2 Constrained probit EM for correct effect sizes
We demonstrate that effect size inflation does occur in conventional applications of logistic
and probit regression by simulating case/control data with a single predictor and known effect size.
From generated case/control samples, we then calculate the log likelihood resulting from scaling
the known effect size by a scalar factor (Fig D.2A). We find that the scalar factor resulting in the
maximum log likelihood does not occur at a value of 1.0, corresponding to the original value, but
rather at roughly 1.4, indicating a significant inflation from the inference.
By simulating case/control data from a probit/liability threshold model, we observe inflation in
the inferred effects of both the logistic and probit models in Fig D.2B. While the log odds ratios of
the logistic model are not expected to map directly onto liability model used to simulate the data,
we should expect to recover effects of the correct magnitude in the probit model. We rescale the
effects by calculating the total variance explained of the predictors as described in the Methods
and then divide each effect size by a constant such that their sum of squares equals the calculated
value. Lastly, the faster constrained EM method produces nearly identical estimates to those of the
slower rescaling method (Fig D.2B).
To demonstrate the performance advantages of the constrained EM algorithm in comparison to
rescaling the conventional liability threshold model, we measured performance time and number of
EM iterations as a function of increasing sample size with other parameters kept constant. Results
are shown in Fig 5.2, where for both methods the number of iterations remains relatively constant
as a function of sample size, and the total execution time increases linearly. By both metrics,
the constrained probit method far outperforms the rescaling method by requiring fewer iterations
despite performing more work per iteration.
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Figure 5.2: Performance of constrained probit model (solid line) versus conventional probit with
rescaling (dotted line). Performance was measured as a function of sample size in terms of total
execution time (red) and total number of iterations to convergence (blue). All simulations are run
with 200 standard normal predictors with a total variance explained of 0.1. The mean and standard
deviation of 10 trials is shown for each sample size.
5.4.3 Reversing TWAS to re-estimate eQTLs
To test whether we can improve estimation of SNP-expression effects (V1) when a reference
panel and GWAS cohorts are analyzed together, we ran the EMBER method for estimating eQTLs
described in the Methods on simulated data. We simulated sample sizes roughly corresponding to
those of the CMC and PGC data: a reference panel size of 500 and GWAS size of 50,000. We
also assumed for now that the variance explained of non-gene mediated SNP effects is zero. An
example run is shown in Fig 5.3. In this single trial, the A2 of EMBER more than doubles that of
linear regression: 0.88863 versus 0.30665. Additionally, EMBER correctly re-scales all effects so
that their magnitudes fall appropriately on the H = G line.
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A B
Figure 5.3: Inference of eQTLs on simulated data by (A) conventional linear regression on the
reference panel only and (B) combining reference panel and GWAS data in EMBER. For simula-
tion we assume a reference panel size of 500, GWAS sample size of 50,000, 100 SNPs and one
gene with total SNP-gene variance explained of 0.1 and gene-trait variance explained of 0.01. A
population prevalence of 0.01 was assumed and allele frequency of 0.5 for all SNPs.
EMBER assumes that there are no non-gene mediated SNP effects, but in practice, this as-
sumption may be violated. To test this, we fixed the gene-mediated SNP variance explained to a
constant, and varied the non-mediated variance as a percentage of that constant. These results are
shown in Fig 5.4. We observe that when the percentage on the x-axis is zero, corresponding to re-
sults shown in Fig 5.3, EMBER significantly outperforms linear regression to a mediated variance
explained of 0.005, after which the expression layer contributes very little signal to the inference.
We also observe that even though the assumption of no non-mediated effects is violated, EMBER
still outperforms linear regression up to a percentage of non-mediated variance between 0.7 and




Figure 5.4: EQTL estimation (A2) as an increasing fraction of non-mediated SNP variance ex-
plained for EMBER (green) and linear regression (black). The gene-mediated SNP variance ex-














the SNP-gene and gene-trait variances explained by V1 and V2, respectively.
5.4.4 Validation in schizophrenia
We applied EMBER to study eQTLs for genes relevant to schizophrenia. We obtained a gene
expression reference panel from the CommonMind Consortium (CMC) and GWAS data from 34
cohorts of the Psychiatric Genomics Consortium (PGC). For quality control, we followed the sug-
gestions in Marees et al. [114]: we removed individuals with genotype missingness rate greater
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than 0.05, and we removed SNPs with missingness rate in the data greater than 0.1, minor allele
frequency less than 0.01, and Hardy-Weinberg equilibrium less than 1 × 10−10. We additionally
filtered for individuals in the CMC data with both genotype data and expression data available.
This preprocessing resulted in 512 individuals from the CMC data and 56,081 individuals from
the PGC. We focused on genes which have been shown to be associated with schizophrenia in
TWAS by Mancuso et al. [31], obtaining 36 genes with TWAS p-value < 10−5 and which are also
present in the CommonMind data. We imputed cis-SNPs using SHAPEIT [86] and Impute2 [115,
116] and obtained ancestry principal components from PLINK [117]. As EMBER is dependent on
gene mediation to improve performance, we calculated the fraction of SNP variance mediated by
expression by separately calculating total SNP variance, and SNP-expression variance multiplied
by inferred TWAS effect squared. These results are shown in Fig D.3A. To obtain the best possible
TWAS effect sizes for our data, we re-calculated them in the usual manner by estimating eQTLs
from the CMC reference data only, imputing gene expression for the PGC data, and then regressing
imputed expression against case/control status. Covariates included for all analyses were sex and
top 10 ancestry PCs.
To validate EMBER, we performed eQTL re-estimation in both EMBER and linear regression
on the CMC and PGC data, and compared the level of concordance with reported eQTLs in GTEx
v7 data for the frontal lobe. A high degree of concordance would suggest reproducibility of effects
and a higher confidence that these are true eQTLs. We obtained GTEx v7 eQTLs effects from the
TWAS/Fusion website (http://gusevlab.org/projects/fusion/), calculated using BLUP.
To sidestep challenges incorporating the model assumptions of EMBER into the BLUP method,
we instead addressed significant LD in cis-SNP regions by performing dimensionality reduction
over the input SNPs and covariates by performing a second PCA over all predictors, not to be
confused with the initial PCA used to discover ancestry covariates. After inferring effects on
the transformed PC variables, the predictor-level effects can be recovered by multiplying the PC
loadings matrix by the inferred effects over PCs. As the number of components to include from
the variable reduction PCA is an open question, we decided to test the performance of linear
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regression results compared to GTEx reported effects as a function of this parameter. The mean
A2 compared to GTEx across all 36 genes is shown in Fig D.3B as a function of number of PCs
of the variable reduction PCA to ensure independence of input predictors. We observe that the
performance plateaus between 5 and 10 PCs and begins to decline afterward, which prompted us
to select 10 PCs for this procedure.
We evaluated the accuracy of baseline linear regression and EMBER, both using the variable
reduction preprocessing step, by the concordance of their inferred SNP-expression effects with
those reported by TWAS/FUSION in GTEx v7 data. As TWAS/FUSION also reports effect size
calculations from the CMC data for 26 out of the 36 studied genes, we compare the A2 of these
results against the GTEx effects when possible, along with our own implementation of the BLUP
method for all genes. We assume in both the EMBER and BLUP models a normal prior effect size
distribution with a variance of 1 × 10−4. Results for these methods across all 36 genes are shown
in Figure 5.5. Across all genes, EMBER achieves an average A2 of 0.235 ± 0.145, improving over
an A2 of 0.200 ± 0.129 obtained by linear regression. EMBER also improves A2 in 26 out of 36
genes (Figure 5.5B), with a one-sided sign test p-value of .00197. However, we do not observe
a significant relationship between improvement in performance and the fraction of gene-mediated
variance explained in Figure 5.5B. Given the generally low fraction of variance explained across
all genes (see Figure 5.4), it is possible that cis-SNP effects not mediated by the studied genes
contribute to a reduction in estimation accuracy. The average A2 achieved by EMBER is slightly
lower that of our implementation of the BLUP model at 0.240 ± 0.123 (Figure 5.5A), though both
methods perform significantly better than the same BLUP model on CMC data as reported by
TWAS/FUSION, with an A2 of 0.201 ± 0.109. As EMBER is currently applied to a baseline linear
regression model with a variable reduction step, further improvements in performance may be
possible by accessing the full SNP covariance matrix as in the BLUP method. Figure 5.6 displays
effect size comparisons for the gene GLT8D1, where we observed the largest increase in A2 in
EMBER compared to linear regression. Additional plots for all genes are shown in Figure D.4.
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Figure 5.5: (A) For 36 genes, concordance of estimated SNP-expression effects with reported
GTEx v7 effects using BLUP versus using EMBER (green) and linear regression (black) with a
variable reduction step. (B) Concordance with reported GTEx v7 effects of linear regression versus




Figure 5.6: Example results for the gene GLT8D1, for which we observe the largest improvement
in A2 using EMBER. (A) GTEx v7 effects reported by TWAS/FUSION versus effects inferred
from linear regression (black) and EMBER (green) with variable reduction. (B) GTEx v7 effects
reported by TWAS/FUSION versus effects inferred from BLUP (blue), as well as BLUP effects
reported by TWAS/FUSION on CMC data (black). (C) Effect sizes for all models arranged by SNP
position in the locus. The top row displays TWAS/FUSION reported BLUP effects on GTEx v7
data; the middle row displays BLUP effects (blue) and TWAS/FUSION reported BLUP effects on
CMC data (black); and the bottom row displays results of EMBER (green) and linear regression
(black), both using variable reduction to resolve high LD across SNP predictors. For all tested
genes, see Fig D.4.
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5.5 Discussion
We presented EMBER, a method to perform inference over gene expression reference panel
data alongside GWAS data simultaneously to improve estimation of effect sizes over a two-stage
regression approach. In developing EMBER, we introduced also a variance correction to incor-
porate both measured and imputed gene expression as predictors into a single regression, and a
constrained EM method to rapidly re-scale effect sizes based on expected variance explained.
We mapped the parameter space where EMBER is effective. Through simulations, we found
that imputed gene-trait associations are quite robust to low reference panel sample sizes, but that
significant improvements in eQTL estimates are possible by including GWAS data with no gene ex-
pression data observed. Additionally, while EMBER focuses on gene mediated effects, we found
that accuracy of inferred effects still improved when the fraction of gene-mediated variance ex-
plained was as low as 0.3.
We observed significant improvement in concordance of inferred eQTL effects when we per-
formed a variable reduction step involving transformation of predictors to lower dimensions by
PCA. This allows us to account for significant multicollinearity resulting from LD. With this step,
ordinary least squares regression achieves an A2 performance nearly equivalent to BLUP effects
reported by TWAS/FUSION on CMC data. This allowed us to build EMBER from a linear re-
gression model, although further improvements may be possible if more sophisticated multi-SNP
models such as BLUP can be incorporated. These designs may present additional challenges: for
example, a model combining EMBER and BLUP would require features from both the probit and
linear mixed models, and while such algorithm have been proposed [118, 119], these typically re-
quire performing operations on the full covariance matrix of random effects, which is increasingly
impractical for large GWAS.
EMBER is not without its limitations. After variable reduction, for several genes the improve-
ment observed in CMC and PGC data is quite small. This is likely because the fraction of variance
explained for these genes is lower than the threshold of 0.2-0.3 for gene-mediated fraction of SNP
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variance, and EMBER is not benchmarked to improve results in this range. Even so, we do not
observe significant reductions in performance in EMBER relative to linear regression, with the
largest drop in A2 being −0.05 in the gene MAPK3.
Going forward, EMBER demonstrates a more general approach to the investigation of
genotype-to-phenotype association. Instead of relying on a single study with its traded-off weak-
nesses of sample size vs. extensiveness of phenotyping, we show that one can leverage modern
inference tools in order to get the best of both worlds across multiple studies of different designs.
In the era of ubiquitous availability of genotype data, this can greatly facilitate the discovery of
new signals.
5.6 Web Resources




For over 15 years, the fundamental study design of GWAS has remained largely unchanged
as the application of linear methods to discover small additive effects from genotype data. In this
thesis, I present strategies and statistical methods to extract additional insights into disease etiol-
ogy beyond often-reported summary statistics. In an environment where direct-to-consumer geno-
typing is becoming increasingly widespread, we demonstrate through DNA.Land that academic
labs can rapidly collect genotypes and phenotypes by crowdsourcing the recruitment process and
providing an online service which engages users. I also address efforts to understand latent hetero-
geneity in GWAS data, which are complicated by the already weak signals of known associations
as well as stratification independent of disease subtypes. I present CLiP, a lightweight test to flag
GWAS cohorts comprising significant heterogeneity, as well as a contrastive binomial mixture
model which decomposes cohorts into subtypes with unique allele frequencies. Both methods ac-
count for background heterogeneity: CLiP by scoring the difference in summed correlations of
cases and controls, and contrastive mixtures by performing tensor decompositions on difference
moments between cases and controls. Lastly, in describing EMBER, I propose that the estimation
of eQTLs can be improved by combining small reference panels with large GWAS cohorts, despite
those cohorts lacking any labeled expression data.
As the genomics field increasingly transitions toward multi-trait analysis at the level of sum-
mary statistics, these methods demonstrate that with the right computational tools there are still
novel insights to be gleaned from individual-level genotype data. The collection of large cohorts
of genotype and phenotype data is likely to continue to benefit from advances in sequencing tech-
nology, integration of genomic information in clinical settings, and potentially digital methods for
genotyping and phenotyping such as DNA.Land. While it is a given that increased power pro-
vided by larger genotype cohorts will continue to yield novel associations, the potential to collect
more detailed phenotypes from cohorts and incorporate gene-environment interactions into future
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analyses will greatly aid the study of disease heterogeneity and other topics in GWAS.
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Appendix A: Supplementary Material for DNA.Land
A.1 Security and Privacy
As DNA privacy is a concern of our users, we have followed many common security practices
to ensure that uploaded genomic data and personal information are not released to unauthorized
parties. We highlight the main security features in our website:
User experience:
• Secure communication: all user transactions with the website are done over HTTPs with a
valid certificate. Unsecure HTTP access is redirected to secure HTTPS. No information is
ever transmitted over HTTP.
• Login: users can only access their account using their email and password. We use Google
ReCaptcha to prevent automated login attempts.
• Protection of passwords: user passwords are stored in a database with industry-standard
security practices. Specifically, Password-Based Key Derivation Function 2 (PBKDF2) is
used to hash and sort passwords.
• Authentication: we ask users to authenticate their email address in their first login attempt.
While users may upload data immediately, they cannot view their data on the website until
they confirm their identity in an email sent to their login address. This allows us to confirm
that our users are real people and to prevent mass uploading of files from many accounts.
• Compartmentalization: Users can only access their own data in the website. They cannot
see the reports of other users on the website.
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• Transient access to raw data: if the user wants to download their imputed data, DNA.Land
generates a cryptographically-signed temporary link that is active for 15 minutes. The link
is then expired.
Architecture:
• Separation of data: the genome data is stored on Amazon S3 without explicit identifiers
such as the user email or name. The explicit identifiers are stored on a separate server.
• Logging: all actions on our website are logged, including each user interaction with our
website.
• In the case of a breach, the logs can be used to take postemptive measures.
• Firewall: web access over HTTPS is open to everyone. All other forms of access to the
servers (such as SSH) are IP-limited to a restricted set of addresses.
• Restricted access to servers: there is no public access to any of the backend/analysis
servers. All communication for maintenance and research is limited to specific IP addresses.
DNA.Land team:
• Security of accounts: all administrative access to our AWS account uses two factor authen-
tication.
• Sand-box: as a lab policy, we do not allow downloading DNA.Land data to personal com-
puters. Any analysis of raw data is done on a dedicated R&D node. This policy allows us to
minimize the number of weak spots in our system. Handling of all DNA.Land data is always
performed on dedicated, restricted servers. Troubleshooting of user errors or development
of new features is done on a dedicated R&D node. Personal laptops and computers are never
used.
• Training: all DNA.Land team members must take the NIH Human Subject Research course
before joining the team.
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• IRB vetting: only individuals with IRB approval are allowed to access the data. Lab mem-
bers without IRB approval cannot log into the servers.
Consent:
• Realistic expectation: our consent states that we cannot guarantee full privacy but will use
the best practices and effort.
• Release of data: at the initial consent, the user has only to agree for release of summary
statistics. We are now testing a secondary consent that allows users to share their raw data
and even contact information with specific and authorized researchers. This gradual ap-
proach allows us to build trust with users.
A.2 Consent Language
This is the Terms of Consent as it appears on the DNA.Land website. The consent is licensed
under a Creative Commons Attribution 2.0 Generic License.
Introduction
You have your genetic data and you want to be part of DNA.Land? Great! Before you can be
part of our community, we want to tell you a few things about DNA.Land, make sure you know
what research is being done, what it will entail, and the risks and benefits. Remember: If you do
decide to participate, you are free to withdraw your consent and to discontinue participation at any
time, no questions asked. Your participation is entirely voluntary. We thank you for considering
being part of our community.
Purpose
DNA.Land is a place where you can learn more about your genome while enabling scientists
like us to make new discoveries for the benefit of humanity. The website is not-for-profit and run by
the Erlich and Pickrell labs affiliated with Columbia University and the New York Genome Center.
The purpose of DNA.Land is to enable you to learn more about your DNA and allow you the
autonomy to share your data to facilitate important scientific research at the forefront of genome
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sciences and medicine. Our goal is to help members interpret their data and connect potential
participants with research studies.
Procedures
After you provide consent, your participation would consist of creating your personal profile
and securely uploading your genetic data to DNA.Land. We will use the most cutting edge genetic
tools to analyze your data and return your results regarding ancestry, relatives, and different traits.
As we want to learn about the genetic basis of different traits, we will ask you to fill out surveys
relating to your (or your family’s) ancestry and health. You will also have the option to automat-
ically contribute data from your social media profiles for new types of analysis, so we can learn
about traits that are dynamic and more difficult to measure, such as social preferences. Your profile
will also display a badge that summarizes your various contributions to DNA.Land. You can tweet
this badge, share it on Facebook, or sew it on your old scout uniform.
There are no costs associated with taking part in DNA.Land and you will not be compensated
for participating.
If any new information is learned about this study that might affect your willingness to stay in
this study, you will be told about it promptly.
Confidentiality
We value your contribution to DNA.Land and to scientific research and respect your privacy.
We are quite familiar with this matter. Our research on genetic privacy was featured in the mass
media, including the New York Times and the Wall Street Journal and leading scientific journals,
including Science, Nature Reviews Genetics, and PLoS Biology. Therefore, we pledge the follow-
ing guidelines that in our perspective will lessen most of the risks while maximizing your impact
on scientific studies:
• By default, we will not share the following with third parties before obtaining your ex-
plicit permission: the personal identifiers in your profile, your contact information, your
individual-level survey results, or your individual-level genomic data.
• If you do decide to connect your social media profiles with DNA.Land, we will never share
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your genomic data or survey data with any of the social media websites.
• To facilitate cutting edge research, by default, we will only share with other researchers
or publish aggregated data. For example, we will mix your genomic information with a
large number of genomes before sharing and only share the average allele frequencies with
other researchers. We will follow the best practices and tools developed according to the
"Framework for Responsible Sharing of Genomic and Health-Related Data" of the Global
Alliance for Genomics and Health of the National Institutes of Health.
• We may release your information if required to do so by law, or if such action is necessary
to comply with state or federal laws or respond to a court order, subpoena, law enforcement
or regulatory request, or search warrant.
We also have a skin-in-the-game philosophy (we are participating too). Both Principal Investiga-
tors of this website have made their own genomes publicly available (Dr. Pickrell’s genome , Dr.
Erlich’s genome). We are in this together.
Code of Conduct
We also have some expectations of you. You agree not to use DNA.Land to promote hate,
discrimination, or violence towards groups or individuals based on race, ethnicity, religion, sexual
preference, gender, age, health data, income, or family heritage or to use DNA.Land for any illegal
activity. We reserve the right to delete user profiles, data and user access at our discretion.
Risks
There are no physical risks in participating in this study but there may be information risks.
We are going to provide you with information about your ancestry, traits, and relatedness with
other individuals. You might learn unexpected findings about you or your family. These can
include finding a certain ethnic heritage, predisposition for a trait, or a non-paternity event in
your family (all examples are from people that we know and have worked with). For some, such
information is empowering; for others, these findings may cause anxiety and discomfort.
As stated above, we will do our best to protect the information you provide to us. Despite our
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efforts, we cannot guarantee that your identity and/or data will never become known, which could
have significant implications in some scenarios. We estimate that the risk for such a confidentiality
breach is low but not zero.
Potential Benefits
By being part of DNA.Land, you will be able to connect with the scientific community and
learn more about your genome for free. Genetic research is important for understanding human
heritage, health, and well-being. Thanks to people like you, our labs were able to solve the genetic
basis of three devastating pediatric diseases ( 1, 2, 3 ), reveal the shared genetic origin of multiple
diseases such as Parkinson’s disease and schizophrenia, and understand how humans evolved. We
expect great outcomes from this project and thank you for being part of this scientific endeavor.
Contact
Dr. Yaniv Erlich is the investigator in charge of the study at the New York Genome Center. If
you have questions, please email us: consent@dna.land
If you have any questions about your rights as a research subject or complaints regarding
this research study, or you are unable to reach the research staff, you may contact a person in-
dependent of the research team at the Biomedical Research Alliance of New York Institutional
Review Board at 516-318-6877. Questions, concerns or complaints about research can also be
registered with the Biomedical Research Alliance of New York Institutional Review Board at
www.branyirb.com/concerns-about-research .
Consent
I have read about this research study. All my questions about the study and my part in it have
been answered. I understand that my participation is voluntary and I freely consent to be in this
research study.
I expressly authorize the collection, processing, use, and disclosure of my data for use in re-
search as indicated in the Confidentiality section.
I permit DNA.Land to contact me as part of the study. I confirm that the data submitted to
DNA.Land belongs to me or that I was explicitly authorized by the data owner to submit it on his
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or her behalf.
I understand that the research in this study may lead to new products, research tools, or inven-
tions that have financial value. By accepting the terms of this consent, I understand that I will not
be able to share in the profits from future commercialization of products developed from this study.
I understand that the information served by DNA.Land is only for educational and research
purposes and it is experimental by nature. It is not intended to diagnose, treat, cure, or prevent any
disease.
I understand that DNA.Land has the right to change the terms of this consent in the future.
By accepting the terms of this consent form I have not given up any of my legal rights. I am free
to withdraw my consent at any time and free of charge without providing a reason. I understand
that results may be published and cannot be destroyed.
A.3 Additional Details on User-Experience Features
A.3.1 Imputation
For imputation, we used ShapeIt [86] to phase the data and the Impute2 program [115] to
impute SNPs so all users have the same variants regardless of the tested platform (we are now in
the process of switching from Impute2 to MiniMac). For the imputation panel, we use the 1000
Genome phase 1 version, which brings that number of variants of each user to 39 million. The
output Gen/Haps files are then converted back into an imputed VCF file. From this file, SNPs
relevant to the trait prediction feature are extracted and stored in a small subset file.
A.3.2 Ancestry
Ancestry inference is performed on unimputed genotype files using a modified version of the
STRUCTURE algorithm [120] and a reference panel with known ancestry composition obtained
from the 1000 Genomes Project [121]. The primary modification incorporates subsampling and
bootstrapping to produce an approximate result that is efficient enough to process genotypes from
new users at a rapid pace of a few minutes of calculation per genome. Because uploaded genotype
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files are typically unphased, an allele for each variant is selected at random in each iteration before
comparison to allele frequencies from the reference panel. We run the modified algorithm for
10 iterations and the resulting population distributions are averaged to produce the final results.
Custom ancestry groups were defined by identifying natural clusters of genotypes in principal
component space. These are reported along with average percentages across users in Table A.2. A
typical ancestry report, viewed on a user’s DNA.Land profile, is shown in Figure 2.1.
A.3.3 Relative Matching
Relative matching is performed on imputed genotypes using a modified version of Germline
[122] and a newly implemented version of the ERSA algorithm [123]. Briefly, Germline compares
pairs of individuals in PED-format genotype files and reports the location and length of sequences
shared by the pair, as marked by shared SNPs. The original software operates by comparing all
genomes to each other in each run, which quickly consumes tens of hours of computation. We
modified the software to allow incremental IBD detection in which newly uploaded genomes are
compared to each other and to the old genomes, but the old genomes that have been already pro-
cessed are not compared to one another. ERSA then calculates the maximum likelihood probability
of relatedness and the degree of relationship between the pair using a likelihood ratio test. This
test calculates the likelihood that each segment is shared identical-by-descent (IBD) and deter-
mines whether the number and length of matching IBD sequences is greater than that expected
under a null (unrelated) model. We also had to completely re-write this software as the original
software contained a few implementation bugs that prevented smooth running on our pipeline.
Finally, we also run a PLINK IBS calculation on pairs of individuals that are closely related ac-
cording to ERSA. We found that ERSA has sensitivity issues in differentiating between avuncular
relationships and first degree relationships such as full siblings. Also, ERSA does not report ‘self-
matches’ (users that uploaded their genome twice). The PLINK IBS step allows us to detect these
issues with these close relatives and self matches and correct them according to the IBS value.
The report shown to users is presented as a table containing rows of identified relatives. Each
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row contains statistics and a visual display of the detected matching segments, as well as contact
information of the matching user, if he or she has chosen to provide it.
After the feature’s launch, we found that genetic genealogists have more relaxed thresholds
for detecting distant relatives. For example, ERSA would indicate that two relatives are related
only if they pass a highly sophisticated test that includes testing for a null hypothesis that the IBD
segments are due to multiple far ancestors. On the other hand, the genetic genealogy community
has developed a practice of calling distant relatives even with single long segments that are 7 cM
long. To accommodate some of these expectations, we also report matches of individuals with
at least two 7 cM segments. Matches that pass the ERSA algorithm are called “high certainty
matches” whereas matches that only pass the length threshold are called “speculative matches”.
These two classes of matches are presented in two tables.
We also developed a new feature, called the “Relatives of Relatives” report, which lists the
relatives of a user’s relatives, or second order connections in a graph of related individuals, who do
not already show up in the list of direct relatives identified by ERSA. These users are distant enough
that they are typically expected to share no common IBD segments despite being true relatives. The
Relatives of Relatives report is also divided into “low” and “high” certainty results, a high certainty
result only occurring when both constituent relationships are high certainty matches determined by
ERSA.
A.3.4 Trait Prediction/Phenotype collection
We developed the trait prediction feature to encourage users to report their phenotypes, an
essential component of our crowd-sourcing efforts. We wanted to avoid a lengthy phenotypes
questionnaire during the registration process, as this might discourage users from completing the
registration. In addition, we wanted to give something back to individuals for their efforts in
answering questionnaires. To address these issues, we decided to tie the questionnaire to the trait
prediction report. Before viewing a report for a specific trait, she or he must first answer a short
questionnaire.
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Upon visiting the trait prediction page for the first time, users are presented with a feature-
specific consent page, as well as risks involved in viewing these reports. After consenting, users
are presented with a menu listing reports for the available traits. Importantly, these traits were
chosen to be engaging and interesting to users without revealing potentially distressing medical in-
formation. Currently, we report genetic predispositions for: Circadian Rhythm [124], Coffee Con-
sumption [125], Educational Attainment [126], Neuroticism [127], Eye Color [128, 129], Height
[130], and Near-sightedness [131].
When clicking on a specific report for the first time, the user is presented with a questionnaire
pertaining to the trait. These questionnaires try to adhere to the questions asked on the GWAS on
which we based our prediction, when they are available. In the case of neuroticism, we present
users with the 12-question short-form Eysenck survey used previously to score the phenotype
[127]. Each survey also has an option for users to mark whether the genome uploaded belongs to
them, or to a family member.
After completion of the survey, users are presented with the trait report, which includes the
trait score (e.g. a predicted height), a histogram showing the user’s score compared to those of the
DNA.Land community, and a table showing the contribution of each variant to the score, and where
those variants are located in the genome. Many traits predicted by GWAS are highly polygenic with
high uncertainty on individual predictions, so we have also attempted to communicate the expected
level of accuracy of the report. These reports were designed with a common template so that new
traits can be added with ease, encouraging users to periodically revisit the site.
Traits are predicted using summary statistics reported in recent genome-wide association stud-
ies and meta-analyses. Polygenic scores are calculated by adding the effect sizes of significant
alleles and normalized by subtracting from an expected polygenic score, based on allele frequen-
cies reported in the 1000 Genomes database. These scores are then treated as a deviation from a




DNA.Land is designed as a "hybrid cloud" platform, relying on several cloud computing prod-
ucts by Amazon Web Services (AWS) as well as a physical server for processes we deemed too
costly to maintain by cloud services. We rely primarily on three AWS services: EC2 for com-
putation, S3 for storage, and SQS for job queueing. Here, we provide a broad overview of the
architecture of DNA.Land accompanying the diagram in Figure 2.3A, followed by more detailed
descriptions of significant steps in our file processing and analysis pipeline.
The DNA.Land frontend is hosted on a single EC2 reserved instance. The instance is an
m4.2xlarge machine with 8 CPUs and 32 GB of memory, and uses Amazon’s Elastic Block Store
(EBS) service, which allows for persistent scalable storage independent of the instance. This
dedicated server handles all web processes including user logins, rendering web pages, and ac-
cessing user data for display. This instance contains PostgreSQL databases storing all results of
user-specific reports, profile options, and survey responses. The website itself is written with the
Python/Flask framework and served using an NGINX web server.
DNA.Land’s back-end architecture heavily relies on Amazon EC2 spot instances. These in-
stances are priced by Amazon according to a bidding system and the number of running spot
instances can be adjusted easily by creating or terminating spot instances from a AWS control
panel. Using this bidding system, we can dynamically accommodate a wide range of user traffic
and quickly scale up, including sudden surges of new users after we launch a new feature on the
website. We have built internal tools to monitor and start spot instance usage in real time according
to price and traffic. However, spot instances are inherently volatile: the bidding system ensures
that available machines are awarded at any time to the customer willing to pay the most for service.
This means that one must either bid exorbitant fees to guarantee possession of instances or expect
running instances to periodically terminate and erase all unsaved data. As users of our website
can wait a few hours for their reports, our approach is to avoid high fees and instead run jobs at
times when the price is low. Therefore, we carefully designed our pipeline components on the spot
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instances to be idempotent and atomic. Namely, if the pipeline is run twice for a given user or
interrupted and run a second time, the resulting data files are simply overwritten but unchanged in
comparison to a single successful run. If the pipeline is interrupted by termination of the instance,
the user is placed back in the queue and assigned to a new instance when available.
AWS S3 is used to store all uploaded genotype files, intermediate file formats for pipeline
processes, and full imputed genotype files. These files are meant to be written once and accessed
infrequently. Results for display on the website are extracted from these files and stored on the
frontend DB for ready access and updating. In keeping with our design requirements, S3 has been
an invaluable tool for flexible, scalable data storage. Because pricing is handled per GB, there is
no practical limit to the amount of available storage.
Lastly, our physical server is responsible for performing steps in our pipeline that require pro-
cessing multiple user genotypes in batches, which cannot be accomplished by our parallelized spot
instances.
A.4.1 Pipeline flow
Given the above architecture, we describe the steps required for processing uploaded genomes,
as shown in Figure 2.3A. An uploaded genotype file on the frontend server is first copied to a
new S3 directory for the given user. For preprocessing, the genome file is converted to a tabular
format similar to the native 23andMe format with a genomic reference of build Ch37, regardless
of the company of origin or genome version. An internal user ID is also placed into an SQS
queue, awaiting an available EC2 instance node. When a free EC2 instance obtains the genotype
file, two processes are run in parallel: ancestry inference, and a longer pipeline for imputation
and generation of all other results. The imputation pipeline performs additional preprocessing and
converts the file to Oxford Gen/Haps format. After imputation, all generated files are copied to the
user’s S3 directory, and the user ID is placed in a second SQS queue awaiting further processing
by the physical server. The final output files include imputed VCF and BCF files, Gen/Haps files,
ancestry distribution file, trait prediction SNPs, and log files.
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The physical server performs relative matching and trait prediction calculations on users that
have completed the imputation pipeline. From the imputed VCF file, a Plink-style PED format list
containing a subset of 4 million SNPs, which is appended to a PED file containing all DNA.Land
users. This file is used as input into Germline for relative matching. For trait prediction, the small
subset file of SNPs, and the ancestry file serve as input and are regularly synced to a local directory
on the physical server. Our relative matching feature uses the IBD algorithm Germline, with a
modification allowing for comparing single users against a growing list of users, rather than the
default of comparing all pairs of users. The physical server is also responsible for generating trait
prediction results using several intermediate files stored on S3 detailing the user’s ancestry distribu-
tion, sex, and selected genotype alleles. These files are periodically synced with users’ S3 folders
into a local directory on the physical server. To prevent frequent modifications to the database, trait
results for multiple users are accumulated periodically before addition to the database.
A.5 Supplementary Tables
Total Cost ($) Participants
COLUMBIA/CORNELL/HARLEM HOSPITAL PRECISION MEDICINE INITIATIVE
HPO
4,461,312 150,000
CALIFORNIA PRECISION MEDICINE CONSORTIUM 1,040,538 10,000
ILLINOIS PRECISION MEDICINE CONSORTIUM (IPMC) 5,301,304 10,000
PRECISION APPROACH TO HEALTHCARE ENROLLMENT SITE (PA CARES) 4,195,725 175,000
A NEW ENGLAND ENROLLMENT CENTER FOR PMI COHORT PROGRAM 652,393 10,000
TRANS-AMERICA CONSORTIUM OF THE HEALTH CARE SYSTEMS RE-
SEARCH NETWORK
498,507 10,000
UNIVERSITY OF ARIZONA BANNER HEALTH PRECISION MEDICINE INITIA-
TIVE COHORT ENROLLMENT CENTER
3,956,243 150,000
PRECISION MEDICINE INITIATIVE COHORT PROGRAM BIOBANK 28,241,165 0
Total 48,347,187 515,000
Per-Individual Cost $93.88
Table A.1: Costs and number of participants for conventional Precision Medicine Initiatives. Costs
cover only recruitment and sample storage, suggesting that the addition of sequencing and experi-
mental costs may be enormous.
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North/Central European 0.76 Kalash 2.6E-03
North Slavic 0.11 Amazonian 2.4E-03
Southwestern Europe 0.10 Cambodian/Thai 2.2E-03
Ashkenazi 0.06 Ambiguous Northeast European 2.1E-03
Lower Niger Valley 0.06 Ambiguous Southwestern Europe 1.7E-03
Finnish 0.05 Mid-Turkic 1.7E-03
Italian 0.05 Mongolic/Tungusic 1.6E-03
Balkan 0.04 Ambiguous African 1.6E-03
South European 0.04 Arab 1.4E-03
Mediterranean Islander 0.03 Native Oceanian 1.4E-03
Native American 0.03 Aka 1.3E-03
Central Indo-European 0.02 Ambiguous Ashkenazi/Levantine 1.1E-03
Mende 0.02 Southern African 1.0E-03
Sardinian 0.02 Tubalar 9.3E-04
Ambiguous West Eurasian 0.02 East-Turkic 8.6E-04
Central Chinese 0.02 Siberian 7.1E-04
Senegal River Valley 0.01 Ambiguous Central Asian 6.3E-04
Central African 0.01 Ambiguous West African 4.9E-04
Dravidian 9.9E-03 Ambiguous East Asian 4.4E-04
Arab/Egyptian 9.0E-03 Nganasan 3.6E-04
North African 9.0E-03 Ambiguous East African 3.2E-04
Southeast Asian 7.7E-03 Mbuti 2.6E-04
Japanese/Korean 6.9E-03 Ambiguous Northeast Asian 2.1E-04
Indus Valley 6.6E-03 Hadza 1.7E-04
Indo-Iranian 5.1E-03 Ambiguous Native American 1.5E-04
Gujarati 3.7E-03 Ambiguous Southeast Asian 1.3E-04
Taiwanese 3.6E-03 Ambiguous Pygmy 1.0E-04
Ambiguous 3.2E-03 Ambiguous South Asian 8.5E-05
East African 3.0E-03 Ambiguous East Asian 5.4E-05
Table A.2: Ancestry categories currently available in the Ancestry report of DNA.Land, along with
average percent membership among DNA.Land users.
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Table A.3: The top websites from which first-time visitors to DNA.Land are linked. While 60
percent of our traffic originates from either Google or Facebook, many our remaining users arrive
from a diverse set of genetics-related blogs, forums, and services.
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A.6 Supplementary Figures
Figure A.1: User activity statistics of DNA.Land. (a) The number of page visits per week to
each type of report on DNA.Land: Ancestry (Red), Relative Matching (Light Blue), Relatives of
Relatives (Green), and Trait Report pages (Dark Blue) (b) The distribution of new user registrations
to DNA.Land by day of the week (c) The percentage of page visits by DNA.Land users by day of
the week.
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Figure A.2: Participation rates in DNA.Land’s trait survey feature. (a) Per-week and cumulative
numbers of total surveys completed by users (b) Per-week and cumulative numbers of total ques-
tions answered by users (c) The distribution of time required by users to complete each type of
survey. The surveyed traits are as follows: Chronotype (Orange), Coffee Consumption (Blue), My-
opia (Red), Eye Color (Green), Neuroticism (Pink), Educational Attainment (Purple), and Height
(Yellow).
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Figure A.3: Relative matching statistics among DNA.Land users. (a) The distribution of the num-
ber of inferred relatives among DNA.Land users based on matching IBD segments. Only 10.5% of
DNA.Land users have no detected relatives (b) The distribution of degrees of relatedness among
matching pairs of DNA.Land users, as calculated by the ERSA algorithm. A degree of 0 indicates
either an identical twin or duplicate genotype file.
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Figure A.4: Demographics of DNA.Land users. (a) Self-reported age distribution in DNA.Land
(b) Ancestry composition of DNA.Land users with aggregated ancestry categories: Northern Eu-
ropean (Red), Northeast European (Orange), Other European (Light Orange), Ashkenazi (Yellow),
African (Yellow-Green), South Asian (Light Green), East Asian (Turquoise), Native American
(Blue). Each column represents a single user, and stacked bars on each column indicate the dis-
tribution of ancestry groups for a given user. Users are sorted by decreasing percentage of their
largest ancestry group (c) Geographic location of DNA.Land users, as determined by IP address.
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Appendix B: Supplementary Material for CLiP
B.1 Negative correlations: an intuitive explanation
Figure B.1: Correlations between PRS predictors are apparent when considering a highly
simplified PRS. Assume a threshold model comprising only two independent haploid SNPs -1
and -2, and V1 = V2 = 1; i.e. an individual with a single risk-allele for either SNP is classified as
a case. The probability of having -1 = 1 given an individual is a case decreases if it is known that
-2 = 1. This results in a negative correlation between the two variables.
We demonstrate that among cases that are selected based on a thresholded linear score, as
in logistic or liability threshold GWAS models, the correlations between SNPs is expected to be
nonzero if those SNPs contribute a nonzero effect to determining the GWAS phenotype. Intuitively,
this can be observed in an extreme scenario in which cases and controls are determined by two
variables, -1 and -2, with a variance explained of 1. This scenario is visualized in B.1A. We
would like to evaluate the probability of an individual possessing -1 = 1 given that that individual
is a case. In the absence of any knowledge of -2, there approximately an equal chance that the
individual is a case because -1 = 1 or -2 = 1, with a typically negligible probability that both are
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However, if it is known that a case has -2 = 1, the case must inhabit the region above the
threshold line on the -2 axis, and so -1 = 1 can only be satisfied if the individual belongs to one
of the rare cases with both variables equal to 1.
%(case 1|case 2) =
+
 0.5 (B.2)
Therefore in this extreme scenario -1 and -2 are negatively correlated. Had one of the variables
decreased the risk score of the individual instead, then by the same logic -1 and -2 would be
positively correlated. A more complete proof is presented in the following section.
B.2 Associated SNPs are correlated among cases in logistic and liability threshold models
Assume there exists a logistic model for disease risk with effects (log odds ratios) for associated
SNPs {V1, ..., V"}. Further, assume we have collected a sample of # cases of a case/control
study for which the model predicts disease risk, represented by genotype matrix - ∈ {0, 1, 2}#×"
and labels . = {0, 1}# . All genotypes in - are independently sampled in controls and are thus
uncorrelated. We demonstrate that among cases, the correlation A between any two SNPs in - with
nonzero effect is nonzero. Specifically, given two SNPs 9 and : with effects V 9 and V: ,
1. V 9 = 0 ∪ V: = 0 =⇒ A 9 : = 0
2. sign(V 9 ) = sign(V: ) =⇒ A 9 : < 0
3. sign(V 9 ) ≠ sign(V: ) =⇒ A 9 : > 0
The correlation between SNPs 9 and : in the sample, represented as - 9 and -: , is by definition
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A 9 : =
E[- 9-: ] − E[- 9 ]E[-: ]√
E[-2
9




] − E[-: ]2
(B.3)
and so the sign of A 9 : is determined by the sign of the numerator. Here  [- 9 ] represents the
expected risk-allele count of SNP 9 within the set of cases.
Using the law of total expectation, rewrite the expectation of the product of - 9 and -: as an
expectation over - 9 conditional on -: :
E[- 9-: ] =E-: [E[- 9-: |-: ]]
=E[-:E[- 9 |-: ]]
(B.4)
This term is substituted into the numerator of the correlation in equation B.3 and expanded
over the marginalization of -: = {0, 1, 2}, with the -: = 0 term canceling.
E[- 9-: ] − E[- 9 ]E[-: ] =E[-:E[- 9 |-: ]] − E[-:E[- 9 ]]
=
[
?(-: = 1)E[- 9 |-: = 1] + 2?(-: = 2)E[- 9 |-: = 2]
]
−[
?(-: = 1)E[- 9 ] + 2?(- 9 = 2)E[- 9 ]
] (B.5)
This expression determines the sign of the correlation between SNPs - 9 and -: . The expecta-
tion  [- 9 ] can be expressed as a sum of conditional expectations on - 9 . After rearranging terms:
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E[- 9-: ] − E[- 9 ]E[-: ]
=?(-: = 1)
[
E[- 9 |-: = 1] −
[
E[- 9 |-: = 0]?(-: = 0)+
E[- 9 |-: = 1]?(-: = 1)+





E[- 9 |-: = 2] −
[
E[- 9 |-: = 0]?(-: = 0)+
E[- 9 |-: = 1]?(-: = 1)+




E[- 9 |-: = 1] (1 − ?(-: = 1)) −
[
E[- 9 |-: = 0]?(-: = 0)+





E[- 9 |-: = 2] (1 − ?(-: = 2)) −
[
E[- 9 |-: = 0]?(-: = 0)+




E[- 9 |-: = 1] (
?(-: = 0)+
?(-: = 2 )) −
[
E[- 9 |-: = 0]?(-: = 0)+





E[- 9 |-: = 2] (
?(-: = 0)+
?(-: = 1) ) −
[
E[- 9 |-: = 0]?(-: = 0)+
E[- 9 |-: = 1]?(-: = 1)
] ]
(B.6)
After collecting the conditional expectation terms:
E[- 9-: ] − E[- 9 ]E[-: ] =E[- 9 |-: = 0]
(
− ?(-: = 0)?(-: = 1) − 2?(-: = 2)?(-: = 0)
)
+
E[- 9 |-: = 1]
(
?(-: = 1)?(-: = 0) + ?(-: = 1)?(-: = 2)−
2?(-: = 2)?(-: = 1)
)
+
E[- 9 |-: = 2]
(
−?(-: = 1)?(-: = 2) + 2?(-: = 2)?(-: = 0)+
2?(-: = 2)?(-: = 1)
)
(B.7)
Assuming Hardy-Weinberg equilibrium in cases, probabilities of -: can be expressed as a
function of the risk-allele frequency ?: .
?(-: = 0) = (1 − ?: )2 ?(-: = 1) = 2?: (1 − ?: ) ?(-: = 2) = ?2: (B.8)
After substitution of these expressions into equation B.7, the result is a sum of polynomial
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functions of ?: .
E[- 9-: ] − E[- 9 ]E[-: ] =E[- 9 |-: = 0]
(












E[- 9 |-: = 2]
(




Note that when E[- 9 |-: = 0] = E[- 9 |-: = 1] = E[- 9 |-: = 2], equation B.9 reduces to 0 for
all values of ?: . When E[- 9 |-: = 0] < E[- 9 |-: = 1] < E[- 9 |-: = 2], equation B.9 is strictly
positive over the [0, 1] domain of ?: whereas when E[- 9 |-: = 0] > E[- 9 |-: = 1] > E[- 9 |-: =
2], the function is strictly negative over the domain. Next we must prove that the former inequality
would result if the signs of the effect sizes of - 9 and -: were different, whereas the latter inequality
would result if the signs were the same.
For any value of -: , the conditional expectation of - 9 in cases can be expanded according to
Bayes’ rule:
E[- 9 |-: ] =
∑
- 9∈{0,1,2}





?(. = 1|- 9 , -: )?(- 9 )∑
- 9∈{0,1,2} ?(. = 1|- 9 , -: )?(- 9 )
=
∑
- 9∈{0,1,2} - 9 ?(. = 1|- 9 , -: )?(- 9 )∑
- 9∈{0,1,2} ?(. = 1|- 9 , -: )?(- 9 )
=
?(. = 1|- 9 = 1, -: )?(- 9 = 1)+
2?(. = 1|- 9 = 2, -: )?(- 9 = 2)
?(. = 1|- 9 = 0, -: )?(- 9 = 0)+
?(. = 1|- 9 = 1, -: )?(- 9 = 1)+
?(. = 1|- 9 = 2, -: )?(- 9 = 2))
(B.10)
The probability ?(. = 1|- 9 , -: ) is the probability of an individual being a case and is de-
termined by a logistic function with fixed values for - 9 and -: . The numerator of Equation
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B.10 differs from the denominator by replacing ?(. = 1|- 9 = 0, -: )?(- 9 = 0) with a second
?(. = 1|- 9 = 2, -: )?(- 9 = 2) term. Consider the expression
?(.=1|- 9=2,-: )?(- 9=2)
?(.=1|- 9=0,-: )?(- 9=0) . We would
like to show first that the magnitude of this term decreases as -: ∈ {0, 1, 2} increases. Express the
probabilities as logistic functions
1
1+exp (−(21 9+-:1:+E[-1]− 9: ))
1
1+exp (−(-:1:+E[-1]− 9: ))
?(- 9 = 2)
?(-: = 0)
=
1 + exp (−(-:1: + E[-1]− 9 : ))
1 + exp (−(21 9 + -:1: + E[-1]− 9 : ))
?(- 9 = 2)
?(-: = 0)
(B.11)
where 1 9 and 1: are the odds ratios of SNPs 9 and : , respectively, and E[-1]− 9 : is the expected
contribution of the remaining undetermined SNPs when SNPs 9 and : are fixed. If the effect size of
-: is positive, the contribution of a particular value of -: can be represented as adding a constant
term 2 within a separate exponential term.
1 + exp(−(E[-1]− 9 : + 2))
1 + exp(−(21 9 + E[-1]− 9 : + 2))
?(- 9 = 2)
?(-: = 0)
=
1 + exp(−(0 + 2))
1 + exp(−(1 + 0 + 2))
=
1 + exp(−0) exp(−2)





exp(−2) + 1 − exp(−2)[
1 + exp(−(1 + 0))
]






+ exp(2) − 1[
1 + exp(−(1 + 0))
]




1 + exp(−E[-1]− 9 : )
)
+ exp(2) − 1(
1 + exp(−(21 9 + E[-1]− 9 : ))
)
+ exp(2) − 1
?(- 9 = 2)
?(-: = 0)
(B.12)
Therefore, fixing -: to a particular value has the effect of adding a exp(2) − 1 term to the nu-
merator and denominator of the ratio. Additionally, as the number of risk-alleles of -: is increased,
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the value of 2 and thus exp(2) − 1 increases. This allows us to take advantage of the following
Lemma:
Lemma: for strictly positive values of 2, 3, 4 with 2 > 3, 2
3
> 2+4
3+4 . 2 > 3 is satisfied for all
conditional expectations of - 9 provided that the effect of - 9 is positive.
2 >3
24 + 23 >34 + 23







Now substitute the fraction ?(.=1|- 9=2,-: )?(- 9=2)
?(.=1|- 9=0,-: )?(- 9=0) for
2
3
. When the value of -: is fixed, the
change to the probability is equivalent to adding a constant 4 to both the numerator and denomina-
tor, as shown in Equation B.12. By the above lemma, an increase in -: and thus an increase in the
magnitude of 4 reduces the value of ?(.=1|- 9=2,-: )?(- 9=2)




Next, rewrite the fraction as ?(. = 1|- 9 = 2, -: )?(- 9 = 2) = 0?(. = 1|- 9 = 0, -: )?(- 9 = 0)
where 0 is some positive constant greater than 1, as with all other variables fixed and a positive
effect 1 9 , - 9 = 2 will always increase the probability of generating a case vs - 9 = 0. We can then
eliminate ?(. = 1|- 9 = 2, -: )?(- 9 = 2) in Equation B.10. For simplicity we have also made the
substitution ?G = ?(. = 1|- 9 = G, -: )?(- 9 = G):
E[- 9 |-: ] =
?(. = 1|- 9 = 1, -: )?(- 9 = 1)+
2?(. = 1|- 9 = 2, -: )?(- 9 = 2)
?(. = 1|- 9 = 0, -: )?(- 9 = 0)+
?(. = 1|- 9 = 1, -: )?(- 9 = 1)+
?(. = 1|- 9 = 2, -: )?(- 9 = 2))
=
?1 + 2?2
?0 + ?1 + ?2
=
?1 + 20?0
?1 + (1 + 0)?0
(B.14)
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(?0 + ?1 + ?00)3
(B.15)
For positive values of 0, the first derivative is always positive, and the second derivative is
always negative, indicating that this is a monotonic, concave function. We have previously es-
tablished that as -: increases in magnitude, 0 decreases; that is, 0:=0 > 0:=1 > 0:=2. As
 [- 9 |-: ] is a monotonically increasing function of 0, then the previous inequality is likewide
true for  [- 9 |-: ]. Therefore, E[- 9 |-: = 0, . = 1] > E[- 9 |-: = 1, . = 1] > E[- 9 |-: =
2, . = 1]. Conversely, when - 9 has an effect size less than 0, and thus opposite that of - 9 , then
E[- 9 |-: = 0, . = 1] < E[- 9 |-: = 1, . = 1] < E[- 9 |-: = 2, . = 1].
B.3 Prediction of heterogeneity scores in homogeneous (null) cohorts
The heterogeneity score relies on the weighted difference in correlations between cases and
controls. The test for heterogeneity assumes in the null situation that a cohort of cases is com-
pletely homogeneous, i.e. sampled and thresholded using the same polygenic risk score model.
Therefore expected sample correlations between every pair of predictors -8 and - 9 (either SNP
allele counts or gene expression measurements) are computed assuming that all individuals are
identically sampled cases.
A (-8, - 9 ) =







] − E[- 9 ]2
(B.16)
By Bayes theorem, each of these expectations can be computed from the posterior probabilities











%(y=1|-8 = I)%(-8 = I)3I
E[-8- 9 |y=1] =
∫ ∫
-8- 9%(y=1|-8, - 9 )%(-8, - 9 )3-83- 9∫ ∫
%(y=1|-8 = I, - 9 = F)%(-8 = I, - 9 = F)3I3F
(B.17)
The prior probability for any predictor %(-8) when - are SNPs in Hardy-Weinberg equilibrium
is simply the binomial distribution parameterized by the risk-allele frequency in controls. As we
assume that in controls SNPs are sampled from independent loci, their joint distributions are simply
the product of these priors.
However, we would like to calculate the expected null score of a homogeneous set of cases
when the input predictors are both quantitative and correlated. In particular, we consider the sce-
nario of scoring heterogeneity in transcriptome-wide gene associations as described in Mancuso et
al. [31]. Assume, over # individuals,  is a genotype matrix comprising ( SNPs and - is a gene
expression matrix comprising " genes. Genes are determined by linear models over SNPs with
SNP-gene effect sizes V((×") .




V28B?B (1 − ?B)
(B.18)
where +8 is the variance explained of the SNPs G on gene -8 and ?B is the allele frequency of
SNP B. Case/control disease status H is then determined by a liability threshold model over genes
with liability effect sizes U("×1) .
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When the genes - are functions of mutually exclusive sets of SNPs, then equation B.19 can
be plugged into the case expectation terms in equation B.17 and solved using numeric integration.
These expectations are then used to solve the expected correlation A (-8, - 9 ) in homogeneous cases.
When multiple genes in - are associated with a common subset of SNPs, then the expected
correlation between these genes is nonzero. Therefore when a particular -8 is fixed to an observed
value, the expected values of the remaining -−8 are also altered, which in turn modify the value of
%(H = 1|-8). To calculate the correct expected correlation, we make use of the following lemma:
Lemma: Given a :-dimensional multivariate normal distribution / ∼ # (`,Λ), assume some
subset of components 1 ⊂ : are fixed with values -1. Define `· andΛ·· as the partitions of the mean
and covariance of a multivariate normal distribution corresponding to the specified component set.
Then the remaining components 0 = : \ 1 are multivariate-normal distributed with the following
mean and covariance [132]
`0 |1 = `0 + Λ01Λ−111 (-1 − `1) (B.20)
Λ0 |1 = Λ00 − Λ01Λ−111Λ10 (B.21)
As the genes are defined as linear functions of SNPs, the covariance between any two genes is
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Cov(-8, - 9 ) = Λ8 9 = Cov(V8, V 9) =
(∑
B=1
V8BV 9 B+8 (B.22)
Calculation of the expectation terms in equation B.17 requires fixing -1 = -8 or -1 = 〈-8, - 9 〉
to some value: the indices of these variables serve as the subset 1 while those of the rest of the "
genes serve as subset 0 = {1, ..., "} \ 1. As the genes in 0 are correlated with those in 1, fixing
values for 1 further informs the probabilities of 0 and thus the mean and variance of the liability
distribution over genes. The case probability given values for subset 1 shown in equation B.19
now becomes
%(H = 1|-1) = Φ
(
-1U1 + (Λ01Λ−111-1)U0 − )√
1 −∑8∈1 U28 +∑F∈{1,...,"}\1 [U2F + 2 ∑I∈{F+1,...,"}\1 UFUIΛFI]
)
(B.23)
This expression now accounts for correlations between genes arising from shared SNP effects
and can be substituted for equation B.19 when calculated the expected correlation in homogeneous
cases.
B.4 Normality of polygenic risk scores
The central limit theorem applies when the random variables to be summed are independent
and identically distributed. When creating polygenic risk scores, independence can be ensured to
a degree by carefully selecting SNPs for inclusion which are not in LD with one another. Any set
of SNPs, however, will not be identically distributed due to differing allele frequencies and scaling
by effect sizes. Additionally, while the prior distribution of effect sizes is itself assumed to be
normal, we cannot assume that the set of significant effect sizes comprising the PRS is likewise
normally distributed. But, we can still show that polygenic risk scores given these specifications
should converge to a normal distribution using Lyapunov’s theorem:
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- 9 − ` 9 → # (0, 1) (B.25)
First, we assume that SNPs are Bernoulli distributed variables scaled by effect sizes V 9 . If desired,
diploidy can be represented by sampling from two Bernoulli variables for each SNP. Secondly,
we assume that the magnitudes of the effect sizes V 9 are larger than some value n , a reasonable
assumption if these are SNPs discovered through GWAS. This prevents scenarios such as V1 > 0
and V2, ..., V" = 0, for which the limit does not converge. Given these assumptions, each SNP 9
in the summed PRS contributes a variance of V2
9

























9=1 |V39 |? 9 (1 − ? 9 )
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Therefore a sum of scaled Bernoulli variables should converge to a normal distribution even
when SNPs are not identically distributed, and effect sizes are not normally distributed.
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B.5 Validation of sample disease prevalences in logistic and liability threshold models
We demonstrate in Figure 3.2A that simulated cases sampled from a logistic model and its
conversion into a liability threshold model exhibit very similar acertainment for effect alleles, with
slight deviations occurring as odds ratios increase. Here we confirm that disease prevalences of
the simulated cohorts also do not deviate significantly between the two models. Given a set of
simulated individuals whose genotypes are randomly sampled, we assign case/control statuses to
the same individuals using either a logistic model or a liability threshold model with the same
parameters as Figure 3.2. The fraction of individuals assigned as cases from each model is plotted
in Figure B.2. Both models were set to produce a desired prevalence of 0.01, with varying odds
ratios specified by color. We observe that the logistic model produces slightly inflated sample
prevalences reaching a maximum of 0.0175 when odds ratios are large, versus a desired prevalence
of 0.01. We suspect the inflation occurs because logistic regression does not explicitly model the
variance of the log-odds. For a log-odds distribution mean-centered at zero, if the odds ratios
increase, so does the log-odds variance, allowing a slightly larger fraction of individuals to be
sampled as cases. This would also explain the decrease in ascertainment of effect alleles relative
to the liability threshold model seen in panel A of Figure 3.2, as increasing the log-odds variance
effectively relaxes the criteria for selecting a case. However, these biases in the logistic model
occur only at large odds ratios unrepresentative of the vast majority of polygenic effects. These
biases are also unlikely to be the primary source of the discrepancy in correlation patterns between
the logistic and liability threshold models in panel B of Figure 3.2, as the heterogeneity scores of
the two models begin to diverge at even small odds ratios.
B.6 Additional technical details on the Risch model
The Risch model assumes disease risk is determined by a product of relative risks.





The constant  is set such that the expected fraction of cases in a random sample of genotypes






] . In our
simulations, we assume that all " SNPs possess a constant odds ratio $' and allele frequency
?, and further that given a small prevalence of 0.01, the odds ratio can be substituted for the
relative risk. These simplifications allow us to define @ as the total effect allele count across all
SNPs, which is approximately normal distributed for large " with mean ` = "? and variance
























































Therefore in equation 1 of the Methods specifying the Risch model, we set the constant
 = +exp(−("?)2+(("?(1−?))2 (log$')+"?)2) where + is the prevalence, and all " SNPs share odds
ratio $' and allele frequency ?.
While the Risch model is calculated using relative risks, relative risks can be approximated by
odds ratios if the prevalence is small [133]. Zhang and Kai [134] propose the following equation to




(1 −+) ++ ∗$' (B.29)
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To verify relative risks do not deviate significantly from odds ratios, we plug in the simulation
parameters used in Figure B.3A, with + = 0.01 and $' = 1.2, to obtain a relative risk of '' =
1.198, and with + = 0.01 and$' = 1.06 in Figure B.3B, to obtain '' = 1.059. As the odds ratios
closely approximate their corresponding relative risks, we substituted the odds ratios directly into
the Risch model for simulations in Figure B.3.
B.7 Additional details on derivation of CLiP-X weight functions
Starting with the expression for correlation weighted by c,



















































Taking the derivative with respect to c at c = 0 allows the cancellation of many terms. If
A 9 : is expressed as A 9 : = 012 , where 0 is the entire numerator and 1 and 2 are the two standard







. With c = 0, the second term in








, which equals zero when we assume there is no correlation








From our assumption that there is no correlation within cases or controls





E[(-+9 )2] =(`+9 )2 + (f+9 )2 (B.32)
where (f+
9
)2 is the variance of SNP 9 within sub-cohort +. Lastly, at c = 0, each standard
deviation term in the denominator reduces to
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E[(-−9 )2] − (`−9 )2 =
[
(`−9 )2 + (f−9 )2
]
− (`−9 )2 = (f−9 )2 (B.33)
This yields the heterogeneity test statistic for continuous inputs.













































Figure B.2: Sample disease prevalences of cohorts simulated according to logistic and liability
threshold models. Each sample comprises 100,000 individuals with randomly sampled genotypes,
and case/control status was assigned according to either a logistic or liability threshold model with
a desired prevalence of 0.01. The resulting fraction of individuals assigned to cases by each model
is plotted. Colors indicate a fixed odds ratio assigned to 10 SNPs, with each value simulated over
10 trials.
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Figure B.3: CLiP performance on simulated control, homogeneous, and heterogeneous co-
horts. Shown are heterogeneity scores resulting from different cohort sizes and genetic architec-
tures. (A) Case/control cohorts generated from logistic or Risch models with 100 diploid SNPs
with allele frequency of 0.2 and odds ratio of 1.2. A prior prevalence of 0.01 is assumed for both
models. Scores of logistic cohorts exhibit a negative bias resulting from correlations between SNPs
not seen in the Risch model. (B) Case/control cohorts generated from logistic or Risch models with
100 diploid SNPs with allele frequency of 0.2 and odds ratios of 1.06, and prior prevalence of 0.01.













1000 0.00 0.08 0.00 0.03
5000 0.55 0.63 0.25 0.17
10000 1.00 0.99 0.60 0.61
20000 1.00 1.00 0.80 0.81
30000 1.00 1.00 1.00 0.95












0.001 0.10 0.08 0.10 0.07
0.01 0.50 0.42 0.05 0.13
0.02 1.00 0.99 0.60 0.61
0.03 1.00 1.00 0.90 0.96
0.05 1.00 1.00 1.00 1.00
0.075 1.00 1.00 1.00 1.00
0.1 1.00 1.00 1.00 1.00
Table B.1: Power calculations accompanying CLiP and BUHMBOX simulation results in
Figure 3.3. For both methods, the reported power is scored on true heterogeneous cases by a Z-
test with mean set to the expected score of homogeneous cases. In BUHMBOX, the expected score
is 0 in keeping with a multiplicative assumption across SNPs. In CLiP, the expected score is some
negative value corresponding to the negative correlations between SNPs expected of cases selected
from a liability threshold model, providing a boost in power. Tables A and B correspond to panels
A and B of Figure 3.3, respectively. “Sample Power” refers to the fraction True Pos.False Neg.+True Pos. of
20 trials shown in Figure 3.3 which pass a 95% confidence interval threshold. “Expected Power”
refers to the percentile of the sample distribution of true heterogeneous cases passing the 95%
confidence interval threshold.
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Figure B.4: CLiP performance as a function of subtype fraction size. Heterogeneity scores
(y-axis) evaluated on heterogeneous cohorts comprising a mixture of true cases and controls at
different proportions (x-axis). Colors indicate the total cohort size. The X-axis indicates the frac-
tion of individuals that are true cases. When the fraction is 0, the cohort contains only controls,
and all expected correlations are 0, producing a heterogeneity score of 0. When the fraction is 1,
the cohort contains only cases, and produces a highly negative score due to negative correlations
between all pairs of SNPs. As expected, a mixture of cases and controls produces positive scores,
with the peak score occurring when the cohort is split evenly. More detailed results of this set of
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Table B.2: Simulated CLiP results over additional parameters. These simulations differ by
total variance explained (ℎ2), cohort size, and percentage of individuals in the cohort that are true
cases, with the remaining individuals being simulated controls. All trials were run with 100 SNPs
with a fixed uniform effect size and an allele frequency of 0.2. Shown are mean and standard
deviations of 20 trials.
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Figure B.5: CLiP is robust to confounding heterogeneity with an BC < 0.05. CLiP corrects for
confounding heterogeneity such as ancestry by calculating the difference in SNP-SNP correlations
between cases and controls. Any confounding patterns that are present in controls as well as cases
are then canceled from the score. (A) Simulated homogeneous and heterogeneous cohorts in which
both cases and controls are sampled from two sub-populations with an BC specified by color. (B)
Power (dotted) and specificity (solid) over 20 trials. At high BC values, both homogeneous and
heterogeneous case scores are attenuated towards zero, and while power remains high, specificity
begins to decline with values of BC greater than 0.05.
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Figure B.6: CLiP performance as a function of number of distinct subtypes. Heterogeneity
scores (y-axis) evaluated on simulated heterogeneous cohorts with disjoint sub-phenotypes. Per-
formance is shown a function of the fraction of SNP effects unique to a particular sub-phenotype
(x-axis). Colors indicate the number of sub-phenotypes. Simulations were performed with 50,000
simulated cases and 50,000 controls, and a total SNP variance explained over all sub-phenotype





0 0.25 0.5 0.75 1
1 −5.08 ± 1.01 −4.92 ± 1.07 −4.93 ± 0.85 −5.16 ± 0.96 −5.32 ± 0.91
2 −1.67 ± 1.12 −1.87 ± 1.07 −2.60 ± 0.67 −3.67 ± 0.91 −5.41 ± 1.12
3 −0.65 ± 0.79 −1.23 ± 0.91 −1.98 ± 0.90 −2.90 ± 0.74 −4.99 ± 0.78
4 −0.49 ± 0.95 −0.61 ± 1.07 −1.33 ± 1.01 −2.74 ± 0.88 −5.48 ± 0.95
5 −0.56 ± 1.00 −0.81 ± 1.01 −0.97 ± 1.02 −2.00 ± 1.23 −5.53 ± 0.80
6 −0.44 ± 1.09 −0.39 ± 1.01 −1.14 ± 0.93 −2.05 ± 0.81 −5.07 ± 0.75
7 −0.05 ± 0.90 −0.12 ± 0.98 −0.43 ± 0.92 −1.68 ± 0.93 −5.42 ± 1.04
8 0.37 ± 0.81 −0.27 ± 0.61 −0.40 ± 1.07 −1.33 ± 0.91 −5.08 ± 1.07
Table B.3: Simulated CLiP results using cases generated from multiple correlated sub-
phenotypes. Entries comprise mean and standard deviations of CLiP scores evaluated over 20
trials, with a total variance explained of 0.05 and total case set size of 50000. All simulations were
performed with 100 SNPs, and in independent sub-phenotypes these 100 were subdivided equally
among the number of sub-phenotypes. The percentage of SNPs shared refers to the percentage of
SNPs within each sub-phenotype which has a fixed effect size across all sub-phenotypes.
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Figure B.7: Creating CliP-Y weight functions using step functions. To demonstrate that opti-
mal quantitative weight functions for heterogeneity are concave functions, two interval indicator
functions in [0, 1], an increasing one for [G, 1] (x-axis) and a decreasing one for [0, H] (y-axis)
are combined so that their sum is the tested weight function. Each bin on the axes represents a
transition point for the two step functions. The heterogeneity score is tested against a single homo-
geneous cohort, so optimal scores should be those that are most negative. (A) The best scores are
those where G is low on the PRS percentile scale but not 0, while H is high on the PRS percentile
scale but not 1. This coincides with the optimal polynomial functions obtained by a local search.
(B) A zoomed view of the top left in A, showing that the optimal scores are not obtained by step
functions at the periphery of the PRS distribution.
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Figure B.8: CLiP-Y scores for quantitative phenotypes split into artificial cases and controls
by a hard threshold, as a function of cohort size. Means and standard deviations of scores are
shown as a function of sample size: (A) homogeneous cohorts, (B) heterogeneous cohorts, and
(C) the difference (heterogeneous minus homogeneous) scores. The color gradient indicates the
location of the threshold separating cases and controls. Each condition was run for 20 trials, and
all cohorts were simulated with 100 SNPs and a total variance explained of 0.1.
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Figure B.9: CLiP-Y scores for quantitative phenotypes split into artificial cases and controls
by a hard threshold, as a function of SNP variance explained. Means and standard deviations
of scores are shown as a function of total variance explained by SNPs: (A) homogeneous cohorts,
(B) heterogeneous cohorts, and (C) the difference between scores of heterogeneous cohorts and
expected homogeneous scores in A. Colors indicate the type of weight function, with blue lines
indicating learned polynomial functions. Each condition was run for 20 trials, and all cohorts were
simulated with 100 SNPs and a sample size of 100,000 cases and 100,000 controls.
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Figure B.10: CLiP-Y scores for quantitative phenotypes with weight functions over individu-
als contributing to the correlation, as a function of cohort size. Means and standard deviations
of scores are shown as a function of sample size: (A) homogeneous cohorts, (B) heterogeneous
cohorts, and (C) the difference between scores of heterogeneous cohorts and expected homoge-
neous scores in A. Colors indicate the type of weight function, with blue lines indicating learned
polynomial functions. In panel A, black dotted lines indicate calculated expected scores for each
homogeneous cohort, given effect sizes and allele frequencies. In practice, these expected scores
will serve as the null scores subtracted from that of test data to produce analogous results to panel
C. Each condition was run for 20 trials, and all cohorts were simulated with 100 SNPs and a total
variance explained of 0.1.
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Figure B.11: CLiP-Y scores for quantitative phenotypes with weight functions over individ-
uals contributing to the correlation, as a function of SNP variance explained. Means and
standard deviations of scores are shown as a function of variance explained: (A) homogeneous co-
horts, (B) heterogeneous cohorts, and (C) the difference between scores of heterogeneous cohorts
and expected homogeneous scores in A. Colors indicate the type of weight function, with blue
lines indicating learned polynomial functions. In panel A, black dotted lines indicate calculated
expected scores for each homogeneous cohort, given effect sizes and allele frequencies. In prac-
tice, these expected scores will serve as the null scores subtracted from that of test data to produce
analogous results to panel C. Each condition was run for 20 trials, and all cohorts were simulated
with 100 SNPs and a sample size of 100,000 cases and 100,000 controls.
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Figure B.12: Additional CLiP-X scores as a function of variance explained by quantita-
tive predictors. Shown are controls (black), homogeneous cases (red), and heterogeneous cases
(green) across different levels of variance explained by generated predictors (+2

). The predicted
score for homogeneous cases (blue), calculated from summary statistics used to generate predictors
from sampled SNPs and phenotypes from predictors, is the true null hypothesis of the heterogene-
ity test. Means and standard errors are shown for 20 trials over 10 expression variables generated
by 100 SNPs.
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Figure B.13: Validation of expected correlations in CLiP-X between expression variables in
cases. Shown are the average standard deviations between predicted and generated correlations
as a function of the case sample size used to estimate the correlation. Predicted values account
for contributions from PRS thresholding and shared SNP-expression effects. Standard deviations
across all pairs of variables are averaged for each experiment. The black line denotes the function
1√
#−3
, the expected standard deviation of the Fisher transformation for sample correlations. Values
on the y-axis are transformed by an inverse hyperbolic function (artanh) for comparison to the
Fisher transformation.
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Figure B.14: Heterogeneity scores of the largest PGC cohorts subdivided by inferred ancestry
group. Original whole-cohort scores are shown in black. Ancestry inference was performed using
fastStructure with number of ancestry groups : = 2 (red), : = 3 (green), and : = 4 (blue). While
subgroups of small size are subject to larger correlation error, generally the heterogeneity scores
of ancestry subgroups achieves the same magnitude as the original score, suggesting ancestry
stratification is not the primary source of heterogeneity in PGC schizophrenia cohorts.
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Algorithm B.1: Sampling procedure for heterogeneous cases with quantitative pre-
dictors. We assume the input predictors are normally distributed gene expression tran-
scripts generated from linear functions of sampled binomial SNPs and total SNP variance
explained +2

. Then cases and controls are sampled based on a liability threshold model
on these gene expression variables.
Function SampleCLiP-X




, c Output: genotypes -#×" , expression /#×!
) = Φ−1(1 − .01); // threshold from 0.01 prevalence
/* define SNP and expression summary statistics */












9∈! Cov(/ ·8 ,/ · 9 ) ;
/* Generate control genotypes and expression */
for = in [1, (1 − c)#], < in [1, "] do
-0=,< ∼ Binom(2, ?<);
end
/0 ∼ Normal(-0 · V, 1 −+2

);
/* Generate case genotypes and expression */
- = []; / = [];
while nrows(-) = nrows(/) < c# do
for < in [1, "] do
G< ∼ Binom(2, ?<);
end
I ∼ Normal(G · V, 1 −+2

);
H ∼ Normal(I · U, 1 −+2

);





/* Simulate heterogeneity by concatenating generated cases
and controls */
- = concatenate(-, -0);
/ = concatenate(/, /0);
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Figure B.15: Sampling procedure for CLiP-X: heterogeneity detection with quantitative input
variables. Because in most scenarios the inputs will represent gene expression, we simulated
transcripts as linear functions of randomly sampled genotypes, allowing for prior correlations from
single genotypes associated with multiple transcripts. To generate a desired number of cases (Red),
batches of random transcripts are generated repeatedly, and those individuals whose liability scores
pass the threshold ) are concatenated to a growing list of cases. Heterogeneous cases are created
by concatenating true cases with controls.
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Algorithm B.2: Sampling procedure for heterogeneous PRS cohorts with quantita-
tive phenotypes. In lieu of explicit case/control labels by which to generate heteroge-
neous cohorts, we define ‘cases’ as individuals whose phenotypes are a function of their
PRSs, whereas ‘controls’ have phenotypes that are sampled completely randomly from
the same distribution.
Function SampleCLiP-Y
Input: #, ", ℎ2
(#%
, 2>ℎ>AC = {ℎ><, ℎ4C}
Output: -#×" , .#×1
/* define SNP and expression summary statistics */






for = in [1, #], < in " do
-=< ∼ Binom(2, ?<);
end
/* if heterogeneous, generate mislabeled individuals */
if 2>ℎ>AC = ℎ4C then
.[1,#/2] ∼ Normal(-[1,#/2],· · V, 1 − ℎ2(#%);











Algorithm B.3: Local search for optimal polynomial weight function q for use with
CLiP-Y. This weight function is applied over individuals according to their phenotypes
as a percentile of the phenotype distribution in the domain [0, 1], and determines the con-
tribution of individuals to the weighted correlation substitution in CLiP-Y. Optimization
is performed over a small set of discovery simulated cohorts, and validated in a larger set
of simulated cohorts. A set of candidate functions which pass a fixed threshold are stored,
and of these the function which performs best on the larger validation set is selected.
Function PolynomialWeightSearch
Input:
346; // Polynomial degree
#; // Size of the case/control cohort to simulate
:38B2 = 5, :E0; = 20; // Number sample cohorts to simulate for discovery,
validation steps
(CℎA4Bℎ; // Threshold score for saving candidate coefficient
coef_sd; // std. dev. for random increments in coefficient search
Output: 2>4 5 B
Function CalScore({-ℎ4C }, {-ℎ><}, 2>4 5 B):
return Mean(CLiP-Y({-ℎ4C }, 2>4 5 B)) −Mean(CLiP-Y({-ℎ><}, 2>4 5 B));
Function DiscoverCandidatePolynomials({-ℎ4C }, {-ℎ><}, (CℎA4Bℎ):
20=3B = {} for Num candidates desired do
2>4 5 B = R(346+1) ∼ # (0, coef_sd);
(ℎ4C = CalcScore({-ℎ4C }, {-ℎ><}, 2>4 5 B);
while Not converged do
increment a randomly selected coefficient in 2>4 5 B by 0 ∼ # (0, coef_sd);
if CalcScore({-ℎ4C }, {-ℎ><}, 2>4 5 B) > (ℎ4C then
update 2>4 5 B and (ℎ4C
end
end
if (ℎ4C > (CℎA4Bℎ then




/* Simulate cohorts for discovery/validation */
{-ℎ4C }38B2 = {-1, ..., -:38B2 |-8 = SampleCLiP-Y(#, 2>ℎ>AC = ℎ4C)};
{-ℎ4C }38B2 = {-1, ..., -:38B2 |-8 = SampleCLiP-Y(#, 2>ℎ>AC = ℎ><)};
20=3B = DiscoverCandidatePolynomials({-ℎ4C }38B2, {-ℎ><}38B2, (CℎA4Bℎ);
{-ℎ4C }E0; = {-1, ..., -:E0; |-8 = SampleCLiP-Y(#, 2>ℎ>AC = ℎ4C)};
{-ℎ4C }E0; = {-1, ..., -:E0; |-8 = SampleCLiP-Y(#, 2>ℎ>AC = ℎ><)};
return argmax2>4 5 B∈20=3B (CalcScore({-ℎ4C }E0;, {-ℎ><}E0; , 2>4 5 B))
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Appendix C: Supplementary Material for Contrastive Mixture Models











Appendix D: Supplementary Material for EMBER
D.1 Scaling of effects with correlated predictors
In our results a variable reduction step using PCA guarantees independence of input predictors.
But in other applications, without this step correlatedness between predictors in a linear model
will alter their total variance explained, so we must account for these correlations in order to
produce the correct re-scaling of effect sizes. Like other regression models, we however cannot
completely resolve multicollinearity from this correlatedness and must rely on large sample sizes
to compensate.
When predictors are independent and normally distributed, the total variance explained of the




) V = f2.
Assume instead that predictors are sampled from a multivariate normal distribution with mean
0 and covariance + . In practice, we need to obtain + from the sample covariance of controls. The





V 9 V: 2>E(. 9 , .: ) = V)+V = f2.





, which rescales the effect sizes to the correct magnitude V
0
as before.
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Because + is not a diagonal matrix, we cannot use the eigendecomposition trick as before.
However, we can apply the following theorem (using Neumann series representation for inverse):




We reduce computation time of V)+V by calculating only half of the symmetric product and




















 (−1! − _−1+−1!)
)
We now must take the sum of squares where each term being summed has the form (A − A′_).
Taken across all terms we have the following
(A − A′_)2 + (B − B′_)2 + (C − C′_)2 =A2 − 2AA′_ + A′2_2
B2 − 2BB′_ + B′2_2
C2 − 2CC′_ + C′2_2
(D.4)
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The solution for _ is then the result of the quadratic equation with 0 = A2 + B2 + C2 + ...,
1 = −2(AA′ + BB′ + CC′), and 2 = A′2 + B′2 + C′2 + .... In the above, A = −1 and A′ = −1+−1!.
D.2 Additional figures and validation in CMC/PGC cohorts
Figure D.1: Accuracy of TWAS inferred gene-trait effects (V2) as a function of reference panel
sample size for 20 simulated genes. A set of SNP-gene effects is learned from this reference panel,
and inferred genes are calculated for a fixed GWAS sample size of 50000 and regressed against
the phenotype using a probit model. Colors indicate the total variance explained by the genes. The




Figure D.2: A. Effect size inflation in the true liability threshold model. A liability threshold
model with a single predictor and known effect size was used to simulate case/control data. The
log likelihood was then tested using the same effect size scaled by a constant on the x-axis, with
1.0 equivalent to the true effect. The maximum log likelihood occurs at a value larger than 1.0,
causing inflation in the inferred effect size. B. True versus inferred effect sizes for simulations
using 20 standard-normally distributed predictors (genes) with a total variance explained of 0.1,
sample size of 5,000, and case/control prevalence of 0.01. While all models correctly infer the
relative magnitudes of effect sizes, the logistic and liability threshold (probit) models by default
over-estimate the scale of effects. By rescaling the effect sizes according to observed variance
explained, we are able to correct for this inflation. The constrained method, which is more time
efficient, produces nearly identical results to the post-inference rescaling.
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A B
Figure D.3: A. For the 36 genes with TWAS p-value < 10−5, plotted are the total SNP variance
explained against the fraction of SNP variance that is mediated by gene expression. B. Linear
regression A2 compared to GTEx v7 effects as a function of number of PCs in PCA for variable
reduction over cis-SNPs.
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Gene EMBER/GTEx A2 LR/GTEx A2 ΔA2 frac mediated ℎ2
GLT8D1 0.530 0.222 0.308 0.189
DUS2 0.194 0.039 0.156 0.060
ZSCAN23 0.481 0.351 0.130 0.250
C5orf63 0.343 0.228 0.114 0.180
ZNF391 0.325 0.217 0.108 0.033
SMIM8 0.427 0.357 0.069 0.093
PRMT7 0.317 0.249 0.068 0.219
NAGA 0.379 0.314 0.064 0.205
BTN3A2 0.345 0.285 0.060 0.097
ZKSCAN3 0.144 0.085 0.059 0.075
RNASEH2C 0.338 0.287 0.050 0.195
BTN2A1 0.109 0.065 0.044 0.004
SNHG5 0.277 0.233 0.043 0.160
HLA-B -0.041 -0.082 0.041 0.143
CORO7 0.365 0.324 0.040 0.187
GIGYF1 0.333 0.302 0.032 0.431
ARL14EP 0.219 0.195 0.023 0.087
SNX19 0.136 0.124 0.012 0.152
GNL3 0.132 0.120 0.012 0.002
TOM1L2 0.012 0.000 0.011 0.379
ZNF738 0.229 0.219 0.010 0.455
ZSCAN31 0.086 0.077 0.009 0.077
PPM1M 0.305 0.298 0.007 0.025
FOXN2 0.039 0.032 0.007 0.058
ZNF192P1 0.102 0.097 0.005 0.113
FAM86B3P 0.153 0.153 0.000 0.338
XPNPEP3 0.134 0.135 -0.001 0.019
AS3MT 0.233 0.236 -0.003 0.247
CBR3 0.232 0.236 -0.004 0.135
BTN2A2 0.417 0.422 -0.005 0.032
WDR73 0.006 0.015 -0.010 0.033
LRRC37A2 0.124 0.145 -0.021 0.007
PPP2R3C 0.269 0.304 -0.035 0.091
SRA1 0.458 0.497 -0.038 0.049
ERCC8 0.014 0.054 -0.040 0.185
MAPK3 0.304 0.353 -0.050 0.272
Table D.1: Data for all genes accompanying Figure 5.5B
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D.3 EMBER and regression results for all genes
Figure D.4: Shown are reported TWAS/GTEx v7 effects versus effects inferred from Common-
Mind gene expression data for all 36 genes with TWAS p-value < 10−5, arrayed according to SNP
position. For each gene, the top row displays TWAS/FUSION reported BLUP effects on GTEx v7
data; the middle row displays BLUP effects (blue) and when available, TWAS/FUSION reported
BLUP effects on CMC data (black); and the bottom row displays results of EMBER (green) and
linear regression (black), both using variable reduction to resolve high LD across SNP predictors.
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